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ABSTRACT 
 
Toxoplasma gondii is an obligate intracellular protozoan parasite of animals and man. 
The asexual life cycle of Toxoplasma involves three very distinct, but tightly coordinated 
developmental stages. In nature, the sporozoite (contained within an oocyst) and bradyzoite 
(contained within a tissue cyst) initiate infection of the intermediate host, followed by rapid 
differentiation into the actively replicating tachyzoite.  When countered by an effective host 
response, the tachyzoite differentiates back into the latent bradyzoite and this unique ability of 
Toxoplasma to interconvert between the replicating tachyzoite and the latent bradyzoite within a 
single host is the cause of life long infection.  The transcriptional mechanisms controlling 
tachyzoite to bradyzoite differentiation and inter-conversion are largely unknown, however, a 
linkage between the parasite cell cycle and differentiation may underlie these developmental 
mechanisms.   
The recent discovery of a family of DNA binding proteins in Apicomplexa (ApiAP2) that 
are distantly related to the APETALA-2 (AP2) class of plant transcription factors has uncovered 
an important set of proteins (ApiAP2 factors) that have critical roles in regulating growth and 
developmental gene expression.  Five Toxoplasma ApiAP2s were studied in this thesis project: 
AP2IX-9, AP2Ib-1, AP2IV-3 (Chapter 2); AP2IV-4 (Chapter 3); and AP2VI-1 (Chapter 4).  A 
major conclusion of this work highlights a novel paradigm in our understanding of the cellular 
mechanisms regulating stage conversion in Toxoplasma.  The study of AP2IX-9 and AP2IV-4 
indicate development of the bradyzoite is governed by transcriptional repressors acting at two 
independent levels, one late in the cell cycle and a second governing the transition from the 
tachyzoite to the end-stage bradyzoite tissue cyst.  The use of repressors to regulate 
development provides flexibility for the parasite to immediately respond to changing host 
	   vii 
conditions and modulate the competing needs of expansion and persistence.  In addition, the 
study of AP2VI-1 demonstrates that Toxoplasma employs ApiAP2s that bind chromosome 
heterochromatin to establish a state of developmental competency 
AP2IX-9 (Chapter 2) has a unique transient expression profile restricted to early 
bradyzoite differentiation, and absent form both the tachyzoite and terminal tissue cyst.  
Disruption of the AP2IX-9 locus resulted in increased tissue cyst formation in vitro while 
conditional overexpression of AP2IX-9 significantly reduced tissue cyst formation, indicating 
AP2IX-9 operates as a repressor of bradyzoite development.  Consistent with a role as a 
repressor, AP2IX-9 specifically inhibited the expression of bradyzoite mRNAs including BAG1, 
B-NTPase and LDH2, common markers for bradyzoite development.  Two other ApiAP2s, 
AP2Ib-1 and AP2IV-3 have similar expression profiles as AP2IX-9 and are candidates for 
expanding our understanding of this repressor mechanisms regulating development.   
A number of mRNAs encoding ApiAP2 proteins are dynamically regulated during the 
tachyzoite cell cycle that also show unique profiles during bradyzoite development.  AP2IV-4 
(Chapter 3) and AP2VI-1 (Chapter 4) represent two of several cell cycle AP2s whose 
expression is associated with specific S-phase and mitotic transitions but illustrate divergent 
roles in regulating growth and development.  The expression of AP2IV-4 is exclusive to the 
tachyzoite stage of development and peak expression coincides with mitosis of the cell cycle.  
Interestingly, deletion of AP2IV-4 results in the up-regulation of tissue cyst wall and bradyzoite 
surface antigens in the tachyzoite.  The mis-expression of bradyzoite proteins in the tachyzoite 
indicate AP2IV-4, much like AP2IX-9, is stage specific transcriptional repressor active only late 
in the tachyzoite cell cycle, likely promoting continued replication of the tachyzoite stage.  
For AP2VI-1 (Chapter 4), an S phase exclusive factor, we have verified S phase 
expression using an HA fusion protein at the endogenous locus, determined its DNA binding 
specificity by EMSA, and developed a genetic model of conditional expression based on the 
small molecule, Shield-1.  Attempts to genetically delete this factor were successful only in 
	   viii 
laboratory adapted strains of Toxoplasma, indicating AP2VI-1 has an essential function in the 
bradyzoite developmental pathway.  Genome-wide binding (chromatin immunoprecipitation and 
microarray analysis (ChIP-chip)) regions of AP2VI-1 are indistinguishable from the recently 
published CenH3 regions (centromere marker) and similarly fall within the H3K9me2 and 
H3K9me3 methylation patterns (heterochromatin markers) that mark the centromere 
boundaries.  AP2VI-1 was also detected in mature bradyzoites from in vitro or animal tissue 
cysts.  This dual expression profile for AP2VI-1 may suggest this factor has a unique role in 
chromosome maintenance or stability during developmental transitions.	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CHAPTER ONE: 
ApiAP2 DNA binding proteins: From plants to Apicomplexan parasites. 
 
Note to reader:  
Portions of this chapter, in part or in entirety, have been previously published in: 
Toxoplasma gondii: The Model Apicomplexan. Perspectives and Methods. Weiss, L.M., Kim, K., 
eds. Academic Press, 2013, Vol. 2, pp. 609-641 (Elsevier Books) and Toxoplasma 
development--turn the switch on or off? Cell Microbiol. 2014 Apr;16(4):466-72. doi: 
10.1111/cmi.12267. Epub 2014 Feb 16 (John Wiley and Sons) and are used with permission 
from indicated publishers. 
 
Background:  
Toxoplasma gondii is a single celled eukaryotic protozoan that belongs to a group of 
tissue-cyst forming coccidia within the Apicomplexa.  Toxoplasma has a complex, heteroxenous 
life cycle with sexual reproductive stages in the felid definitive host and asexual reproductive 
stages occur in most endothermic animals including humans, which results in the life long 
infection of the intermediate host.  It is estimated that nearly one-third of the global population is 
infected with Toxoplasma, with seropositive populations in some European and South American 
countries reaching nearly 80% (1).  In the United States, estimates of seropositive individuals 
range from 11% to 22.5% in those older than 12 years of age and it is estimated nearly 225,000 
clinical cases of toxoplasmosis are presented annually (2, 3).  Humans contact Toxoplasma 
through consumption of tissue cyst contaminated meats such as pork or sheep and through 
direct contact with the environmentally stable oocyst that is shed into the environment in feline 
feces.  Therefore, possible sources of human infection by oocysts range from soil or litter boxes 
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used by cats for defecation, to unwashed fruits and vegetables, or through contaminated 
drinking water (1). 
The remarkable promiscuity in choosing intermediate hosts underlies the public health 
hazard for millions of individuals that contact this pathogen annually, particularly those with 
immune systems weakened by aging, chemotherapy or AIDS; and women that acquire the 
infection during pregnancy.  The primary infection of a woman during gestation poses a serious 
health risk if transmitted to the fetus.  An estimated 400 to 4,000 cases of congenital 
toxoplasmosis occur each year in the United States and lead to significant health problems 
including mental retardation, blindness and death during infancy (4).  In AIDS patients, the 
ability of bradyzoites and tachyzoites to interconvert is considered to be the underlying cause of 
Toxoplasma-induced encephalitis (5).  The recrudescence of the dormant bradyzoite leads to 
repeated cycles of acute toxoplasmosis that can ultimately cause mortality in AIDS patients (5).  
Clinical toxoplasmosis (acute infection) can be treated with a combination of trimethoprim or 
pyrimethamine/sulfamethoxazole (6-8), however, there is a lack of drugs to treat or prevent the 
tissue cyst that is responsible for long-term infections (3).  Its is the unique ability of Toxoplasma 
to interconvert between replicative (tachyzoite) and non-replicative stages (bradyzoites within a 
tissue cyst) of asexual development within a single host that provides the biological source for 
recrudescent infection of immunosuppressed individuals and is the reason Toxoplasma is an 
important human pathogen.  Thus, given the importance of tissue cyst formation to human 
disease there has been intensive focus on the development of methods to study bradyzoite 
differentiation, although the molecular underpinnings for developmental switching are still 
unknown.   
 
Cell cycle and development:   
In the Toxoplasma life cycle parasites must replicate and produce forms able to evade 
host immunity and achieve efficient transmission to the next host.  The end-stage of the 
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intermediate life cycle is the bradyzoite (1N genomic DNA) contained within the tissue cyst and 
in the felid definitive life cycle the end-stage is the sporozoite (1N DNA) housed in the oocyst 
(Fig. 1.1, model) (9, 10).  The macro and microgametes of the definitive cycle are two other end-
stages, while replicating tachyzoites of the intermediate cycle and merozoites of the definitive 
cycle are responsible for asexual amplification of parasite numbers.  The Toxoplasma 
tachyzoite has become a major model to understand apicomplexa division.  The basic cell cycle 
periods are defined (11-13), which provided evidence for major control points that were 
exploited to synchronize parasite growth (13, 14).  Budding structures are assembled internally 
in tachyzoites and new invasion organelles are synthesized and packaged into new daughter 
parasites (reviewed in (15)) guided by a unique cell cycle transcriptome that delivers proteins in 
a "just-in-time" order (11).     
The question of how Toxoplasma replication and development is coordinated at the 
molecular level is yet to be answered.  In metazoans semi-conservative chromosome replication 
is postulated to provide the driving force behind development that results in altered epigenetic 
states and changes in gene expression (16, 17).  This general theme also appears to fit our 
understanding of Apicomplexa development where changes in stage-specific gene expression 
are reported to first appear in the cell division cycle immediately prior to developmental 
commitment.  In Eimeria bovis, merozoite gene expression is detectable in fully sporulated 
sporozoites (18), and in Plasmodium falciparum sexual stage commitment occurs in a subset of 
merozoites that will emerge from the erythrocyte as quiescent gametocytes (19).  It is 
understood that Toxoplasma tissue cyst formation requires replication (20), thus there is 
enrichment for S phase and mitotic parasites that characterizes the intermediate steps of 
bradyzoite development (10), and basal expression of some bradyzoite mRNAs are detectable 
only in the S/M period of synchronized tachyzoites (11).  Therefore, it is reasonable to view 
replication in the Apicomplexa as re-programing states required for changing one transmissible 
end-stage (G1/G0 phase) into another to ensure transmission to future hosts (Fig. 1.1, model).  
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The parasite transcriptome:   
The first microarray transcriptome studies of the Apicomplexa in P. falciparum illustrated 
that more than 80% of the transcripts were regulated, with most having a peak expression within 
a single timeframe in the sexual stages or intraerythrocytic cycle. The proper timing of mRNA 
accumulation applies not only to genes associated with parasite cell cycle that might be 
expected to have similar kinetics (21), but also for genes encoding protein components of 
subcellular structures as the narrow window when these structures form during the division 
cycle may also require coordinated gene expression (22).  The large changes in transcript levels 
in P. falciparum suggested mRNA expression is governed by “just-in time” mechanisms; and the 
relatively low proportion of constitutive mRNAs in these parasites may reflect this concept (23). 
Taken together, these results demonstrate that transcription is a major mechanism controlling 
gene expression in these parasites and this view is supported by comparison of the changes in 
the P. falciparum transcriptome and proteome that indicates alterations in mRNA levels have a 
higher correlation to protein changes in this parasite than is observed in yeast or higher 
eukaryotes (24).  
 Initial transcriptome studies in Toxoplasma relied upon cDNA derived from EST projects 
for Apicomplexan protozoa that were subsequently used to construct a limited Toxoplasma 
cDNA microarray that focused on tachyzoite-bradyzoite transitions in cell culture models of 
bradyzoite differentiation (25) and explored gene expression in mutants that were unable to 
differentiate (26, 27). These studies supported a role for transcriptional mechanisms in 
determining developmental stage characteristics in Toxoplasma and evidence for co-regulation 
of transcription in this parasite (28).  In the transcripts of four mutants generated by chemical 
mutagenesis, and selected against the ability to differentiate, a common set of mRNAs was 
affected and unable to be induced, while other affected mRNA groups appeared to cluster with 
2 or 3 mutants suggesting hierarchical gene expression may direct bradyzoite development 
(26).  Subsequent SAGE and microarray projects supported the concept of co-regulated 
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transcription and demonstrates that some of the general concepts emerging from the 
Plasmodium spp. studies apply to gene expression in Toxoplasma.  A community effort led to 
the fabrication of an Affymetrix gene array that has now become one platform of choice for 
transcriptome analysis along with newer deep RNA sequencing methods (29).  Currently there 
are numerous published expression datasets from different strains of parasites exposed to 
different experimental conditions, including bradyzoite inducing conditions (30-32). Most of 
these datasets are summarized at www.toxodb.org and the primary data are usually accessible 
in the GEO or ArrayExpress databases. 
 
Gene expression mechanisms:   
 The mechanisms of gene expression are not fully understood in Apicomplexa parasites.  
It is clear that the basal transcriptional complex that controls the expression of protein encoding 
genes (class II) is present in these parasites.  The analysis of protein encoding genes in the 
Apicomplexa indicates that conventional RNA polymerases with similarity to other crown 
eukaryotes are present.  Homologues for all known required eukaryotic RNA polymerases have 
been found in the Toxoplasma genome: RNA polymerase I (transcribes ribosomal RNA), RNA 
polymerase II (transcribes protein encoding transcripts), and RNA polymerase III (transcribes 
small RNA) (33-35, 36). Thus it appears that Plasmodium and Toxoplasma possess the 
conserved eukaryotic machinery whereby RNA polymerase II transcribes protein encoding 
genes.  Many of the core elements of class II eukaryotic promoters that includes TATA box, 
Initiator (Inr), and downstream promoter elements (DPE) that are recognized and bound by 
several GTFs: TFIIA, TFIIB, TFIID, TFIIE, TFIIF, and TFIIH (37-39, 40) are also present in these 
pathogens.    
What is less understood are activating transcription factors (ATF) that bind to cis-acting 
promoter element(s) and recruit chromatin remodeling enzymes which relax the chromatin 
around the cis-element-containing region and recruits the RNA polymerase II preinitiation 
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complex (PIC) directly (37).  Classical promoter mapping strategies utilizing conventional protein 
reporters, including choramphenicol acetyltransferase (CAT), βgalactosidase (βgal), green 
fluorescent protein (GFP) or firefly/renilla luciferase (luc), have been employed to map 
regulatory sequences in several promoters in Toxoplasma.   Deletion studies to identify 
promoter cis-elements have been reported for various constitutive genes (GRAs and DHFR-
TS), tachyzoite-specific genes (SAG1 and enolase 2), and bradyzoite specific genes 
(hsp30/BAG1, hsp70, LDH2 and enolase 1) and confirm that promoter elements are primarily 
located upstream from the translational start site (41-48).   
 Development-specific changes in mRNA levels are a dominant feature of the 
Apicomplexa transcriptome.  Nearly one quarter of the transcripts detected in the Toxoplasma 
SAGE project were observed to be uniquely expressed during parasite development and similar 
observations have emerged from functional genomics studies of the Plasmodium 
intraerythrocytic cycle (21, 49). Promoters controlling bradyzoite-specific genes, BAG1, hsp70 
and LDH2, have now been mapped using alkaline-stress induction at a similar resolution to (45, 
50, 51), while these studies support the role of promoter elements in regulating stress-response 
in Toxoplasma, their resolution is too low to allow for the identification of common cis-elements.  
Employing a dual luciferase model, we have mapped bradyzoite-specific cis-elements within a 
Toxoplasma gene encoding a novel NTPase (Brady-NTPase; TGME49_225290) (30).  A series 
of sequential and internal deletions followed by 6bp substitution mutagenesis have identified a 
15bp cis-element that is responsible for induction of the Brady-NTPase promoter under a variety 
of drug and stress conditions that co-induce native bradyzoite gene expression.  This element 
lies within the first 500bp of the Brady-NTPase promoter and 90% of the induction is lost when 
the element is mutated in the context of the full length promoter fragment (1495 bp).  Mutation of 
this element does not lead to increased expression in the tachyzoite stage indicating that it is a 
true inductive element.  
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The evolution of APETALA2-related proteins:   
The recent discovery of a class of DNA-binding proteins in the Apicomplexa that are 
related to the APETALA-2 (AP2) class of plant transcription factors (ApiAP2 proteins) has 
uncovered an important set of proteins that are likely to have critical roles in parasite gene 
expression (52).  Apicomplexan genomes including Plasmodium spp., Toxoplasma gondii, 
Cryptosporidium parvum and Theileria spp. encode multiple ApiAP2 proteins that may have a 
similar endosymbiotic origin (52, 53). Unlike plant AP2 factors, ApiAP2 proteins have undergone 
a lineage-specific expansion of a few progenitor genes leading to ApiAp2 factors carrying up to 
eight AP2 domains (52, 53).  Nearly 70 distinct ApiAP2 domain proteins are present in the 
Toxoplasma genome alone (54). Interestingly, phylogenetic analysis of ApiAP2 proteins from 
Plasmodium (27 total), Theileria (19 total) and Cryptosporidium (21 total) suggests the common 
ancestor of these three protozoa contained nine conserved ApiAP2 proteins, with a higher 
number of orthologous pairs found in Plasmodium spp. and Theileria spp. genomes (52). It is 
notable that with the exception of the ApiAP2 domain, these proteins are otherwise not 
conserved and there are no other known protein domains (activation, localization, or protein-
protein interaction) found in any of the Plasmodium spp. or Toxoplasma ApiAP2 proteins (53, 
55), lending further support to lineage-specific expansion of these DNA binding proteins.  
Until recently, AP2 domain-containing proteins were thought to be a plant-specific family 
of DNA binding proteins (56, 57).  AP2 homologues in non-plant species such as 
cyanobacterium, ciliates, and viruses indicate AP2 DNA-binding domains are widely conserved 
(58, 59).  Many of these proteins contain a second domain encoding a homing endonuclease 
function that confers the ability to operate as mobile genetic elements with the capacity to 
transpose, invade, and self-replicate by exploiting genome repair mechanisms (60, 61). While 
most homing endonucleases generally have no core cellular function and are eventually 
discarded, the HO endonuclease in yeast was adapted to trigger mating type interconversion 
(62) and other proteins in this family function to catalyze intron self-splicing in yeast (60). 
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Importantly, homing endonucleases are thought to have expanded through lateral gene transfer 
and are represented in all biological kingdoms, including mitochondrial and chloroplast genomes 
in eukaryotes (60).  Magnani et al., (2004) hypothesized that the plant AP2/ERF (ethylene 
response factor) family of transcription factors arose from the HNH-AP2 family of homing 
endonucleases present in bacteria or viruses and was incorporated into plant genomes via 
horizontal gene transfer (59), or alternatively was acquired indirectly from an endosymbiotic 
event, likely with a cyanobacterium with an early plant progenitor.  Regardless of the source, 
over time the homing endonuclease function has been lost in plants as the AP2 DNA-binding 
domain has taken on specific regulatory roles in gene expression associated with plant 
development and stress response (53, 59). 
 
ApiAP2 structure determination and DNA binding:  
The AP2 domain consists of approximately 60 amino acids and was first shown to confer 
DNA-binding specificity to the AP2/ethylene response element binding family (EREBP) found in 
plants (52, 63, 64). AP2/EREBP proteins represent the second largest class of transcription 
factors in Arabidopsis thaliana, consisting of 145 proteins that are subdivided further into 5 sub-
families based on AP2 domain architecture (65). DREB (dehydration responsive element 
binding) and ERF (ERF is identical to EREBP) protein groups constitute the two largest sub-
families (56 DREB compared to 65 ERF) and contain one AP2 domain and a conserved WLG 
motif (65). While identical in domain architecture, these groups are defined by single amino acid 
changes within the DNA-binding domain that alter DNA-binding specificity (65). Proteins that 
include two AP2 domains (14 total) are further divided into two subfamilies based on the 
presence or absence of a second non-AP2 DNA binding domain (59, 65). 
Alignment of ApiAP2 domains from Plasmodium, Cryptosporidium, and Theileria to the 
structure of the ERF1 from Arabidopsis indicates strong conservation of 12 residues that 
correspond to areas of hydrophobic interactions responsible for the backbone of the DNA 
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binding domain rather than specifying DNA binding (52) (Fig. 1.2). Campbell et al., (2011) 
determined the DNA-binding specificity of 20 of the 27 P. falciparum ApiAP2s, revealing an 
unusual diversity of binding motifs that are either classically palindromic or nucleotide biased, 
and similar results are seen in Toxoplasma ApiAP2s (Kim, Sullivan, White, Llinas, unpublished). 
The structural basis of DNA-binding is evident in ApiAP2 factors that share sequence beyond 
these 12 core hydrophobic residues. For example, orthologues from P. falciparum (PF14_0633) 
and Cryptosporidium parvum (cgd2_3490) that share 68% similarity in the AP2 domain show 
nearly identical DNA-binding specificities, providing evidence that with respect to DNA 
recognition there is conservation of function across divergent apicomplexan species (66). 
Whereas the majority of plant AP2 domains cluster tightly around DNA contact residues, 
ApiAP2 domains exhibit considerable flexibility within the domain, a feature that suggests a 
greater diversity in DNA-binding specificity (52). Supporting this hypothesis, individual PfAP2 
domains showed affinity for more than one sequence motif implying a single ApiAP2 factor 
could indeed regulate multiple gene targets. If ApiAP2 factors operate under a relaxed DNA 
sequence recognition (66, 67), then this feature could account for the smaller repertoire of other 
transcription factor orthologues encoded in Apicomplexa genomes. Interestingly, the limited 
domain architecture in plants (1 or 2 domains) is not conserved among the Apicomplexa, where 
proteins with up to eight ApiAP2 domains are found (52, 53). The protein diversity in the ApiAP2 
family of proteins is also large.  ApiAP2 factors in P. falciparum and Toxoplasma range in size 
from 200 to greater than 4,000 amino acids that are highly disordered outside the globular AP2 
domain(s) (See Fig. 1.2) ((67); personal communication, V. Uversky). Proteins of this secondary 
structure type are thought to undergo conformational changes upon interacting with other 
proteins (68), consistent with transcription factor functions. The high content of disordered 
proteins in parasitic eukaryotes (68) is thought to be a crucial adaptation to distinct environment 
niches. 
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Structural determination of representatives of the Arabidopsis and Plasmodium ApiAP2 
families has provided valuable insight into the mechanism by which the AP2 domain binds 
target DNA sequences. The conserved secondary structure for the monomeric AP2 domain 
predicts three N-terminal anti-parallel b-sheets and a C-terminal a-helix (55, 69). The NMR 
structure of Arabidopsis ERF1 GCC box binding domain (GBD is AP2 domain, target sequence 
= 5’-A/GCCGAC-3’) in complex with DNA revealed a novel interaction. AtEFR1 binds DNA via 
interaction with the b-sheets at specific locations along the DNA backbone while being 
supported by the a-helix (69). This interaction, as depicted in the structure of the single AP2 
domain containing ERF1, is based on 11 highly conserved residues, 7 of which target specific 
interaction with the GCC box (5’-AGCCGCC-3’). These residues are located within the b-sheets 
that bind to the sugar-phosphate backbone and comprise the framework for specific DNA 
interaction (69). The delineating feature of the DREB sub-family from the ERF sub-family of 
single domain AP2 proteins is a change in two conserved amino acids; V14 to A, E19 to D 
respectively. This alters the target DNA-binding sequence (5’-TACCGACAT-3’) illustrating that 
the diversity of recognition sequence is dictated by a limited number of evolutionarily conserved 
residues (65). Interestingly, the dual AP2 domain containing AINTEGUMENTA contains the 
conserved arginine and tryptophan residues, but mutation of these residues has little to no 
effect on DNA binding, suggesting dual AP2 domain proteins exhibit a greater complexity in 
target DNA-binding sequences and each domain utilizes unique residues to facilitate binding 
(target sequence = 5’-gCAC(A/G)N(A/T)TcCC(a/g)ANG(c/t)-3’) (57). These results from plants 
suggest dual AP2 domain proteins are more complex in their DNA binding and this may also 
apply to ApiAP2 factors. In Plasmodium, initial characterization of the dual ApiAP2 protein 
PFF0200c indicated only one AP2 domain actively bound to a specific 10 mer sequence (66). 
However, studies of the full-length protein in parasites clearly demonstrate that PfSIP2 
(PFF0200c) requires both AP2 domains in order to bind the 16bp bipartite SPE2 sequence motif 
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(70, 71). This highlights the limitations associated with using any single approach to determining 
ApiAP2 function. 
Solving the crystal structure of the prototypical ApiAP2 domain from P. falciparum 
(PF14_0633) provided further insight into AP2 function (55). While ApiAP2 domains retain many 
of the canonical features previously described in the Arabidopsis thaliana (69), key differences 
have been identified. In contrast to the A. thaliana structure, which acts as a monomer, PfAP2s 
are thought to dimerize via a domain-swapping mechanism, with the a-helix of one promoter 
packed against a b-sheet of its partner (55). This model suggests that DNA binding triggers 
stabilization of the homodimer or that an ApiAP2 binds DNA as a monomer, elucidating a 
conformational change that then attracts the second monomer to bind (55). In the case of 
Pf14_0633, dimerization is thought to be critical to combining distal regions of DNA to function 
in gene-specific transcription of sporozoite stage genes (55). In addition, ApiAP2 may work in 
concert as proteomics studies of nuclear complexes have often identified more than one ApiAP2 
in pull-downs of macromolecular complexes ((71); Sullivan, White, Kim, unpublished). 
 
The function of ApiAP2 factors in transcription: 
Discovered just a few years ago, evidence is quickly emerging that ApiAP2 proteins 
interact with the epigenetic machinery, bind DNA as dimers with diverse sequence motifs, and 
have essential roles in P. falciparum developmental gene expression (54).  In the rodent malaria 
P. berghei, it was determined that an ookinete specific AP2 (AP2-O, PF11_0442 orthologue) is 
critical to mosquito mid-gut invasion. AP2-O was found to directly interact within the proximal 
promoter regions of 15 genes, including 10 that had previously been defined as ookinete 
specific or required for ookinete development within the mosquito mid-gut. AP2-O knockout 
parasites exhibited normal gametogenesis, however lacked the ability to infect mosquitos (72). 
A second P. berghei AP2, AP2-Sporozoite (AP2-Sp), is a trans-acting factor whose cognate 
binding site is enriched in proximal promoter regions of known sporozoite specific genes, likely 
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interacting with cis-elements to promote stage-specific gene expression (73, 74). The P. 
falciparum orthologue of this protein, PF14_0633, has a DNA binding domain that shared a 
conserved DNA binding motif (GCATGC) with both C. parvum (66) as well as Toxoplasma 
orthologues (Kim, unpublished). In contrast to Plasmodium, the Toxoplasma gene appears to be 
essential and to date it has been refractory to disruption. In Toxoplasma, this motif is a cis-
acting motif required to drive luciferase activity in reporter constructs (Kim, unpublished). While 
many of the DNA binding motifs of ApiAP2 appear to be phylogenetically conserved, there is no 
conclusive evidence as to whether or not these factors have orthologous functions. 
Analysis of ApiAP2 mRNA expression patterns in P. falciparum reveals an ordered 
timing of expression for 22 of 26 ApiAP2 proteins during the intraerythocytic development cycle 
(IDC) (52, 67). The distribution of expression across the IDC suggests that ApiAP2 factors could 
be responsible for controlling the dynamic changes in gene expression during apicomplexan 
replication (67). The enrichment of PfAP2 binding motifs in the promoters of cell cycle 
transcripts lends support to the idea that the trans-acting ApiAP2 regulator of groups of cell 
cycle genes will likely be co-expressed (67). For example, the putative target genes for 
Pf13_0235, which includes ribosome function and heat shock genes, all have the same timing in 
the IDC. Also, enrichment of PfAP2 target sequences that are found in invasion and host cell 
entry genes may be regulated by Pf10_0075, and transcripts encoding DNA replication factors 
could be controlled by MAL8P1.153 (67). In each case, the binding motif of the co-expressed 
PfAP2 was enriched in the promoters of the inclusive mRNA cluster.  A similar distribution of 
cyclically regulated ApiAP2 factors is observed in the cell cycle transcriptome of the 
Toxoplasma tachyzoite (11).  However, in both the replicating P. falciparum merozoite and 
Toxoplasma tachyzoite evidence that ApiAP2 factors control the extensive transcriptional 
cascades remains to be established. 
 Further evidence for transcription factor activity for ApiAP2 proteins comes from a 
promoter mapping study of a liver stage exclusive promoter. Four repeats of the ApiAP2 
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PB000252.02.0 (PF11_0404 orthologue) DNA-binding motif were found in the minimal 
promoter. Interestingly, mutation of a single copy of the binding site within the liver stage 
promoter increased promoter luciferase gene expression, suggesting PbAP2 PB000252.02.0 
has a role as a transcriptional repressor (74), which is a common mechanism used by plant AP2 
factors to regulate the timing of developmental gene expression (75-77). Finally, the Bilker and 
Soldati groups used the DNA binding domains of ApiAP2 to develop regulated promoters that 
work in both Plasmodium species as well as Toxoplasma, further bolstering the hypothesized 
role of these proteins in transcriptional regulation (78).  
In this thesis I will interrogate the function of ApiAP2 factors in the regulation of the 
intermediate life cycle in Toxoplasma (replicating tachyzoite to end-stage bradyzoite).  Multiple 
studies catalogue the changes in gene expression associated with Toxoplasma bradyzoite 
tissue cyst formation (30, 79) and mechanisms potentially operating during tissue cyst 
development can be observed in the basal expression of bradyzoite transcripts and the pre-
activation of bradyzoite gene promoters in the tachyzoite of low passage strains (30).  Applying 
stress to primary tachyzoite strains strongly induces bradyzoite mRNAs and suggests a shift 
from repressor to activator type mechanisms operating on relevant promoters.  The studies of 
the transcriptional repressors AP2IX-9 and AP2IV-4 highlight this intimate relationship between 
the tachyzoite and bradyzoite stages and provide novel insight to the central importance of the 
tachyzoite in determining the course of parasite development within the intermediate host.  
Absent from the tachyzoite and the terminally differentiated bradyzoite, AP2IX-9 acts to prevent 
pre-mature commitment to the bradyzoite, either to promote further expansion of parasite 
biomass or to help guide the parasite to the correct tissue in which to develop (80).  On the 
other hand, AP2IV-4 is present only during the lytic cycle, yet actively represses bradyzoite 
specific transcripts during each round of tachyzoite replication.  The observation that repressors 
regulate the developmental switch to the bradyzoite developmental pathway indicates the 
default mechanism for the Toxoplasma asexual life cycle is to differentiate to the latent, tissue 
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cyst form.  These data also highlight important changes in chromatin that must occur in order to 
set the stage for developmental changes in the parasite (81).  It is possible that dual-
developmental stage expressed AP2 factors such as AP2VI-1 fill this niche by interacting with 
chromatin remodeling machinery to stabilize the centromeric regions of chromatin during the 
course of development.  Thus, ApiAP2 factors have evolved critical roles in guiding bradyzoite 
development in the intermediate host of Toxoplasma.   
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Figure 1.1: The model of Toxoplasma asexual development.  The asexual life cycle of 
Toxoplasma exhibits three distinct stages.  The sporozoite and bradyzoite stages can initiate 
infection and the tachyzoite is responsible for parasite expansion in the intermediate host.  It is 
the ability of the tachyzoite and bradyzoite to interconvert (recrudescence) that is the cause of 
life long infection.   
 
  
 16 
 
 
 
Figure 1.2: The ApiAP2 family of Toxoplasma gondii. There are 68 members of the 
Toxoplasma ApiAP2 family as determined by a Toxoplasma community annotation effort (White, 
Sullivan, Kim, Croken and Wootton; see http://www.toxodb.org). A schematic of the consensus 
DNA binding domain of the Toxoplasma family is shown in the upper left (53). The inferred 
protein size and AP2 domain location within each TgAP2 is heterogeneous as can be seen in 
the stick figures representing TgAP2 whose mRNA vary during the cell cycle (right). The peak 
timing of mRNA of the cell cycle regulated TgAP2 within the cell cycle is indicated, as 
determined by Affymetrix microarray analysis (11). The mRNA expression of some additional Tg 
ApiAP2 members suggests that they are expressed in other developmental stages (11). 
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CHAPTER TWO: 
An ApiAP2 transcription factor restricts development of the  
Toxoplasma tissue cyst. 
 
Note to reader: 
 Portions of this chapter, in part or in entirety, have been previously published in An 
ApiAP2 transcription factor restricts development of the Toxoplasma tissue cyst. Proc. Natl. 
Acad. Sci. 110(17):6871-6. doi: 10.1073/pnas.1300059110 and is used with permission of the 
publisher.   
 
Introduction: 
Toxoplasma gondii has an exceptional range of animals that may serve as host for its 
intermediate life cycle, while the definitive life cycle occurs in a feline host (1).  Together, 
oocysts shed by cats into the environment and tissue cysts in food products contribute to rates 
of human exposure that are estimated at one in three by age 50 in the US (25% for >20yrs of 
age) (2, 3) and nearly 100% by the end of childhood in other parts of the world (4).  Toxoplasma 
infections are thought to be life-long due to the development of the tissue cyst, which is 
effectively invisible to the immune system and clinically untreatable.  The bradyzoite tissue cyst 
is an essential part of the life cycle of Toxoplasma, and recrudescence of the tissue cyst leading 
to chronic cycles of toxoplasmosis is a major cause of mortality in AIDS patients.  Experimental 
data indicates Toxoplasma sporozoite or bradyzoite infections follow a similar developmental 
course through the tachyzoite stage that is characterized by changes in growth and stage-
specific gene expression leading ultimately to the mature tissue cyst (5-7).  Determining how 
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gene expression is regulated in these critical developmental transitions will be important to 
unraveling the underlying mechanisms responsible for chronic Toxoplasma infections.   
 The mechanisms of gene-specific regulation in Apicomplexa have remained elusive. The 
expression profiles of large portions of the cell cycle transcriptome of Plasmodium falciparum 
and Toxoplasma asexual stages are progressive with little understanding yet as to how these 
serial patterns are controlled (8, 9).  In Toxoplasma, conversion between developmental stages 
is also linked to significant changes in gene expression (5).  Data mining of genome sequences 
has recently identified a family of plant-related AP2 domain (DNA-binding) containing proteins in 
the Apicomplexa (ApiAP2 proteins)(10).  Based on genome sequence annotation, 68 of these 
factors are found in Toxoplasma and 27 in P. falciparum (8, 11, 12).  In Toxoplasma, 24 ApiAP2 
factors are cell cycle regulated in tachyzoites (8), while 18 are expressed in a cascading fashion 
during the P. falciparum intraerythrocytic cycle (12).  Relatively few ApiAP2 proteins are 
characterized, however, stage-specific gene activation (13-16) as well as chromatin biology and 
genome maintenance (17) are functions identified so far.  Like their plant counterparts, ApiAP2 
factors can bind promoter elements of distinct co-regulated gene clusters (12), and therefore it 
is likely these proteins will be major regulators of apicomplexan transcription.  
Here, we report the characterization and functional validation of an ApiAP2 transcription 
factor in Toxoplasma.  AP2IX-9 is a nuclear-restricted protein expressed transiently during 
tachyzoite to bradyzoite development.  AP2IX-9 specifically binds cis-regulatory elements (CRE) 
functionally mapped to bradyzoite promoters (18) including the classic bradyzoite marker, small 
heat shock protein BAG1 (19).  Using gene disruption and conditional expression, we 
demonstrate AP2IX-9 is the first Apicomplexa transcriptional repressor operating to regulate 
developmental gene expression.  By preventing bradyzoite gene expression and promoting 
parasite growth, AP2IX-9 regulates the balance between parasite expansion and forming end-
stage bradyzoites required for transmission to the definitive host. 
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Results: 
Toxoplasma ApiAP2 factors are induced during early bradyzoite differentiation.  
Of the 68 ApiAP2 encoding genes predicted in the Toxoplasma genome (11) there is evidence 
for expression by microarrays for 44 of these genes (>40th percentile) in the tachyzoite 
(constitutive and stage specific)(8).  To identify ApiAP2 genes regulated during early bradyzoite 
differentiation in Toxoplasma, we queried developmental transcriptome data representing the 
three genetic lineages (Type I-GT1, Type II-ME49, and Type III-CTG) that dominate parasite 
populations of North America and Europe (18).  From these microarray data, we classified 15 
ApiAP2 mRNAs as increased (9 down-regulated) during in vitro bradyzoite induction in at least 
one strain (heatmap, Fig. 2.1A).  This collection of developmentally regulated ApiAP2 genes are 
predicted to encode a diverse group of proteins ranging in size from 286 to 3,256 amino acids 
containing one to three ApiAP2 domains (protein maps, Fig. 2.1A).  Interestingly, more than half 
of the ApiAP2 genes showing regulated mRNA expression (up and down) in the bradyzoite (14 
of 24 total) also had cyclical mRNA profiles in the tachyzoite cell cycle.   
 One of the largest expression changes of any ApiAP2 mRNA was AP2IX-9, which was 
consistently increased during early bradyzoite induction in all three Toxoplasma lineages.  To 
verify that the mRNA profile was predictive of AP2IX-9 protein expression, we endogenously 
tagged the AP2IX-9 locus in a Type II Prugniaud strain carrying a disruption of the KU80 gene 
that enhances gene targeting (strain designated PruQ)(20).  PruQ-AP2IX-9HA parasites induced 
to differentiate by pH 8.2 media were positive for tissue cyst wall formation by Dolichos biflorus 
agglutinin (DBA) lectin staining and they co-expressed AP2IX-9HA protein exclusively in the 
nucleus (Fig. 2.2A) similar to other ApiAP2 factors (8).  The number of vacuoles positive for 
AP2IX-9HA reached 79% by 2 days post-shift into pH 8.2 media (%HA positives) and this 
induction profile was confirmed by Western analysis and semi quantitative RT-PCR (Fig. 2.1B).  
By contrast, microarray analysis (see www.ToxoDB.org for data summary) indicates AP2IX-9 
mRNA is minimally expressed in tachyzoites and in mature bradyzoites in tissue cysts (isolated 
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from 21 day infected mice)(21) indicating AP2IX-9 mRNA expression is transient.  AP2IX-9HA 
protein largely followed the native mRNA profile with minimal expression in tachyzoites of the 
PruQ-AP2IX-9HA transgenic strain (Fig. 1.1) and AP2IX-9HA protein was not detected in mature 
bradyzoites from PruQ-AP2IX-9HA-infected mice (30 day post-infection, Fig. 1.1C).  Parasites 
from in vivo tissue cysts are capable of expressing other ApiAP2 proteins, such as the cell cycle 
factor AP2VI-1HA (Fig. 1.1C)(8).  Altogether, these results indicate AP2IX-9 is only expressed 
during early bradyzoite differentiation, and consistent with this conclusion, we found AP2IX-9HA 
positive vacuoles decreased after peaking at 2 days in alkaline-shifted cultures (Fig. 2.2A).  The 
decrease in AP2IX-9HA nuclear fluorescence was not associated with a loss of tissue cysts as 
the number of DBA positive vacuoles continued to increase throughout the experiment (Fig. 
2.2A, % DBA); by four days post-alkaline shift nearly half the DBA positive vacuoles were 
negative for AP2IX-9HA protein. 
To determine if other Toxoplasma AP2s had a similar transient mRNA expression 
pattern to AP2IX-9, we further examined AP2 expression across the developmental 
transcriptome. Two other AP2s, AP2Ib-1 and AP2IV-3, exhibited mRNAs whose expression 
pattern was limited to early bradyzoite development, but absent from both the tachyzoite and 
late stage bradyzoite in all three clonal lineages (Fig. 1.1A). To verify this expression pattern, we 
introduced a C-terminal 3xHA epitope at the endogenous locus for both AP2Ib-1 and AP2IV-3 in 
the PruΔku80 (designated PruQ) transgenic parasite that preferentially undergoes homologous 
recombination (20). So far, the AP2Ib-1 locus has been refractory to C-terminal fusion of the 
3xHA epitope and expression data is not presented. Similar to PruQ-AP2IX-9HA, PruQ-AP2IV-
3HA expression was exclusive the nucleus after induction of bradyzoite differentiation by pH 8.2 
(Fig. 2.2B, red).  Co-staining with DBA (green) indicates PruQ-AP2IV-3HA expression 
accumulates over a 72h time course (%HA positive), but does not increase between 48h and 
72h, though tissue cyst wall (%DBA) continued to increase (Fig. 2.2B).  Though the heatmap in 
Fig. 1A suggests AP2IV-3 is expressed late in the tachyzoite cell cycle, PruQ-AP2IV-3HA was 
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only detected in 2% (data not shown) of tachyzoite vacuoles, indicating AP2IV-3 is largely 
absent from the tachyzoite and only detected when induced by stress.  These data suggest 
PruQ-AP2IV-3HA is expressed in a pattern similar to PruQ-AP2IX-9HA, and, therefore, may 
regulate similar cellular processes during bradyzoite development.   
AP2IX-9 binds cis-regulatory elements of the bradyzoite NTPase promoter.  To 
determine the DNA binding motif recognized by AP2IX-9, we expressed the single ApiAP2 
domain of AP2IX-9 as a GST fusion protein (GST-IX-9).  Affinity-purified GST-IX-9 recombinant 
protein was assayed using a protein binding microarray (PBM)(12) and the top three motifs from 
this analysis revealed a conserved 6bp core DNA sequence motif 5’-CAGTGT-3’/3’-GTCACA-5’ 
(enrichment scores >0.45, Fig. 2.3A).  GST-IX-9 binding to this motif was validated using 
electrophoretic mobility shift assays (EMSA)(Fig. 2.3B, see Table 2 for all sequence designs).  
Few functional CRE sequences are known in Toxoplasma, however, the promoter CRE 
controlling a bradyzoite NTPase isoform (B-NTPase) shares the GT/CA repeats (18) found in 
the AP2XI-9 binding motif.  In EMSA assays, GST-IX-9 protein bound the B-NTPase CRE 
sequence in a manner consistent with the results of previous promoter mutagenesis (Fig. 
2.4)(18).  GST-IX-9 binding to the B-NTPase CRE was effectively competed by a mutant 
sequence (Fig. 2.4-mut 4) that retains 51% of promoter function, whereas binding to the B-
NTPase probe was not effected by a mutant sequence that fully disrupts promoter function (Fig. 
2.4-mut 3)(18).  These results suggest AP2IX-9 could regulate the transcription of B-NTPase 
and perhaps other bradyzoite genes.   
AP2IX-9 regulates bradyzoite differentiation in multiple strains.  The induction of 
AP2IX-9 during bradyzoite differentiation suggests this factor may serve a role in promoting 
parasite development, and by extension deleting this factor might block development.  Several 
attempts to verify this hypothesis by gene knockout in Type II Prugniaud parasites failed despite 
successful epitope tagging by recombination of the AP2IX-9 locus in this strain (Fig. 2.2A).  We 
also failed to disrupt the AP2IX-9 locus in low passage isolates of GT1, ME49 and CTG (Types 
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I-III, respectively).  By contrast, disruption of the AP2IX-9 gene was readily achieved in the PLK 
clone of Type II ME49 (PLKΔap2IX-9) and in the lab strain RHΔhxgprtΔuprt developed 
previously as a model for bradyzoite differentiation using CO2-starvation (22).  These genetic 
results suggest that AP2IX-9 may be essential to developmentally competent Toxoplasma 
strains, while dispensable in parasites adapted to cell culture (Table 2.2, Knockout frequencies).  
AP2IX-9 is inducible in the parental parasites of both RHΔhxgprtΔuprt and PLK strains and 
these strains are able to form tissue cysts, although they have lost the capacity to complete the 
definitive life cycle in the feline host (23).  Therefore, we examined in vitro tissue cyst formation 
of PLKΔap2IX-9 clones as well as RH strain clones carrying a AP2IX-9 knockout in addition to 
the deletion of the HXGPRT and UPRT genes (triple knockout strain designated RHΔap2IX-
9)(Fig. 2.5).  Contrary to expectations, under CO2-starvation culture conditions (22), RHΔap2IX-
9 clones differentiated much better (49 % tissue cysts, Fig. 2.5 grey bars) than the double 
knockout parent (15% cysts in RHΔhxgprtΔuprt strain).  Tissue cyst numbers were also 
increased in PLKΔap2IX-9 clones when compared to the PLK parent strain following pH 8.2-
induction (Fig. 2.5 black bars). 
The increased formation of tissue cysts in PLK and RHΔhxgprtΔuprt parasites lacking 
the AP2IX-9 protein suggested this factor might operate as a repressor rather than an activator 
of bradyzoite development.  To test if AP2IX-9 is a repressor, a conditional expression allele of 
AP2XI-9 was engineered in the developmentally competent Prugniaud strain (Pru) by creating a 
fusion of the FKBP destabilization domain (DD) (24) with the N-terminus of AP2IX-9 (DDAP2IX-9; 
see design Fig. 2.6A).  In this ectopic expression design, DDAP2IX-9 transcription was controlled 
by the constitutive α-tubulin promoter, and as expected steady-state levels of DDAP2IX-9 mRNA 
were independent of Shield-1 addition or the media pH (mRNA panel Fig 2.6A).  Importantly, 
regulation of the DDAP2IX-9 fusion protein was achieved by stabilization of the DD-domain using 
the small molecule Shield-1 (see Western and IFA analysis, Fig. 2.6A and B) (24).  Endogenous 
post-transcriptional mechanisms also contributed to DDAP2IX-9 protein levels with the highest 
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expression resulting from the combination of pH 8.2 media plus Shield-1, while in tachyzoites 
(pH 7.0 media) DDAP2IX-9 expression was lower due to native degradation that could be 
partially overcome with Shield-1 (Fig. 2.6A and B).   
Using this conditional model, we explored how extended stabilization of DDAP2IX-9 
under alkaline conditions influenced tissue cyst formation.  In the Pru-parental strain, tissue cyst 
formation in pH 8.2 media was robust and independent of Shield-1 (>75% cysts formed by 72 h, 
Fig. 2.6C).  By contrast, Pru-DDAP2IX-9 parasites pretreated with Shield-1 (250nM Shield-1, 6 h 
prior to alkaline shift) produced half the number of tissue cysts (32%) as parent controls (75%) 
(Fig. 2.6C).  Addition of Shield-1 at the time of pH 8.2 shift inhibited cyst numbers in Pru-
DDAP2IX-9 parasites by 60%.  To confirm AP2IX-9 inhibition of tissue cyst formation was not 
strain-specific, we obtained a DDAP2IX-9 expressing clone in a low passage Type III CTG strain 
(Fig. 2.7).  CTG-DDAP2IX-9 parasites shifted into pH 8.2 media plus Shield-1 were severely 
restricted in tissue cyst formation (12% tissue cysts, Fig. 2.7A), and this inhibition was 
substantially reversed if DDAP2IX-9 levels were lowered by omitting Shield-1.  Thus, AP2IX-9 
acts to repress bradyzoite differentiation in developmentally competent Type II and III strains.   
It is generally accepted that bradyzoite differentiation requires a slowing of parasite 
growth (25), and ultimately this leads to growth-arrest in the tissue cyst as mature bradyzoites 
with nearly 100% haploid DNA content (7).  The tight association between bradyzoite 
development and the parasite cell cycle led us to explore the growth rate of parental CTG and 
CTG-DDAP2IX-9 parasites.  Parental CTG showed the expected slowing of growth in pH 8.2 
media reaching an average vacuole size of ~22 in 96 h (Fig 2.7B), and these populations fully 
growth-arrested before lysing the host cell monolayer.  By contrast, CTG-DDAP2IX-9 parasites 
grew faster in pH 8.2 media than parental controls, and unlike parental CTG cultures, CTG-
DDAP2IX-9 infected monolayers were lysed by 96 h (Fig. 2.7B, arrows).  Resistance to the 
growth inhibition of alkaline media was independent of Shield-1 in CTG-DDAP2IX-9 parasites.  
The low levels of DDAP2IX-9 in pH 8.2 media (see Fig. 2.7B inset gel) appeared to be sufficient 
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to confer pH-resistant growth on CTG-DDAP2IX-9 parasites, and they also prevented a full 
reversal of the AP2IX-9 block to tissue cyst formation (Fig. 2.7A, pH 8.2 minus Shield-1=55% 
cysts compared to >75% cysts in the induced CTG parent).  These results suggest AP2IX-9 
may act to forestall the growth changes that ultimately lead to the dormant bradyzoite in mature 
tissue cysts (6, 7).  In such a growth promoting role, deletion of AP2IX-9 could cause 
developmentally competent strains to readily leave the cell cycle perhaps explaining why 
knockouts of APIX-9 were not recovered in low passage strains.  To support this idea, we easily 
disrupted the AP2IX-9 locus in CTG-DDAP2IX-9 parasites (17% of stable transgenics were 
knockouts), whereas repeated knockout attempts had failed in the developmentally competent 
CTG parent strain.  The phenotype of CTGΔap2IX-9-[DDAP2IX-9] parasites with respect to 
tissue cyst formation was unchanged from the CTG-DDAP2IX-9 transgenic strains indicating the 
DDAP2IX-9 fusion protein had fully replaced the function of the native protein. [Tissue cyst 
results: CTGΔap2IX-9-[DDAP2IX-9] in pH 8.2 minus shield produced 74% DBA positive 
vacuoles, while only 28% DBA positive were counted in cultures where Shield-1 was added]. 
AP2IX-9 represses major elements of the bradyzoite transcriptome.  To identify the 
genes potentially controlled by AP2IX-9, duplicate total RNA samples from parental CTG and 
CTG-DDAP2IX-9 parasites induced by pH 8.2 media plus Shield-1 were isolated and analyzed 
on a custom Toxoplasma Affymetrix GeneChip (26).  A total of 116 mRNAs were altered (5% 
FDR) in this comparison (full gene lists in Tables 2.4 and 2.5) with the largest changes resulting 
from the down-regulation of transcripts in CTG-DDAP2IX-9 parasites including many known 
bradyzoite mRNAs (e.g. BAG1, LDH2, ENO1, B-NTPase; Fig. 2.8A and Table 2.5).  The 
inhibition of BAG1 and LDH2 mRNA induction in CTG-DDAP2IX-9 parasites was verified by semi 
quantitative RT-PCR analysis (Fig. 2.9A).  Several lines of evidence indicated AP2IX-9 was 
directly responsible for bradyzoite transcriptional repression.  First, the AP2IX-9 binding motif 
(CAGTGT) was enriched in the promoters of the genes showing the highest levels of AP2IX-9 
repression (18 of 35 promoters have ≥3 CAGTGT repeats, Fig. 2.8A red boxes).  Particularly for 
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BAG1, we found 14 repeats of a CAGTG motif (5/6bp of the AP2IX-9 motif) in the 2kbp 5'-
flanking sequence upstream of the BAG1 translational start that includes the mapped BAG1 
CRE (repeats and CRE sites are marked in Fig. 2.8D diagram).  Given the multiple copies of the 
AP2IX-9 motif in the BAG1 promoter, it was not surprising this transcript was the most down-
regulated in the microarray analysis (Fig. 2.8A).  Secondly, the direct regulation of BAG1 by 
AP2IX-9 is supported by repression of luciferase activity in a transgenic clone where the BAG1 
promoter controls the firefly luciferase gene (PruIC2, Fig. 2.8B)(18).  As expected, the 
introduction and stabilization of DDAP2IX-9 expression by Shield-1 in the PruIC2 strain strongly 
inhibited luciferase induction under alkaline-stress (Fig. 2.8B) and this repression was partially 
reversed by omitting Shield-1 (Fig. 2.8B).  Finally, the direct interaction of AP2IX-9 with the 
BAG1 promoter was supported by GST-IX-9 binding to the BAG1 CRE (18) in EMSA assays 
and chromatin immunoprecipitation followed by qPCR of DDAP2IX-9-bound genomic DNA 
showed specific enrichment across the BAG1 promoter (Figs. 2.4D and 2.9B).  Altogether, 
these results support the view that ApiAP2 factors may have greater flexibility in DNA binding 
than plant AP2 factors (9, 11).  AP2IX-9 was able to bind the B-NTPase functional CRE (Fig. 
2.4) through the GT/CA repeat feature found in the APIX-9 binding motif (CAGTGT), and with 
the BAG1 promoter CRE (Fig. 2.8) binding appears to be through the shared CAGT/ACTG 
feature. 
 To further our understanding of the AP2IX-9 repressor mechanism, we selected B-
NTPase and LDH2, two genes whose mRNA is suppressed in the CTG-DDAP2IX-9 model (Fig. 
2.8A and Table 2.5). Similar to BAG1, both the B-NTPase (5 repeats) and LDH2 (3 repeats) 
promoters were enriched for the AP2IX-9 DNA binding motif (Fig. 2.3A) and the previously 
mapped B-NTPase CRE contains a TGTG motif, not unlike the predicted AP2IX-9 motif (18). To 
verify AP2IX-9 acts directly on the promoters of B-NTPase and LDH2, we transiently transfected 
each promoter driving firefly luciferase (18) (B-NTPase, -1201bp upstream of ATG; LDH2, -
1510bp upstream of ATG) into CTG-DDAP2IX-9. Following overnight recovery, cultures were 
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induced with pH 8.2 media (control) or pH 8.2 media supplemented with 200nM Shield-1 and 
allowed to grow for 48h post-induction (see (18) for experimental details and plasmids). As 
predicted by previous experiments (Fig. 2.8B), stabile overexpression of CTG-DDAP2IX-9 with 
Shield-1 results in decreased luciferase activity of BAG1, B-NTPase and LDH2 (Fig. 2.8E; black 
bars, -Shield-1; white bars, 200nM Shield-1), further confirming the direct interaction of AP2IX-9 
with the regulatory mechanisms of each gene.  All promoter firefly luciferase activity was 
normalized to co-transfected alpha-tubulin renilla luciferase activity (18). The suppression of 
BAG1, B-NTPase and LDH2 promoter luciferase expression by modulation of the DDAP2IX-9 
transgene with Shield-1 further verifies our understanding of AP2IX-9 as a repressor of 
bradyzoite developmental program.   
 
Discussion: 
In this study, we show a member of the large Toxoplasma ApiAP2 protein family (AP2IX-
9) regulates parasite development.  Disruption of the AP2IX-9 gene promotes formation of the 
Toxoplasma tissue cyst, while overexpression of this factor inhibits this developmental pathway 
along with major features of the bradyzoite transcriptome.  We demonstrate AP2IX-9 is a 
nuclear protein induced in response to alkaline stress in the early bradyzoite, whereas it is 
minimally expressed in tachyzoites and end-stage bradyzoites in murine brain tissue cysts.  
AP2IX-9 binds DNA in a sequence-specific manner and the AP2IX-9 binding motif is repeated in 
many bradyzoite promoters where direct binding of this factor to the BAG1 promoter in 
chromatin was established.  ApiAP2 factors have roles in activating developmental gene 
expression (13-16), and there is evidence an ApiAP2 factor may assist the silencing of var gene 
expression in P. falciparum (17).  The AP2IX-9 factor is the first ApiAP2 transcriptional 
repressor to be characterized in the Apicomplexa and this mechanism begins to explain how the 
early steps in tachyzoite to bradyzoite development are regulated in Toxoplasma.  The extent of 
transcriptional repressors among the ApiAP2 family is unknown, however, this type of 
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mechanism is commonly associated with related AP2 factors of plants.  Multiple AP2 family 
members in plants are repressors of stage-specific gene regulation, especially in flowering (27) 
and stress responses (28).   
In its natural life cycle Toxoplasma is a heteroxenous parasite.  Its sexual reproductive 
cycle is exclusive in the felid host with a second clonal reproductive phase that is possible in 
virtually any endothermic animal.  The traditional developmental course widely assumed to 
unfold in the intermediate host involves three sequential stage switches (e.g. sporozoite to 
tachyzoite to bradyzoite), although this scheme is likely oversimplified (see model Fig. 2.10).  
The developmental and cell cycle transitions of the intermediate life cycle are accessible in host 
cells infected with sporozoites or bradyzoites (6, 7) where these end-stages first differentiate 
into the tachyzoite stage (<2 days) followed by limited replication of the emergent tachyzoite 
(day 3-6, Fig. 2.10).  Spontaneously switching to a longer division cycle (day 7) signals 
formation of a pre-bradyzoite, which is primed to develop into the end-stage bradyzoite (G1/G0 
state)(6, 7).  Studies in animals reinforce these basic outlines (29-31) which established the 
minimal timing of tissue cyst formation using a sensitive cat bioassay (reviewed in ref (32).  In 
metazoans semi-conservative chromosome replication is postulated to provide the driving force 
behind development that results in altered epigenetic states and changes in gene expression 
(33, 34).  As a framework this model appears to fit our understanding of Toxoplasma 
development.  It is well known tissue cyst formation requires replication (25), enrichment for S 
and mitotic parasites characterizes the course of bradyzoite development (7), and peak 
expression of bradyzoite transcripts coincides with the S/M periods of the tachyzoite cell cycle 
(8).  Thus, replicating forms in Toxoplasma can be envisioned as re-programing states required 
for changing one transmissible end-stage (G0/G1 phase) into another to ensure survival in 
multiple hosts (e.g. sporozoite switch to bradyzoite).  A precise relationship between 
chromosome replication and transcriptome re-modeling is not established, however, a 
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surprisingly short timeframe (1-4 days) produces infectious tissue cysts following bradyzoite 
inoculation of mice (32). 
The pre-bradyzoite is an important, if also a poorly understood transition of the 
intermediate life cycle.  Low passage strains readily form this developmental stage that is 
characterized by a spontaneous switch to slower growth, while retaining tachyzoite proteins on 
the parasite surface (7).  Here the activity of AP2IX-9 provides new insight into the molecular 
mechanisms regulating Toxoplasma development.  We propose that the pre-bradyzoite stage 
produced by native parasite proliferation is held in the poised state by ApiAP2 factors like 
AP2IX-9 (see model Fig. 2.10).  As a transcriptional repressor, the role for AP2IX-9 could be to 
prevent premature commitment of the pre-bradyzoite in a less optimal host tissue or balance the 
parasite response to different immune system reactions.  There is little evidence for quorum 
sensing mechanisms in apicomplexa infections, although if they occur, the AP2IX-9 mechanism 
could play a role here as well.  Importantly, AP2IX-9 expression may be the first marker for this 
specific developmental transition.   In providing a transient adaptive response, the AP2IX-9 is 
similar to the AP2 factor, ABI4 of plants that is induced by stress (high sugar) where it reduces 
critical gene expression to protect these sensitive plants during early stages of development 
(35).  In later stages of seedling development ABI4 does not appear to be required and is no 
longer induced by stress (36) much as AP2IX-9 is dispensable for the mature bradyzoite.  
Dividing tachyzoites appear to actively degrade AP2IX-9, which could reflect a protective 
response or alternatively, stabilization of AP2IX-9 may be tied to mechanisms active only during 
the pre-bradyzoite developmental transition.  The latter explanation has some support because 
conditional overexpression of AP2IX-9 in the Shield-1 model was tolerated by tachyzoites (Figs. 
2.3 and 2.6A) and induction of this protein is tightly associated with strain developmental 
competency.  In Prugniaud and CTG strains AP2IX-9 is inducible by stress, while in the 
developmentally resistant RH strain AP2IX-9 does not accumulate under any pH condition even 
though the encoded mRNA is inducible.  Based on transcriptome profile, RH strain is trapped 
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upstream of the pre-bradyzoite (equivalent to D3-6, Fig. 2.10)(37), and supporting this 
assignment, the chromatin signature of bradyzoite promoters in RH indicates they are 
transcriptionally inactive (18).  Therefore, we interpret the difference in AP2IX-9 expression in 
these strains to indicate that when the AP2IX-9 repressor complex is bound to chromatin it is 
stabilized, and therefore, the native transient pattern of AP2IX-9 expression is strongly 
influenced by histone modification at specific promoters.  The changing epigenetic landscape 
during bradyzoite differentiation may also explain the decline of AP2IX-9 as development 
progresses to the mature tissue cyst.  Here other ApiAP2 factors likely replace AP2IX-9 to 
activate the bradyzoite transcriptome such as the newly described bradyzoite activator AP2XI-4 
that binds GT/CA DNA repeats (14).  We suspect the principle of ApiAP2 post-transcriptional 
control orchestrated by dynamic chromatin states will apply to many other family members 
including those in the large group of cycling ApiAP2 factors that act in the tachyzoite cell cycle 
(8).  In conclusion, evidence presented here indicates AP2IX-9 is a major regulator of the 
intermediate life cycle of Toxoplasma where it may help control the balance between parasite 
expansion and transmission, and through the prevention of premature commitment to the 
bradyzoite end-stage could help steer tissue cyst formation to a favorable host cell environment.  
 
Material and Methods:  
 
A summary of the parent strains used and transgenic clones produced for this study is provided 
in Table 2.1 along with the oligonucleotide primers used for cloning (Table 2.3).  All sequences 
were accessed using www.ToxoDB.org.  
Cell culture, in vitro bradyzoite development and conditional expression.  Parasite 
cultures were maintained in primary human foreskin fibroblasts (HFF) as previously described 
(38). To induce bradyzoite differentiation in vitro, infected cultures were subjected to alkaline 
media (pH 8.2) for indicated time periods according to (22) with media replaced every 24 h to 
maintain pH.  Conditional expression of the AP2IX-9 protein fused to the DD domain (DD=FKBP 
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106 amino acid peptide plus 3xHA epitope tag is 16.2 kDa) utilized the small molecule Shield-1 
at concentrations in media <500 nM (24), which had no adverse effect on parasite invasion or 
growth rate.   A dose of 100-500 nM Shield-1 gave equivalent levels of the DDAP2IX-9 protein in 
pH 8.2 media supplemented with Shield-1.  To determine growth rates for CTG and CTG-
DDAP2IX-9 parasites, HFF monolayers were inoculated at a 4:1 MOI, the parasites allowed to 
invade for 3 h, and then shifted to pH 8.2 media plus or minus 250nM Shield-1.  The parasite 
population in each flask was monitored in real time every 24 h for 4 days with 50 randomly 
selected vacuoles counted in triplicate at each time point and the values averaged. 
Genomic locus epitope fusions with hemagglutinin (HA) tags.  Toxoplasma ApiAP2 
factors AP2IX-9 (TGME49_306620), AP2VI-1 (TGME49_240460) and AP2IV-3 
(TGGT1_318610), were tagged at the endogenous locus with a triple copy of the HA epitope in 
the Type II Prugniaud strain lacking the KU80 gene (designated in this study as the PruQ strain) 
by homologous recombination using the pLIC-HA3x plasmid as described in (39).   
Conditional expression model for AP2IX-9.  For conditional expression, the AP2IX-9 
single exon coding region was PCR amplified from genomic DNA to incorporate in frame 
Mfe1/Sbf1 sites, which were used to clone the purified PCR fragment into the pCTDDHA3x 
plasmid provided by Dr. Striepen, University of Georgia (40).  This cloning results in the fusion 
of the FKBP peptide (11.2 kDa) and 3 copies of the HA epitope for detection (4.4 kDa) in frame 
with the N-terminal end of AP2IX-9 protein with a final fusion protein mass of ~128kDa 
(designated DDAP2IX-9).  The plasmid pCTDDHA3x-AP2IX-9 was introduced by electroporation 
into the Prugniaud strain (wild type for KU80), and also into a Prugniaud transgenic clone, 
PruIC2, expressing firefly luciferase under the BAG1 promoter (see details of the PruIC2 strain 
in ref (18)).  Transgenic parasites were selected using chloramphenicol (34µg/ml) and clones 
were isolated by limiting dilution.  To produce Type III CTG parasites expressing the conditional 
DDHA3x-AP2IX-9 allele (DDAP2IX-9), the pCTDDHA3x-AP2IX-9 plasmid was digested with 
SpeI/NotI to remove the sagCAT selectable marker and this was switched with the DHFR-TS 
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selectable marker from the pT7S4HA plasmid. The resulting pDHFR/DDHA3x-AP2IX-9 plasmid 
was introduced by electroporation into low passage CTG strain parasites, selected with 
pyrimethamine (1µM) and resistant clones isolated by limited dilution.   
Gene knockout strategies for AP2IX-9.  Transgenic parasites carrying a deletion of the 
AP2IX-9 gene were obtained in the PLK, CTG-DDAP2IX-9 transgenic, and the RHΔhxgprtΔuprt 
strains as follows.  To generate the PLK-Δap2IX-9 transgenic strain the pTCY plasmid (a kind 
gift from Dr. Striepen, University of Georgia) was first modified to expand the multiple cloning 
sites surrounding the sagCAT selectable marker (5’ KpnI-ApaI-XhoI-SalI-ClaI-HindIII--sagCAT--
3’AatII-SmaI-AvrII-NheI-BglII-SpeI) to generate the pTCY-exMCS vector.  The plasmid pTCY-
AP2IX-9KO was then constructed in this new vector by cloning the 5’ and 3’ flanking regions of 
the single AP2IX-9 coding exon; a 3,067bp PCR product (primer sequences are listed in Table 
2) amplified from Prugniaud Type II strain genomic DNA supplied the left arm using KpnI/HindIII 
to clone and a 1960bp PCR fragment down stream of the single AP2IX-9 exon was cloned by 
AatII/SpeI sites in order to supply the right arm.  The resulting pTCY-AP2IX-9KO plasmid was 
electroporated into PLK strain, transgenic parasites selected using chloramphenicol (34µg/ml), 
and cloned by limiting dilution.  To produce CTG-Δap2IX-9-[DDAP2IX-9] parasites the sagCAT 
selectable marker in pTCY-AP2IX-9KO was swapped with a phleomycin (Ble) expression 
cassette using PCR using HindIII/AvrII sites to generate the plasmid pT(ble)Y-AP2IX-9KO.  This 
Ble knockout plasmid was electroporated into CTG-DDAP2IX-9 parasites, subjected to two 
rounds of extracellular phleomycin (50µg/ml) selection and resistant parasites cloned by limiting 
dilution.  Finally, to generate an AP2IX-9 knockout in the RHΔhxgprtΔuprt strain, cosmid 
TOXP727 containing the AP2IX-9 locus was modified by recombineering to delete the single 
AP2IX-9 exon as previously described (41).  The resulting TOXP727-AP2IX-9KO cosmid was 
electroporated into RHΔhxgprtΔuprt strain, selected in chloramphenicol and resistant clones 
isolated by limiting dilution.  
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Immunofluorescence assays (IFA).  Parasites were inoculated on confluent HFF 
coverslips for indicated time and IFA assays performed as previously described (42) using the 
following primary reagents: HA (Roche; rat mAb 3F10; 1:500), biotin-labeled Dolichos biflorus 
agglutinin (1:3000, Vector labs, CA), and DAPI (0.5mg/ml).  All Alexa (Molecular Probes, CA) 
and streptavidin (Vector Labs, CA) conjugated secondary antibodies were used at 1:1000.  
Image acquisition was performed on a Zeiss Axiovert microscope equipped with 100x objective.   
 For IFA analysis of in vivo tissue cysts from murine brain, glass cover slips were treated 
with 1% polylysine for 20 min and then washed with PBS.  Tissue cysts were placed on the 
cover slips and left at room temperature (RT) for 15 min followed by incubation with trypsin 
solution (4µl of a 1mg/ml solution, Sigma-Aldrich) for 4 min at RT.  Cover slips were then fixed 
4% paraformaldehyde for 30 min, washed with PBS and permeabilized with 0.2% Triton X-100 
for 20 min.  Lastly, cover slips were blocked with 3% BSA and 5% goat serum overnight at 4°C.  
IFA was preformed using the following antibodies at 370C for 90 min: HA (Roche; rat mAb 3F10, 
1:500) and articulin 4 (polyclonal mAb, Dr Louis Weiss, 1:500) and visualized using Alexa-
conjugated secondary antibodies at 1:1000 (Molecular Probes). 
Production and purification of cysts.  Mice (Balb/cDM1) were infected by i.p. with 1x104 
parasites and 2 days post-inoculation Sulfamerazine (30mg/l, Sigma-Aldrich) was added to the 
drinking water for the duration of the experiment.  Four weeks after infection, mice were 
sacrificed and the cysts were purified from brain tissues as follows: Five mouse brains were 
washed with 10 ml PBS, placed in 10 ml 0.9% NaCl and homogenized with a potter glass 
homogenizer.  The homogenized tissue was layered on top of 25 ml Percoll buffer (45 ml 
Percoll solution and 55 ml PBS ) in a 50 ml centrifugation tube and separated by centrifugation 
(20 min at 1,500 rpm, 40C).  After centrifugation, 20 ml of the middle layer solution containing 
the cysts was transferred to a new 50 ml tube.  Cysts were washed with 30 ml of PBS by 
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centrifugation (10 min, 750 rpm, 40C).  The resulting pellet was resuspended in 1 ml PBS and 
cyst number quantified by light microscopy. 
Western analysis.  Freshly needle passed and filtered parasites were collected by 
centrifugation and total lysates made by boiling for 10 min at 950C in Laemmli buffer (42).  Each 
lane on a SDS-PAGE gel was loaded with 25x106 parasites, separated by electrophoresis and 
transferred to a nitrocellulose membrane. The blots were probed with anti-HA (Roche, 3F10, 
1:500) for AP2IX-9, stripped with Ponceau S (0.1%) and re-probed with anti-TgPCNA1 (1:1000) 
(43) to monitor nuclear TgPCNA1 as a loading control.  Proteins were detected with HRP-
conjugated secondary antibodies (Jackson ImmunoResearch, PA) and visualized using 
enhanced chemiluminescence reaction.  
Protein and RNA microarray analysis.  The AP2IX-9 DNA binding domain (amino 
acids 1142-1204) was cloned in pGEX4T3, expressed as a GST-fusion in BL21DE3 cells 
(Novagen), and purified by glutathione affinity column.  Protein binding microarrays were 
performed as previously described (12).  All RNA samples were collected as independent 
biological replicates.  RNA quality was determined using the Agilent Bioanalyzer 2100 (Santa 
Clara, CA).  Total parasite RNA was collected and prepared for hybridization on the 
ToxoGeneChip as described in (8).  Data was analyzed in Genespring GX software (v11.5, 
Agilent) and in Bioconductor (44).  Microarray data is available in the gene expression omnibus 
repository under accession GSE3630. 
Electrophoretic mobility shift assays (EMSA). Complementary single stranded DNA 
oligonucleotides that included a 5’-biotinylated nucleotide were annealed to produce DNA 
probes from 35-65bp in length.  Standard binding reactions were carried out at RT for 20 min 
using 20fmol of biotinylated DNA probe and varying concentrations of GST-AP2IX-9 protein (70-
900ng) according to manufacturer’s protocol (Pierce, IL).  Non-biotinylated competitor DNA 
probes were added at 100-300x concentrations as indicated.  Complexes were resolved on 6% 
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PAGE gel, transferred to nylon membrane and detected according to manufacturer’s protocol 
(Pierce, IL).  All EMSA oligonucleotides are listed in Table 2.3.   
Luciferase assays.  Luciferase assays were performed according to manufacturers 
protocols (Promega, Madison, WI) with modifications as previously described (18).  Briefly, HFF 
cells in T25cm2 flasks were inoculated with PruIC2 parent or PruIC2-DDAP2IX-9 transgenic 
parasites at 3:1 MOI, parasites were allowed to invade for 3 h, and the culture media changed 
to either pH 8.2 or 7.0 media plus or minus 200nM Shield-1 (Clontech).  The alkaline-shifted 
cultures were grown in non-CO2 conditions for 72 h and then harvested for whole cell lysates 
according to manufacturers protocols.  Each experimental condition was assessed in three 
independent cultures with average statistical significance for parental PruIC2 compared to the 
PruIC2-DDAP2IX-9 transgenic strain determined by the unpaired t-test.  Average luminometer 
values for the results shown in Figure 2.4B: PruIC2 parent grown as tachyzoites=674 light units; 
pH 8.2 media alone=284,476 units; pH 8.2 plus Shield-1=327,870 units.  PruIC2-DDAP2IX-9 
parasites grown as tachyzoites=216 units; in pH 8.2 media alone=56,574 units; in pH 8.2 media 
plus Shield-1=11,839.  
Chromatin immunoprecipitation and quantitative PCR.  Parasites were inoculated at 
3:1 MOI in T175cm2 flasks, allowed to invade for 3 h, rinsed 3x with Hanks balanced salt 
solution to remove free floating parasites and media replaced with pH 8.2 media supplemented 
with 200nM Shield-1 (Clontech).  ChIP-qPCR was performed by published methods (45) with 
the following modifications. Following intracellular formaldehyde crosslinking and purification of 
the nuclear fraction, lysed nuclear material was subjected to sonication (Misonix S-4000, 
cuphorn probe, 30min at 80% amplitude, 30sec ON/OFF pulse) to produce 200-1000bp 
fragments.  The soluble fraction was then isolated by centrifugation at 4°C and pre-cleared with 
protein-G dynabeads (Dynabeads, Invitrogen) before overnight incubation with rabbit anti-HA 
antibody (5µg, ab9110; Abcam).  Anti-HA-DNA complexes were purified using protein-G 
coupled magnetic beads (Dynabeads, Invitrogen) for 1 h at 4°C, subjected to salt and lithium 
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chloride washes and incubated overnight at 65°C in 1%SDS/TE to reverse cross-links.  
Samples were treated with RNase cocktail (Ambion) prior to standard phenol-chloroform 
extraction and DNA precipitation with ethanol.  Whole genome amplification (Sigma-Aldrich) 
was performed on ChIP-DNA and purified using Qiagen Mini-Elute PCR Kit.  Quantitative PCR 
(qPCR) was performed on amplified ChIP-DNA (20ng/rxn) using Fast SYBR © green master mix 
on an ABI 7900 according to manufacturers protocols.  All qPCR DNA probes were designed 
using Primer3 software (46) and amplified 75-364bp fragments.  The primer sequences can be 
found in Table 2.  Here, ChIP was performed DDAP2IX-9 (specific chromatin) or parent strains 
(non-specific chromatin).  Relative enrichment values were determined using the equation 2^-(ΔCt 
target-ΔCt non-target) where the change in Ct value of specific versus nonspecific chromatin at target 
and non-target loci was calculated. 
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Table 2.1: Parent and transgenic strains of AP2IX-9 and AP2IV-3 
 
 
  
Designated name in this study Genotype Reference
Prugniaud (Pru) Type II strain with Δhxgprt Martrou, 1965
Prugniaud-Δku80 (PruQ) Type II strain with Δhxgprt, Δku80 Fox, 2011
Pru-IC2
Type II trangenic strain with Δhxgprt, 
expressing BAG1::firefly luciferase transgene Behnke, 2008
PLK Type II strain ATCC#: 50841
ME49B7 Type II strain reference strain, ToxoDB.org
CTG Type III strain ATCC#: 50842
RHΔhxgprt, Δuprt Δhxgprt, Δuprt (Type I strain) Bohne, 1997
Name in this study experimental use Parent strain Transgene/selectable marker Drug Selection Clone #
PruQ-AP2IX-9HA endogenous expression of AP2IX-9 PruQ endogenous promoter::AP2IX-9(3xHA)/DHFR-TS pyrimethamine B6, B7
PruQ-AP2VI-1HA endogenous expression of AP2VI-1 PruQ endogenous promoter::AP2VI-1(3xHA)/DHFR-TS pyrimethamine B6, B7
Pru-DDAP2IX-9 conditional expression of AP2IX-9 Pru tub::(DD-3xHA)-AP2IX-9/sagCAT chloramphenicol A6, B4
CTG-DDAP2IX-9 conditional expression of AP2IX-9 CTG tub::(DD-3xHA)-AP2IX-9/DHFR-TS pyrimethamine IVB4
PruIC2-DDAP2IX-9 conditional expression of AP2IX-9 PruIC2 tub::(DD-3xHA)-AP2IX-9/sagCat chloramphenicol D5
PLK-Δap2IX-9 knockout of AP2IX-9 PLK TCY-AP2IX-9KO/sagCat chloramphenicol IC2, IC3
RH-Δap2IX-9 knockout of AP2IX-9 RHΔhxgprt, Δuprt TOXP727- AP2IX-9KO/sagCAT chloramphenicol IC3, IIC2, IIC3
CTG-Δap2IX-9-[DDAP2IX-9] knockout of AP2IX-9 CTG-DDAP2IX-9 T(ble)Y-AP2IX-9KO/phleomycin pyrimethamine, phleomycin B3, C2
PruQ-AP2IV-3HA endogenous expression of AP2IV-3 PruQ endogenous promoter::AP2IV-3(3xHA)/HXGPRT/loxP pyrimethamine D8
Published parent and trangenic strains used in this study
Transgenic strains produced for this study
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Table 2.2: AP2IX-9 knockout frequencies. 
 
 
 
  
Strain designation Clonal lineage Knockouts/Total screened Frequency of knockout Total electroporations Transgene/Selectable marker
11/12 91.6% 1 TOXP727- AP2IX-9KO/sagCAT
1/17 5.9% 1 PSBL68-AP2IX-9KO/sagCAT
PLK Type II strain 16/22 72.7% 1 TCY-AP2IX-9KO/sagCat
12/48  (30uM Shield-1) 25.0% 1
4/48  (No Shield-1) 8.3% 1
Totals 50/147 34.0% 5
Strain designation Clonal lineage Knockouts/Total screened Frequency of knockout Total electroporations Transgene/Selectable marker
GT1 Type I strain polyclonal negative 0% 2 TCY-AP2IX-9KO/sagCat
polyclonal negative 0% 2 TCY-AP2IX-9KO/sagCat
0/88 0% 1 TCY-AP2IX-9KO/sagCat
ME49B7 Type II strain polyclonal negative 0% 2 TCY-AP2IX-9KO/sagCat
polyclonal negative 0% 2 TCY-AP2IX-9KO/sagCat
0/175 (0%) 0% 2 T(ble)Y-AP2IX-9KO/phleomycin
Totals 0/263 0% 11
Unsuccessful Knockout Attempts
Prugniaud (Pru)
CTG
Type II strain
Type III strain
Succesful Knockout Attempts
RHΔhxgprt, Δuprt Type I strain
CTG-DDAP2IX-9 Type III strain T(ble)Y-AP2IX-9KO/phleomycin
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Table 2.3: Oligonucleotides used in AP2IX-9 and AP2IV-3 studies.  
 
 
  
Oligonucleotide function Gene/locus Orientation Oligonucleotides (5'->3')
Tagging of endogenous gene loci with 
3xhemagglutinin (HA) epitope tags
LIC 5' primer for AP2IX-9 AP2IX-9 Forward TACTTCCAATCCAATTTAATGGCTTCTGTCTTTGCTGTCTCGGTC
LIC 3' primer for AP2IX-9 AP2IX-9 Reverse TCCTCCACTTCCAATTTTAGCGGCTGACGTTGTTCGCGCTC
LIC 5' primer to check for 5' recombination AP2IX-9 Forward TATCAATTGCAGAGAGTGCCGTGAACAGTC
LIC-HA 3' primer to check for 3' recombination AP2IX-9 Reverse CGCATATCGGGCACATCATAGGGAT
LIC 5' primer for AP2VI-1 AP2VI-1 Forward TACTTCCAATCCAATTTAATGCGAACAGACATTCACATCGGACTTATCTCCAAC
LIC 3' primr for AP2VI-1 AP2VI-1 Reverse TCCTCCACTTCCAATTTTAGCCGCGTGGGCCGCTGATACTTCAGC
LIC AP2VI-1 5' primer to check for recombination AP2VI-1 Forward GAGAAGCAAGAGGCCACAGAGGCC
LIC 5' primer for AP2IV-3 AP2IV-3 Forward TACTTCCAATCCAATTTAATGCACTGTCGATTGGTACCGGATCTGG
LIC 3' primr for AP2IV-3 AP2IV-3 Reverse TCCTCCACTTCCAATTTTAGCCGCTGCGTTGTCCCCTGATGAAG
LIC AP2IV-3 5' primer to check for recombination AP2IV-3 Forward GCAGGGGCATCCACGACTACG
Overespression construct
AP2IX-9 CDS cloning into pCTDDHA3 AP2IX-9 CDS Forward TATCAATTGATGCCAAGGCCAGTGCCCGCTGCCATTCAG
AP2IX-9 CDS cloning into pCTDDHA3 AP2IX-9 CDS Reverse ATACCTGCAGGTTAGGCTGACGTTGTTCGCGCTCGTCTCTC
AP2IX-9 knockout constructs
5' MCS pTCY linker pCTY plamsid manipulation Forward CGGGCCCCCCCTCGAGGTCGACGGTATCGATA
5' MCS pTCY linker pCTY plamsid manipulation Reverse TCGAATAGCTATGGCAGCTGGAGCTCCCCCCCGGGCCATG
3' MCS pTCY linker pCTY plamsid manipulation Forward CCCCGGGCCTAGGGCTAGCAGATCTA
3' MCS pTCY linker pCTY plamsid manipulation Reverse GATCATCTAGACGATCGGGATCCGGGCCCCTGCA
5' AP2IX-9 pTCY 5' UTR of AP2IX-9 Forward TATGGTACCATATGGGCCACACGCTTTGGGTTCTTAG
5' AP2IX-9 pTCY 5' UTR of AP2IX-10 Reverse ATAAAGCTTGGTGAGGATGTCTGTTTCATG
3' AP2IX-9 pTCY 3' UTR of AP2IX-11 Forward TATGACGTCCGGTCAGTGTCTCAGATTGTGCGT
3' AP2IX-9 pTCY 3' UTR of AP2IX-12 Reverse ATAACTAGTCCCACACCGAAGTATCCAACTG
AvrII linker for 5'AP2IX-9_pCTY_3'AP2IX-9 pCTY plamsid manipulation Forward AGCTTAAACCTAGGTTT
AvrII linker for 5'AP2IX-9_pCTY_3'AP2IX-10 pCTY plamsid manipulation Reverse AGCTAAACCTAGGTTTA
Insert phleomycin marker pHBG plasmid Forward TATCCTAGGCCTCGACTACGGCTTCCATTGGCAAC
Insert phleopmycin marker pHBG plasmid Reverse ATAATTTAAATATACGACTCACTATAGGGCGAATTGG
Cosmid recombineering Cosmid recombineering Forward CGCGTGCACAGTCACTCGAGCGGCGTAGTTCGGCCATGCCGTTGGAGGGACCTCGACTACGGCTTCCATTGGCAAC
Cosmid recombineering Cosmid recombineering Reverse CGCATGCCGCGGCACGCTGCGCAGTACAACCGGTTGAAACCTGACTTCTCATACGACTCACTATAGGGCGAATTGG
Recombinant protein construct
pGEX4T3 AP2IX-9 recombinant protein PBM Forward ATACCATGGATCCCGAGCTGTCCGAGGTGTTTATTTCGAC
pGEX4T3 AP2IX-9 recombinant protein PBM Reverse ATGGTATGCGGCCGCAGACACTGACCGTCCGAAATCTCTCTC
Target regions for ChIP-qPCR
ChIP-qPCR BAG1 region 1 Forward GCCAGTCGAAAGCCATTAAA
ChIP-qPCR BAG1 region 1 Reverse TCACGCGTTCACTGCTACTC
ChIP-qPCR BAG1 region 2 Forward CGTCCTCTCTGTCCACGAAC
ChIP-qPCR BAG1 region 2 Reverse ATGGGGAACTGGAGGAAGAT
ChIP-qPCR BAG1 region 3 Forward AGGTCGCCCGTCTTATTCTT
ChIP-qPCR BAG1 region 3 Reverse ACCCAAACATGGAGTTCAGG
ChIP-qPCR BAG1 region 4 Forward GACGAGTTCCCGTTTTTCCT
ChIP-qPCR BAG1 region 4 Reverse ACAGAGGTCGCTGCGTAGAC
ChIP-qPCR BAG1 region 5 Forward CTTTTGCCAAAGGAGACCTG
ChIP-qPCR BAG1 region 5 Reverse ATGCCACTGAGCTACACACG
ChIP-qPCR BAG1 region 6 Forward GTCGTCTGTGAGAGCGTCAA
ChIP-qPCR BAG1 region 6 Reverse GACCTGGGCTTTGCAGATAA
ChIP-qPCR ChrVI non-target 1 Forward CAGGTTCCACGTCTTCGTGAACC
ChIP-qPCR ChrVI non-target 1 Reverse GGGCATGCGAAGGATCGTACTC
ChIP-qPCR ChrIa non-target 2 Forward GGATGACACGCTGCGATGACC
ChIP-qPCR ChrIa non-target 2 Reverse GGGCGGAAGTCGCTGTTTCTCAC
ChIP-qPCR ChrVI non-target 3 Forward GGCTGGCGAAGAAGTTTCCGC
ChIP-qPCR ChrVI non-target 3 Reverse CACGAGAGACGAGGAACTGCG
Semi quantitive RT-PCR 
RT-PCR DDAP2IX-9 Forward GGAACCTAGGTACCCGTACG
RT-PCR DDAP2IX-9 Reverse ACCTTGCTGCTGCCCTGATGC
RT-PCR AP2IX-9 endogenous Forward GCCTTCGTGGAATCCTAAAATGC
RT-PCR GAPDH Forward GTCAATCATTCTGTCAATTCGA
RT-PCR GAPDH Reverse ACACCATGTAGTCCAGGGACATG
RT-PCR BAG1 Forward TGAGCGAGTGTCCGGTTATTT
RT-PCR BAG1 Reverse TAGAACGCCGTTGTCCATTG
RT-PCR LDH2 Forward ACAATGGCCCAGGCATTCT
RT-PCR LDH2 Reverse CAATAAACATATCGTGAAGCCCATA
DNA probes for EMSA
EMSA PBM validation Forward TGACGGTGCGTGCAGTGTAACAGCGCACTCTACAT
EMSA PBM validation Reverse ATGTAGAGTGCGCTGTTACACTGCACGCACCGTCA
EMSA PBM motif scrambled Forward CGGGTTGAATATGGCGAAACTCGCCGGCCTACTAT
EMSA PBM motif scrambled Reverse ATAGTAGGCCGGCGAGTTTCGCCATATTCAACCCG
EMSA Brady NTPase Forward TAATCGATAGATACCTGACGGTGCGTGTGTGCGTGCAGCGCACTCTACATCGTTCGAATATTGGA
EMSA Brady NTPase Reverse TCCAATATTCGAACGATGTAGAGTGCGCTGCACGCACACACGCACCGTCAGGTATCTATCGATTA
EMSA Brady NTPase AAAA Forward TGACGGTGCGTGAAAACGTGCAGCGCACTC
EMSA Brady NTPase AAAA Reverse GAGTGCGCTGCACGTTTTCACGCACCGTCA
EMSA Brady NTPase TGTG Forward TGACGGTGCGTGTGTGCGTGAAAAGCACTC
EMSA Brady NTPase TGTG Reverse GAGTGCTTTTCACGCACACACGCACCGTCA
EMSA BAG1 Forward TCGCCTGCTCACTGGCGACGGTACTGGCCGCACGGTTTCACGATCCTGAGGTCGGCGA
EMSA BAG1 Reverse TCGCCGACCTCAGGATCGTGAAACCGTGCGGCCAGTACCGTCGCCAGTGAGCAGGCGA
EMSA BAG1 unlabeled Forward CACTGGCGACGGTACTGGCCGCACGGTTTCACG
EMSA BAG1 unlabeled Reverse CGTGAAACCGTGCGGCCAGTACCGTCGCCAGTG
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Table 2.4: AP2IX-9 microarray data, FC>1.5, p<0.05. 
 
 
  
Gray hightlight are genes included in Fig. 2.8A, FC>2, p<0.05
Genbank
Fold Change (FC)                            
(OE vs WT) 
CTG-DDAP2IX-9                       
(RMA Value OE)
CTG                               
(RMA Value WT) Gene description
TGME49_059020 -7.92 128.21 1014.91 BAG1
TGME49_009760 -5.83 36.83 214.84 hypothetical protein
TGME49_016140 -5.40 66.67 355.40 ankyrin repeat-containing protein
TGME49_091040 -4.97 95.96 476.19 LDH2
TGME49_068860 -4.24 17.05 71.90 ENO1
TGME49_093790 -4.20 65.11 273.05 hypothetical protein
TGME49_002020 -4.03 67.41 271.98 DnaK-TPR
TGME49_007150 -3.67 92.95 341.39 SAG2D (=SRS49C)
TGME49_090970 -3.66 118.55 435.13 serine palmitoyltransferase
TGME49_032400 -3.48 21.65 75.39 PAN domain-containing protein
TGME49_007210 -3.47 427.07 1486.84 hypothetical protein
TGME49_061650 -3.47 99.12 344.77 hypothetical protein
TGME49_080570 -3.32 169.21 561.13 bradyzoite surface antigen
TGME49_068210 -3.11 108.44 336.99 AGC kinase
TGME49_007140 -3.10 70.18 217.97 SAG2X (SRS49B)
TGME49_052640 -2.95 30.01 88.23 TgPMA1
TGME49_007130 -2.76 139.28 384.76 SAG2Y (= SRS49A)
TGME49_112320 -2.63 506.99 1335.49 hypothetical protein
TGME49_018910 -2.54 69.08 175.19 hypothetical protein
TGME49_055210 -2.54 43.73 110.98 peroxisomal-type ATPase, putative
TGME49_068220 -2.44 38.00 93.12 hypothetical protein
TGME49_119340 -2.31 113.20 261.54 kelch motif domain-containing protein
TGME49_080580 -2.24 184.29 412.00 SAG4.2 (=p18)
TGME49_053330 -2.24 517.55 1160.13 BPK1
TGME49_091910 -2.22 32.36 71.36 hypothetical protein
TGME49_090000 -2.21 50.06 110.72 hypothetical protein
TGME49_040930 -2.17 114.46 249.48 molybdenum cofactor biosynthesis protein c
TGME49_067670 -2.17 87.46 189.52 hypothetical protein
TGME49_025290 -2.07 95.51 197.53 B-NTPase
TGME49_008730 -2.05 236.23 485.58 MCP4
TGME49_003290 -2.05 506.10 1036.78 hypothetical protein
TGME49_106450 -2.04 88.10 180.74 short chain dehydrogenase family protein
TGME49_008740 -2.04 786.80 1604.74 microneme protein, putative
TGME49_089920 -2.03 684.40 1378.28 hypothetical protein
TGME49_009980 -2.00 195.20 390.53 Rhoptry kinase family protein ROP42 (incomplete catalytic triad)
TGME49_027630 -1.93 162.57 314.33 hypothetical protein
TGME49_017400 -1.92 40.84 78.27 hypothetical protein
TGME49_031160 -1.91 835.47 1592.91 hypothetical protein
TGME49_115560 -1.91 35.83 68.31 ABC transporter
TGME49_086460 -1.90 273.12 520.07 hypothetical protein
TGME49_014980 -1.90 40.56 73.49 hypothetical protein
TGME49_113050 -1.89 100.18 188.89 short-chain dehydrogenase/reductase family protein
TGME49_113940 -1.89 92.16 173.91 hypothetical protein
TGME49_042730 -1.82 124.38 226.43 guanylate kinase
TGME49_104940 -1.80 43.72 78.81 hypothetical protein
TGME49_118880 -1.78 60.98 108.34 hypothetical protein
TGME49_024800 -1.77 116.05 205.38 hypothetical protein
TGME49_115510 -1.75 160.81 281.25 hypothetical protein
TGME49_013880 -1.75 31.04 54.25 hypothetical protein
TGME49_086750 -1.73 111.63 192.74 MA3 domain protein
TGME49_077230 -1.73 127.53 220.27 hypothetical protein
TGME49_047360 -1.71 608.56 1036.61 lipid phosphate phosphohydrolase 3
TGME49_025540 -1.69 270.54 456.90 hypothetical protein
TGME49_007890 -1.66 50.41 83.80 hypothetical protein
TGME49_116360 -1.66 60.56 100.72 hypothetical protein
TGME49_031960 -1.66 75.05 124.32 ppg3
TGME49_002140 -1.66 63.35 105.04 enoyl-CoA hydratase/isomerase family protein
TGME49_017530 -1.64 351.37 577.90 hypothetical protein
TGME49_002180 -1.64 154.75 253.34 hypothetical protein
TGME49_015770 -1.63 232.44 379.07 Rhoptry kinase family protein ROP8 (incomplete catalytic triad)
Conditions for microarray: pH8.2 + Shield-1 (200nM)
Strains: CTG (WT), CTG-DDAP2IX-9 (OE)
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Table 2.4 continued: 
 
 
 
  
Genbank
Fold Change (FC)                            
(OE vs WT) 
CTG-DDAP2IX-9                       
(RMA Value OE)
CTG                               
(RMA Value WT) Gene description
TGME49_061370 -1.63 43.98 71.49 hypothetical protein
TGME49_013450 -1.62 330.90 537.64 hypothetical protein
TGME49_061400 -1.59 158.46 250.99 hypothetical protein
TGME49_049030 -1.59 46.46 74.03 endonuclease/exonuclease/phosphatase domain-containing protein
TGME49_068220 -1.59 64.11 101.62 hypothetical protein
TGME49_015090 -1.58 69.17 108.57 conserved hypothetical ATP-binding domain-containing protein
TGME49_021180 -1.57 188.32 294.84 transmembrane domain-containing protein
TGME49_005160 -1.57 107.89 168.64 hypothetical protein
TGME49_002050 -1.56 40.82 63.89 hypothetical protein
TGME49_037230 -1.56 599.92 928.13 hypothetical protein
TGME49_060620 -1.56 65.42 102.18 hypothetical protein
TGME49_040950 -1.56 112.49 175.17 hypothetical protein
TGME49_081920 -1.55 83.31 129.57 vacuolar ATP synthase subunit D
TGME49_033490 -1.55 117.53 182.75 hypothetical protein
TGME49_045490 -1.55 155.94 240.24 microneme protein 8
TGME49_024170 -1.55 78.06 120.84 SRS domain-containing protein
TGME49_092050 -1.55 38.60 59.72 EF hand domain-containing protein
TGME49_007880 -1.54 62.45 95.98 hypothetical protein
TGME49_090700 -1.54 106.16 162.71 hypothetical protein
TGME49_109930 -1.52 49.98 76.14 alpha-N-acetylgalactosaminidase
TGME49_017740 -1.52 166.48 250.00 oxoacyl-ACP reductase
TGME49_065770 -1.52 43.14 65.43 hypothetical protein
TGME49_093780 -1.52 259.99 394.45 hypothetical protein
TGME49_053930 -1.51 247.02 373.05 hypothetical protein
TGME49_119360 -1.51 46.51 70.38 SRS17
TGME49_063320 -1.51 571.07 859.95 hypothetical protein
TGME49_027890 -1.51 108.30 162.95 hypothetical protein
TGME49_097160 -1.51 92.10 138.22 hypothetical protein
TGME49_094970 -1.51 97.25 146.27 hypothetical protein
TGME49_034270 -1.50 66.80 100.76 hypothetical protein
TGME49_033200 1.51 154.69 102.47 hypothetical protein
TGME49_109100 1.52 126.12 82.77 hypothetical protein
TGME49_050940 1.52 321.86 211.16 hypothetical protein
TGME49_064220 1.53 118.79 77.70 hypothetical protein
TGME49_092270 1.53 185.50 121.13 SAG5A (=SRS36C )
TGME49_095020 1.54 212.32 137.63 hypothetical protein
TGME49_077490 1.55 125.37 80.74 hypothetical protein
TGME49_019570 1.56 60.25 38.66 hypothetical protein
TGME49_107030 1.57 257.47 163.97 purine nucleoside phosphorylase
TGME49_040540 1.58 98.00 61.93 hypothetical protein
TGME49_101890 1.58 101.18 64.05 hypothetical protein
TGME49_044400 1.62 217.51 134.68 hypothetical protein
TGME49_120170 1.63 51.95 31.88 SRS16E (= SRS6)
TGME49_055060 1.65 3924.36 2378.40 cytochrome oxidase I
TGME49_095480 1.69 350.58 207.19 hypothetical protein
TGME49_091860 1.70 197.26 115.95 hypothetical protein
TGME49_051870 1.71 73.32 43.90 histone H2B
TGME49_049180 1.71 1735.37 1014.25 bifunctional dihydrofolate reductase / thymidylate synthase
TGME49_048270 1.77 126.93 70.63 zinc finger (CCCH type) protein
TGME49_105160 1.78 148.20 82.42 histone H2B
TGME49_024760 1.83 328.72 180.20 SRS40E (= SRS4)
TGME49_086010 1.84 990.35 538.25 hypothetical protein
TGME49_080500 8.26 650.87 78.75 sulfate transporter
TGME49_106620 117.05 1171.63 10.05 AP2IX-9
Conditions for microarray: pH8.2 + Shield-1 (200nM)
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Table 2.5: AP2IX-9 microarray data, FC>2, p<0.05 
 
 
 
 
 
 
 
  
Genbank Description # of AP2IX-9 motifs in promoter color in Fig. 2.8A
TGME49_059020 BAG1 14 partial (5 of 6 bp)
TGME49_009760 hypothetical protein 1
TGME49_016140 ankyrin repeat-containing protein 3
TGME49_091040 LDH2 3
TGME49_068860 ENO1 2
TGME49_093790 hypothetical protein 1
TGME49_002020 DnaK-TPR 6
TGME49_007150  SAG2D (=SRS49C) 2
TGME49_090970 serine palmitoyltransferase 0
TGME49_032400 PAN domain-containing protein 1
TGME49_007210 hypothetical protein 4
TGME49_061650 hypothetical protein 5
TGME49_080570 bradyzoite surface antigen 3
TGME49_068210 AGC kinase 4
TGME49_007140 SAG2X (SRS49B) 2
TGME49_052640 TgPMA1 2
TGME49_007130 SAG2Y (= SRS49A) 1
TGME49_112320 hypothetical protein 3
TGME49_018910 hypothetical protein 1
TGME49_055210 peroxisomal-type ATPase, putative 6
TGME49_068220 hypothetical protein 2
TGME49_119340 kelch motif domain-containing protein 1
TGME49_080580 SAG4.2 (=p18) 3
TGME49_053330 BPK1 5
TGME49_091910 hypothetical protein 1
TGME49_090000 hypothetical protein 6
TGME49_040930 molybdenum cofactor biosynthesis protein c 2
TGME49_067670 hypothetical protein 1
TGME49_025290 B-NTPase 5
TGME49_008730 MCP4 2
TGME49_003290 hypothetical protein 4
TGME49_106450 short chain dehydrogenase family protein 3
TGME49_008740 microneme protein, putative 1
TGME49_089920 hypothetical protein 6
TGME49_009980 Rhoptry kinase family protein ROP42 1
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Figure 2.1:  The expression of 24 ApiAP2 mRNAs regulated during in vitro tachyzoite to 
bradyzoite development. 
(A) Heatmap showing mRNA levels for ApiAP2 mRNAs that have >2 fold change in alkaline 
media (pH 8.2) and/or compound 1 (3 µM) bradyzoite induction conditions in at least one of 
three major genetic lineages (Type I=GT1, Type II=ME49, Type III=CTG; for microarray dataset 
see ref (18).  Relative mRNA levels obtained from bradyzoite-induced cultures compared to the 
mRNA level in the matching tachyzoite strain are shown.  Fold change color scale is indicated: 
green=down-regulated; red=up-regulated; black=no mRNA change compared to tachyzoites.  
Fourteen of these AP2s were previously identified as periodic in the tachyzoite cell cycle (8).  
Note that 13 of 14 cell cycle AP2s with modulated expression (up or down) during bradyzoite 
differentiation had maximum mRNA levels in late S to mitotic periods of tachyzoite replication 
(cell cycle peak times indicated on left, see also ref (8).  The predicted protein sizes with the 
position of the ApiAP2 domain(s) indicated by black boxes for all included proteins are indicated 
(11).  (B) mRNA panel: AP2IX-9HA mRNA could be detected in alkaline-induced PruQ-AP2IX-
9HA clones (48 h in pH 8.2 media).  AP2IX-9 primers are designed from a single exon, while 
GAPDH mRNA primers span a 432bp intron (TGME49_089690) (See Table 2.3 for primer 
designs).  PCR fragments generated for GAPDH were included as loading and template quality 
controls. The presence of a larger GAPDH PCR fragment would indicate possible genomic DNA 
contamination (g lane indicates the genomic DNA fragment size), as the smaller GAPDH 
fragment is produced only from mRNA sequence.  The absence of bands in the no reverse 
transcriptase controls (lane -) also indicate the RNA templates were DNA-free.  Protein panel: 
AP2IX-9HA tagged protein (endogenous promoter control) was highly expressed only in alkaline-
stressed PruQ-AP2IX-9HA transgenic parasites (lane Bz=72h post-infection in pH 8.2 media) 
and not in PruQ-AP2IX-9HA tachyzoites (lane Tz=40 h post-infection in pH 7.0 media).  Staining 
for Toxoplasma nuclear protein TgPCNA1 is included as a loading control.  Molecular mass 
standards (kDa) are indicated to the right.  Note AP2IX-9HA is a larger mass than currently 
annotated (ToxoDB.org; 112 kDa prediction plus 4.4kDa 3xHA tag) due to mis-prediction of an 
intron, which was confirmed by sequencing of AP2IX-9 cDNA fragments (not shown).  (C) PruQ 
transgenic clones epitope tagged with 3xHA by genetic knock-in at the endogenous AP2IX-9 or 
the AP2VI-1 locus were used to individually infect mice.  At four weeks post-infection murine 
brain cysts were purified for immunofluorescent analysis of expression (see Materials and 
Methods for full details).  No expression of AP2IX-9HA was observed in any tissue cyst, while all 
cysts stained positive for AP2VI-1HA.  Antibodies against mouse α-articulin 4 included here allow 
visualization of the tissue cyst and was used as a co-stain in AP2IX-9HA IFAs.   
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Figure 2.2:  Toxoplasma AP2IX-9 and AP2IV-3 are nuclear factors induced by alkaline-pH 
stress.  Both AP2IX-9 and AP2IV-3 were C-terminally tagged at the endogenous locus via 
homologous recombination in the PruΔku80 strain (designated PruQ).  Transgenic PruQ-AP2IX-
9HA and PruQ-AP2IV-3HA parasites grown in HFF cell monolayers were co-stained with anti-HA 
antibody (red for AP2IX-9HA expression), biotin-labeled Dolichos biflorus agglutinin (DBA; green 
for the presence of cyst wall), and DAPI (blue for genomic DNA).  (A) After exposure to pH 8.2 
media, AP2IX-9HA protein was detected exclusively in the parasite nucleus (co-positive for 
DAPI).  Few vacuoles were positive for AP2IX-9HA expression in parasites grown under 
tachyzoite conditions (12% pH 7.0 media). Note that AP2IX-9HA staining declined after 2 days in 
both the number of vacuoles positive and the intensity of nuclear fluorescence. (B) PruQ-AP2IV-
3HA localizes exclusively to the nucleus when induced by pH 8.2 and is nearly absent from the 
tachyzoite (2% HA+, not shown). HA- and DBA-positive vacuoles (%) for each condition are 
indicated on the right.  Note that AP2IX-9HA staining declined after 2 days in both the number of 
vacuoles positive and the intensity of nuclear fluorescence. 
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Figure 2.3:  AP2IX-9 binds to DNA with sequence specificity. 
(A) Sequence logo representation of the position weight matrices generated by the Seed and 
Wobble algorithm from probing an Agilent DNA microarray with purified GST-IX-9 protein.  The 
three related DNA motifs identified a 6bp consensus sequence CAGTGT.  (B) An 
electrophoretic mobility shift assay was performed with 0, 0.5 and 2.5 µg of purified GST-IX-9 
protein and 20fmol of 59bp 5’-biotin-labeled probe containing the CAGTGT motif or a scrambled 
probe (Scram; see Table 2.3 for all sequence designs). The arrow denotes a single band with 
slower electrophoretic migration only observed when GST-IX-9 is incubated with the CAGTGT 
but not the scrambled probe.   
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Figure 2.4:  AP2IX-9 binds functional sequence elements of the bradyzoite NTPase (B-
NTPase) promoter. 
Recombinant GST-AP2IX-9 protein binds DNA (arrow) carrying the B-NTPase CRE in a dose 
dependent manner and was inhibited by competition with unlabeled mut 4 DNA but not with mut 
3 DNA.  The probe and competitive DNA sequences used here duplicate key features of the 
CRE sequence controlling the B-NTPase promoter (probe) and two mutant promoters (mut 3 
and 4) previously tested for activity in luciferase reporter assays (in vivo*, promoter mutations 
are underlined; see ref (18) for original luciferase results).  Lane 1, biotin-labeled probe alone; 
lanes 2-4, 0.1, 0.3 or 0.9 µg of GST-IX-9; lanes 5–7, probe plus 0.3µg GST-IX-9 and 50-, 100- 
or 300-fold unlabeled mutant 3 competitor DNA; Lanes 8-10, probe plus 0.3µg GST-IX-9 and 
50-, 100- and 300-fold unlabeled mutant 4 DNA.  Black triangles represent increasing amounts 
of protein or unlabeled competitor DNA fragments.   
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Figure 2.5:  Targeted disruption of the AP2IX-9 gene in lab-adapted strains increases 
tissue cyst formation in alkaline media.  
Dolichos bifluorus agglutinin (DBA) positive vacuoles in RHΔhxgrt,Δuprt,Δap2IX-9 and 
PLKΔap2IX-9 transgenic parasites after in vitro bradyzoite induction were counted in triplicate.  
Tissue cyst number was determined after 4 days of CO2 starvation for the RHΔhxgrtΔuprt strain 
background or 3 days in alkaline media (pH 8.2) media for the PLK strains.  Results reflect the 
average of two independent clones in each knockout strain.  Tissue cyst counts for the parent 
strains RHΔhxgrtΔuprt (22) and PLK (23) are included.  The legend indicates strain genetic 
background; RHΔhxgrtΔuprt=grey bars, PLK=black bars.  Statistical significance compared to 
parental strain was determined using the unpaired two-tailed Student’s t-test (***: p-value 
=0.006).   
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Figure 2.6:  The development of a conditional expression model for AP2IX-9 in the 
Prugniaud strain.  (A) Schematic of the AP2IX-9 conditional expression design.  The DDHA3x 
sequence was N-terminally fused to the single coding exon of AP2IX-9 (designated DDAP2IX-9).  
The construct was driven by the Toxoplasma α-tubulin promoter and terminated with the DHFR-
TS 3’-untranslated region.  The DDAP2IX-9 expression construct was transfected into the 
Prugniaud strain (Pru) and stable clones obtained under 20µM chloramphenicol selection in the 
absence of Shield-1. (mRNA panel)  Total RNA purified from Pru-DDAP2IX-9 parasites was 
reverse transcribed and relative levels of mRNA compared following limited PCR with primers 
specific for the DDAP2IX-9 transgene.  Expression was assessed in parasites cultured under 
tachyzoite (pH 7.0 for 24 h) and alkaline induction conditions (pH 8.2 for 48 h) with or without 
100nM of Shield-1.  Constitutive GAPDH mRNA was included as a control and was evaluated 
as in Figure 2.1.  (protein panel) Following a limited invasion (3 h), Pru-DDAP2IX-9 parasites 
were shifted into alkaline media (pH 8.2 lanes) for 72h plus or minus 250nM Shield-1 and 
compared to parasites grown in standard pH 7.0 media (24 h growth +/- Shield-1).  Note that 
DDAP2IX-9 expression was detected in parasites grown in either media condition when Shield-1 
was added especially in pH 8.2 media, which combines natural and Shield-1 influences leading 
to sustained high levels of DDAP2IX-9.  Each gel lane was loaded with 25x106 purified parasites 
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lysed in SDS-PAGE buffer.  Following transfer to nitrocellulose the membrane was probed with 
anti-HA antibody, stripped and re-probed with a rabbit anti-PCNA1 antibody as a loading 
control.  (B) Pru-DDAP2IX-9 parasites were cultured in tachyzoite (pH 7.0 media for 24 h) or 
bradyzoite-induction conditions (pH 8.2 for 72 h) plus or minus Shield-1 (0, 100nM, 500nM) and 
then examined by immunofluorescence for DDAP2IX-9 expression (red).  Red stain=anti-HA 
antibody and blue=DAPI staining.  DIC images are shown for reference with scale bar=5 µm.  
(C)  Expression of DDAP2IX-9 reduces the occurrence of tissue cysts in vitro.  HFF cells were 
grown on glass coverslips and parasites allowed to invade for  3 h (1:1 MOI).  Pru-DDAP2IX-9 
parasites were pretreated for 6 h with 250 nM Shield-1 prior to shifting the cultures into pH 8.2 
media with (black bars) or without (grey bars) 250nM Shield-1 for 72h.  Induction of tissue cysts 
by pH 8.2 media in the Pru-parental strain was robust and unaffected by Shield-1 addition.  All 
experimental conditions were run in triplicate with 50 vacuoles/experiment counted and scored 
for a full DBA staining. The average results from two independent transgenic clones (A6 and 
B4) are shown.  A significant 2-fold difference in tissue cysts number was observed between the 
Pru-parent and Pru-DDAP2IX-9 parasites (Student’s two-tailed t-test, *** p-value <0.001).  
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Figure 2.7: Overexpression of AP2IX-9 inhibits tissue cyst formation and promotes 
alkaline-resistant parasite growth. (A) Stimulation of tissue cyst formation in parental Type III 
CTG and CTG-DDAP2IX-9 transgenic parasites was compared 72 h post-shift into pH 8.2 media 
with or without 250nM Shield-1.  The addition of Shield-1 reduced tissue cyst counts ~5-fold in 
CTG-DDAP2IX-9 parasites.  Statistical significance was evaluated using the unpaired t-test 
between the parent and the transgenic strain (***: p-value <0.001; **: p-value<0.01; n=5).  (B) 
The effect of stabilizing DDAP2IX-9 with Shield-1 on parasite growth rates was determined by 
measuring the average vacuole size of CTG parent versus CTG-DDAP2IX-9 parasites.  Parental 
CTG is shown in white bars; no Shield-1=light dots, plus 250 nM Shield-1=open bars.  CTG-
DDAP2IX-9 parasites; no Shield-1=grey bars, plus Shield-1=black bars.  Due to host cell lysis the 
vacuole size for CTG-DDAP2IX-9 parasites was not determined at 96 h (n/a). (Inset gel) 
DDAP2IX-9 was induced to detectable levels by pH 8.2 media alone and to higher levels when 
Shield-1 was added.  Anti-PCNA1 antibody staining was included as a loading control.  
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Figure 2.8:  AP2IX-9 regulates key features of the bradyzoite genetic program. 
(A) Nearly three dozen mRNAs (35) are significantly down-regulated (fold change shown) in 
CTG-DDAP2IX-9 parasites compared to CTG parental controls under pH 8.2 media plus Shield-1 
induction conditions.  BAG1 mRNA was the most repressed along with other known bradyzoite 
mRNAs: LDH2=#4 mRNA, ENO1=#5, SAG2D=#8, SAG4.2=#23, BK1=#24, and B-NTPase=#29 
(see Table 2.5 for full gene list).  Colored boxes indicate the number of AP2IX-9 motifs present 
in each promoter (2kbp upstream of ATG start).  (B) DDAP2IX-9 expression represses induction 
of a firefly luciferase transgene controlled by the BAG1 promoter (-1195bp region)(18).  
Luciferase activity in whole cell lysates from PruIC2 parent and PruIC2-DDAP2IX-9 parasites 
was determined at 72 h following shift to pH 8.2 media plus or minus 200 nM Shield-1 and 
compared to the appropriate pH 7.0 controls (data presented as the ratio pH8.2/7.0, see 
Materials and Methods for average light unit values).  Grey bars=PruIC2-DDAP2IX-9 parasites; 
black bars=PruIC2 parent (***: p-value <0.001)  (C) An EMSA was performed with 0, 70, 200 
and 600ng (lanes 1-4) purified GST-IX-9 and 20fmol of 59bp 5’-biotin-labeled probe containing 
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the BAG1 CRE sequence (5’-TACTGG-3’/3’ATGACC-5’) (18).  A large complex (arrow) above 
the two probe-associated bands was competed with an unlabeled probe (300x, lane 5).  See 
Table 2.3 for all oligonucleotide sequences.  (D) DDAP2IX-9 occupies the BAG1 promoter in 
parasite chromatin. Specific binding was observed in all six target regions (1-6) tiled across the 
BAG1 promoter (-950bp flanking the ATG indicated by arrow in diagram) with the central three 
regions showing the highest enrichment (see Fig. 9 for full experimental details).  Ten repeat 
motifs matching 5 of 6 bases in the AP2IX-9 DNA binding motif are indicated by black triangles 
above the diagram, while the BAG1 promoter CRE previously mapped by luciferase assay lies 
within region 4 and is marked by triangle below the diagram (18). (E) CTG-DDAP2IX-9 
expression also regulates BAG1, B-NTPase and LDH2 promoters. Transient transfection of 
BAG1 (-1195), B-NTPase (-1201) and LDH2 (-1510) promoters into CTG-DDAP2IX-9 transgenic 
parasites results in diminished luciferase activity.  Luciferase activity was assessed 48h post-
transfection from cultures maintained in pH 8.2 (black bars) or pH 8.2+ 200nM Shield-1 (white 
bars) for each promoter indicated (normalized activity represented in 1000s of counts). 
Luciferase activity was normalized by average expression of the co-transfected alpha tubulin 
renilla luciferase plasmid (18).    
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Figure 2.9:  AP2IX-9 overexpression inhibits bradyzoite gene expression through direct 
promoter interaction. 
(A) To validate the microarray results in Figure 4A, duplicate total RNA samples (S1 and S2) 
from the CTG or CTG-DDAP2IX-9 parasites were purified and analyzed for BAG1 and LDH2 
mRNAs as well as control GAPDH mRNA by semi quantitative RT-PCR.  Following stimulation 
with pH 8.2 media (plus or minus Shield-1) DNA fragments for BAG1 and LDH2 mRNAs were 
amplified from CTG parent RNA, but not from CTG-DDAP2IX-9 RNA.  Consistent with induced 
expression during bradyzoite differentiation, BAG1 and LDH2 mRNAs were not detected in 
tachyzoite RNA samples (Tz), while the constitutively expression GAPDH mRNA was detected 
in all RNA samples.  The lack of BAG1 and LDH2 mRNA expression detected in CTG-DDAP2IX-
9 parasites by RT-PCR is comparable to the low RMA values observed in the microarray 
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analysis, which likely underestimates the repression caused by AP2IX-9 overexpression on 
these mRNAs (Tables 2.4 and 2.5).  Microarray analysis does not perform as well as PCR 
methods when expression levels are near or below the fluorescent background for the 
GeneChip (50-100 RMA) as occurs for these mRNAs.  A genomic DNA reference (g) was 
included here as control.  Note that intron containing fragments are larger for GAPDH and 
BAG1, while LDH2 primers did not span an intron (see Table 2.3 for primer designs).  The lower 
diffuse bands in the DDAP2IX-9 transgenic PCR reactions are primer-dimers that form in the 
absence of real product.  Shield-1 (200nM) additions are indicated above each lane. (B) 
DDAP2IX-9 is enriched at the BAG1 promoter.  Chromatin immunoprecipitation was performed 
using anti-HA antibodies on DDAP2IX-9 (specific chromatin) and parent strains (non-specific 
chromatin).  Equal amounts of specific or nonspecific chromatin were subjected to quantitative-
PCR at six target regions (1-6) tiled across the BAG1 promoter and compared to three non-
target loci within the genome (Non-target 1=TgME49_chrVI, 1,281,571-1,281,849bp, non-target 
2=TgME49_chrIa: 31,895-32,259bp, non-target 3=TgME49_chrVI: 1,595,703-1,596,052bp).  
Relative enrichment values for each BAG1 promoter region was determined as the change in Ct 
value of specific versus nonspecific chromatin at target and non-target loci, using the equation 
2^-(ΔCt target-ΔCt non-target).  The relative enrichment was calculated for each target region of the BAG1 
promoter versus each individual non-target region and all showed similar DNA enrichment 
patterns.  The average of BAG1 enrichment against all three non-target chromosome sites is 
presented in Figure 4D.  The diagram below shows the arrangement of the six BAG1 promoter 
regions (-1195 to translation start indicated by arrow) with triangles above showing placement of 
AP2IX-9 motifs in the promoter.  The results of published promoter mutagenesis that localizes 
the BAG1 CRE to region 4 and the specific mutations in the BAG1 promoter with reference to 
the results of luciferase reporter activity (*in vivo, promoter mutations are underlined)(18).   
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Figure 2.10:  Model for control of bradyzoite development by the AP2IX-9 transcriptional 
repressor. Four major transitions are thought to occur in the intermediate life cycle: a) following 
infections with sporozoites (or bradyzoites) parasites rapidly differentiate into replicating 
tachyzoites, b) limited tachyzoite proliferation leads to a slower growing pre-bradyzoite state, 
and c) the timing of commitment to the dormant bradyzoite in the mature tissue cyst is 
asynchronous (D*).  AP2IX-9 balances the competing interests of parasite expansion and 
efficient transmission through direct inhibition of commitment to the mature bradyzoite.  This 
model is based on studies here and published results with the VEG strain (6, 7) that has been 
maintained in the Dubey laboratory by exclusive mouse-cat serial passage to preserve the 
native Toxoplasma developmental pathway (32).  
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CHAPTER THREE: 
A tachyzoite-specific ApiAP2 is a repressor of bradyzoite gene expression in 
Toxoplasma gondii. 
 
Introduction:  
Toxoplasma gondii is an obligate intracellular parasite that exhibits a multi-host and 
multi-stage developmental life cycle.  Sexual stages are restricted to the gut mucosa of the 
feline definitive host and asexual stages occur within any warm-blooded host, including humans.  
Acute disease is generally asymptomatic in immune-competent hosts, however, primary or 
recrudescent infection from latent bradyzoites in humans with AIDS, those undergoing 
chemotherapy or in the unborn cause significant disease and death (1).  While the tachyzoite 
lytic cycle is responsible for disease pathology in human hosts, the interconversion of the 
tachyzoite stage (growth) into the bradyzoite stage (dormant) that underlies chronic infection 
and ensures host to host transmission (2).  Evidence indicates that mechanisms regulating the 
tachyzoite cell cycle are intricately tied to bradyzoite differentiation with the choice to continue 
tachyzoite replication or develop into the latent bradyzoite containing tissue cyst made during S-
phase and mitosis of the immediate prior cell cycle ((3-5) reviewed in (6)).  Transcriptome data 
demonstrates that unique changes in mRNA expression occur in the tachyzoite cell cycle and 
during development (7-9).  An estimated ~5% of all transcripts are exclusive to a single 
developmental stage with and nearly 40% of the mRNAs in the tachyzoite division cycle 
periodically expressed.  How these changes are controlled is largely unknown (7-9).  Early 
genome mining for known gene specific transcription factors revealed two important 
observations.  While the general transcriptional machinery is present in the genomes of 
Apicomplexa species, initial studies failed to identify classic gene specific transcriptional 
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regulators common to higher eukaryotes.  Second, an overall lack of genes encoding DNA 
binding proteins suggested a limited arsenal from which to regulate these dynamic changes in 
developmental gene expression.  In 2005, a family of DNA binding proteins distantly related to 
the APETALA (AP2) family plant transcription factors was discovered encoded in the genomes 
of Apicomplexa species, providing the first evidence for gene specific transcription factors to 
date (10).  In Plasmodium spp., ApiAP2 factors bind DNA with distinct sequence specificity (11, 
12) via a novel domain swapping mechanism (13) and have non-transcriptional roles in sub-
telomeric chromosome biology (14).  Ookinete (AP2-O) and sporozoite (AP2-Sp) ApiAP2s are 
stage specific transcriptional activators regulating motile stages within the definitive host 
mosquito (15, 16).  Genetic disruption of AP2-O results in non-invasive ookinetes (16) whereas 
disruption of the AP2-Sp locus yields a parasite unable to form viable sporozoites (15).   
The Toxoplasma genome encodes 68 ApiAP2 domain-containing proteins (17), with 24 
of these genes expressed cyclically during the tachyzoite division cycle (7).  Interestingly, the 
peak mRNA expression of the cell cycle regulated ApiAP2s forms a time order sequence that 
spans the complete division cycle, providing a mechanism to provide “just in time” delivery of 
gene products throughout the cycle (10).  The S/M sub-transcriptome in Toxoplasma is enriched 
for Apicomplexa specific mRNAs, including 13 ApiAP2 mRNAs that peak from S-phase through 
cytokinesis of the tachyzoite division cycle (7).  In Toxoplasma, ApiAP2s have been implicated 
in virulence and invasion mechanisms (18), as part of chromatin remodeling complexes (19, 20) 
and RNA processing machinery (21) and there is evidence for ApiAP2 factors regulating 
bradyzoite development.  AP2XI-4 is up-regulated during bradyzoite development and is an 
activator of bradyzoite specific transcripts, including the canonical marker, BAG1 (22).  The 
novel inducible repressor AP2IX-9 acts to prevent premature commitment to the bradyzoite end 
stage through direct interaction with bradyzoite specific promoters ((23), Chapter 2). In this 
chapter we describe the discovery of yet another level of developmental control in the 
intermediate life cycle that leads to the chronic tissue cyst stage.  AP2IV-4 is exclusively 
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expressed in the tachyzoite division cycle with peak expression of the encoded mRNA and 
protein during early mitosis.  Surprisingly, genetic knockouts of AP2IV-4 demonstrate it is non-
essential to the replicating tachyzoite but is instead critical for the expression of bradyzoite 
developmental surface antigens and cyst wall proteins.  Results from microarray analysis and 
promoter assays demonstrate that AP2IV-4 is a repressor of bradyzoite gene expression acting 
to control the outcome of downstream development in the Toxoplasma intermediate life cycle. 
 
Results: 
AP2IV-4 is dynamically regulated during the tachyzoite cell cycle.  Previous studies 
identified 24 ApiAP2 genes that are cyclically transcribed once per tachyzoite cell cycle with 
peak mRNA levels distributed throughout the division cycle, including 13 that peak in S/M sub-
transcriptome (Fig. 3.1A) (7).  At the mRNA level, AP2IV-4 stood out as extremely dynamic with 
a greater than 10-fold change in mRNA abundance during the eight hour tachyzoite cell cycle.  
To verify protein expression correlates to the changes in mRNA profile, we introduced a C-
terminal HA tag at the endogenous locus by genetic knock-in, which preserved the native 
context of expression in the type I RHΔku80 strain (24).  As with previously tagged Toxoplasma 
ApiAP2s (7, 18, 23, 25), AP2IV-4HA localized exclusively to the nucleus and was expressed from 
late S-phase through mitosis, confirming the cyclical mRNA expression curve predicts dynamic 
protein expression in the tachyzoite cell cycle (Fig. 3.1B).  In an asynchronous tachyzoite 
population AP2IV-4HA is detectable in 20-25% of vacuoles due to its cell cycle periodicity.  The 
gene model for AP2IV-4 (ToxoDB.org) predicts a single exon structure that includes a single 
AP2 DNA binding domain (Fig. 3.1C) and this was verified through measurements of AP2IV-4HA 
mass (expected size ~250kDa) by western blot using α-HA antibodies (Fig. 3.1C).   
To further pinpoint the exact cell cycle expression of AP2IV-4HA a series of co-markers 
were utilized to define the timing of initiation, accumulation and degradation of the AP2IV-4HA 
fusion protein within a single cell division by immunofluorescence assay (IFA).  There are well-
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defined markers for the apical cap (IMC sub-compartment protein 1, TgISP1) (26) and the inner 
membrane complex (TgIMC1) (27-30) whose morphological changes from S-phase through 
cytokinesis of tachyzoite division cycle were used here to define the expression timing AP2IV-
4HA.  Having demonstrated the nuclear expression of AP2IV-4HA (Fig. 3.1B), we used the 
morphology of the daughter apical cap (α-ISP1 (clone 7E8) a gift from Dr. Peter Bradley, 
University of California, Los Angeles) to determine that the initiation of AP2IV-4HA expression 
preceded the appearance of the internal daughter scaffold (Fig. 3.2Aa).  The detection of 
AP2IV-4HA prior to internal daughter structures indicates a late S-phase cell cycle timing, just 
prior to the start of mitosis, where nuclear division has yet to commence.  The rapid 
accumulation of AP2IV-4 paralled the formation of ISP1 rings of the daughter parasites (Fig. 
3.2Ab).  Maximum expression of AP2IV-4HA was coincident with the expansion and elongation 
of the ISP1 cap structure (Fig. 3.2Ac)(26) and AP2IV-4 levels were then sustained throughout 
budding (distinct mitotic U-shaped nuclear morphology, DAPI staining, Fig. 3.2Ad) before 
expression rapidly declined (Fig. 3.2Ae).  The timing of AP2IV-4 expression was also 
determined by co-localization with IMC1 (α-IMC1, a gift from G. Ward, University of Vermont) 
and was consistent with the ISP marker.  AP2IV-4HA first appeared in parasites lacking internal 
daughter IMC structures (Fig. 3.2Ba), reached maximum expression during daughter budding 
(Fig. 3.2Bb) and persists as daughter IMC extends down the newly formed bud (Fig. 3.2Bc).  
AP2IV-4HA began to disappear in late cytokinesis (Fig. 3.2Bd) and was no longer detectable 
after resolution of the mother IMC (Fig. 3.2Be).  There was no expression of AP2IV-4HA in early 
G1 parasites.  Combined, the co-localization of AP2IV-4HA with ISP1 and IMC1 markers 
demonstrated that AP2IV-4HA expression was exclusive to the second half of the tachyzoite cell 
cycle; late S-phase through cytokinesis.  
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Genetic knockout of AP2IV-4 indicates a non-essential role for the tachyzoite 
stage of development.  To understand the role AP2IV-4 serves in the tachyzoite cell cycle we 
attempted gene deletion in the type I RHΔku80 strain designed to preferentially undergo 
homologous recombination (24).  We cloned the 5’ and 3’ UTR of AP2IV-4 around the HXGPRT 
selectable marker using 3-fragment Gateway recombinational cloning (Invitrogen, (31)) and 
introduced the construct into the RHΔku80 strain.  After drug selection, we were unable to 
isolate a viable Δap2IV-4 strain (0 of 60 clones screened), suggesting that AP2IV-4 was 
possibly essential for tachyzoite cell cycle progression.   Other explanations could explain the 
inability to disrupt the AP2IV-4 gene including low frequency double crossover or growth defects 
that could prevent the recovery of the knockout parasites.  To overcome these potential 
problems, we applied CRE recombinase-enhanced recombination to disrupt AP2IV-4 using a 
model developed in Toxoplasma (32).  The inducible diCRE model was recently introduced into 
the type I RHΔku80 strain (24) providing a transgenic strain where CRE activity is controlled by 
the addition of rapamycin ((32), reviewed in (33)).  In the absence of rapamycin, the “floxed” 
gene of interest is expressed in its native context and suitable clones were isolated for knockout 
attempts.  A short incubation with rapamycin (6h) induces CRE mediated excision of the “floxed” 
gene and parasites are immediately cloned by limiting dilution to prevent growth competition 
from wild-type cohorts.  To “flox” the AP2IV-4 gene, we performed serial epitope tagging of the 
upstream gene (TGGT1_318480, www.ToxoDB.org) and the AP2IV-4 gene, which are in a head 
to tail configuration (see Fig. 3.3A for a diagram of the knockout designs).  Briefly, the upstream 
loxP site was introduced immediately downstream of gene TGGT1_318480 by epitope knock-in 
using a LIC/myc3 HX vector carrying a single loxP recognition site.  This was followed by 
epitope tagging AP2IV-4 using the LIC/HA3 DHFR vector that also carries a single loxP site 
downstream of the HXGPRT selectable marker (Fig. 3.3A).  The expression of the AP2IV-4HA 
fusion protein in this transgenic strain (clone ID6) was identical to previously tagged AP2IV-4HA 
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strain (Fig. 3.1B and Fig. 3.2) and tagging the upstream also had no deleterious affect on 
tachyzoite replication.  CRE mediated excision of the AP2IV-4 locus was induced by a 6h 
incubation with rapamycin (50nM) (Fig. 3.3A) and clones were immediately isolated by limiting 
dilution (32).  In contrast to the initial failure to knockout AP2IV-4 using genetic replacement with 
a drug selectable marker, ~20% (10/51) of isolated clones from the parent AP2IV-4 “floxed” 
strain were negative for the AP2IV-4 locus by PCR (data not shown) and the absence of AP2IV-
4 mRNA was verified for two clones (Δap2IV-4 clones 27 and 30, Fig. 3.3B). The isolation of 
viable Δap2IV-4 transgenic parasites indicates AP2IV-4 is non-essential for the tachyzoite 
stage.   
To assess if the deletion of AP2IV-4 had an effect on progression of the tachyzoite cell 
cycle, we used the co-markers IMC1 and ISP1 to indicate structural changes during daughter 
formation and DAPI to monitor changes in nuclear morphology.  AP2IV-4 knockout parasites 
progressed through the cell division cycle without noticeable changes in the structure of 
daughter IMC1 or in the apical cap ISP1 protein and nuclear division was also identical to 
parental strain (data not shown).  To assess overall growth effects we performed plaque assays 
to determine if there were any changes in the growth rate or ability for Δap2IV-4 to reinvade host 
cells.  A total of 500 parasites were inoculated into three T25s for AP2IV-4 knockout strains 27 
(Δap2IV-4 27) and 30 (Δap2IV-4 30) and compared to the “floxed” parental strain (clone ID6) 
that carries dual-epitope tags in gene TGGT1_318480 (MYC tag) as well as AP2IV-4 (HA tag).  
Parasite strains lacking AP2IV-4 exhibited a diminished ability to form plaques (Fig. 3.3C, early 
and late passage) that showed a passage-dependent tissue-culture adaptation.  Early passage 
(<10 passages from isolation) Δap2IV-4 27 (ave. 31.3 plaques, 3 replicates) and Δap2IV-4 30 
(ave. 15.6, 3 replicates) parasites exhibit a ~20 fold decrease in plaque efficiency when 
compared with parental strains (ave. 408, 3 replicates) (Fig. 3.3C, early passage).  Interestingly, 
plaque assays conducted after ~5 passages (two weeks of culture) exhibited more robust 
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growth, although the plaque efficiency did not rise to the level of the parent strain (Fig. 3.3C).  
Adaption of Toxoplasma mutants to in vitro culture is a common phenomenon that reflects the 
active selection for better growing parasites in these tissue culture models (34, 35). 
AP2IV-4 represses components of the cyst wall and bradyzoite surface antigens. 
To identify target genes regulated by AP2IV-4, duplicate total RNA from parental (dual tagged 
strain), both AP2IV-4 knockout strains (Δap2IV-4 27 and 30) as well as cosmid complemented 
strains (cosmid PSBM794, (36)) were isolated (standard tachyzoite conditions, pH 7.0) and 
prepared for hybridization on the custom Toxoplasma Affymetrix GeneChip (37).  The lack of 
AP2IV-4 mRNA in the knockout strains and re-expression in the PSBM794 complemented 
population was verified by RT-PCR (Fig. 3.3B).  In total, 35 mRNAs were altered (FDR=5%, 
FC>+/-2, p=0.05, Table 3.1) in the AP2IV-4 knockout strains, including 22 genes that were up-
regulated, indicating that the major function for AP2IV-4 may be to repress gene expression 
during the tachyzoite cell cycle.  Somewhat surprisingly, the mRNAs with the greatest up-
regulation (FC>+/-5) encode proteins that are known bradyzoite surface antigens (e.g. SRS9 
(38-40), SAG4.2 (41); Table 3.2) or cyst wall components (e.g. BPK1 (8, 42), MCP4 (8), CST1 
(43); Table 3.2) suggesting AP2IV-4 acts to repress bradyzoite-specific proteins during 
tachyzoite replication.  This observation is the second repressor of bradyzoite gene expression 
discovered in our laboratory (23).  Interestingly, AP2IV-4 and AP2IX-9 share 10 possible 
regulatory targets, including eight that are greater than 5-fold up-regulated in AP2IV-4 (Table 
3.3, yellow highlight).  Furthermore, AP2IV-4 and AP2IX-9 act to repress 73% (16/22, Table 3.4) 
of the genes thought to be activated by AP2XI-4, suggesting that while these ApiAP2s do not 
directly regulate each other, they are intimately tied to the regulation of the bradyzoite 
developmental pathway (23, 25).  Of the 13 mRNAs down-regulated in the AP2IV-4 knockout 
strain, seven have nearly identical cell cycle expression profiles as AP2IV-4 mRNA itself.  
Intriguingly, a single mRNA, TGGT1_226310 (a putative C3H type zinc finger protein, C3H Znf) 
is the only mRNA down regulated greater than 5 fold (15.7) by the loss of AP2IV-4 and its 
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mRNA profile is nearly identical to that of AP2IV-4 (Fig. 3.1A).  These data indicate AP2IV-4 
could have dual function as a repressor of bradyzoite genes and activator of tachyzoite cell 
cycle genes, a phenomenon previously described in Plasmodium spp. (10, 12) (Tables 3.1 and 
3.2). In all cases, complementation with cosmid PSBM794 (36) restored expression of target 
mRNAs to parental levels (Tables 3.1 and 3.2).  
Stage specific markers have been developed for the Toxoplasma tissue cyst that identify 
antigens that are induced by stress conditions.  These include bradyzoite surface antigens 
(SAG4.2, SRS9) and components of the tissue cyst wall (BPK1, MCP4, CST1) (38-43).  In 
parasites lacking AP2IV-4, we see the up-regulation of mRNAs for several of these markers 
(Tables 3.1 and 3.2) in the absence of stress conditions.  To verify mis-expression of bradyzoite 
proteins in replicating tachyzoites, we completed immunofluorescence assays (IFA) using native 
antibodies to four bradyzoite specific proteins (α-BPK1, α-MCP4, α-CST1, α-SRS9) whose 
mRNAs were up-regulated in the Δap2IV-4 27 transgenic and the standard cyst wall marker 
Dolichos biflorus agglutinin (DBA).  Co-staining with CST1, a required protein for tissue cyst wall 
integrity (43), shows ~3 fold increase in CST1 positive vacuoles in the Δap2IV-4 27 strain, when 
compared to parent and complemented strains (Fig. 3.4A).  Western blot analysis verifies the 
increased expression of CST1 (~250kDa) in the knockout strains (Δ lanes, Fig. 3.4A).  Similar 
analysis was completed with native antibodies to other known bradyzoite markers (Fig. 3.4B).  
In each case, the corresponding protein was expressed in the Δap2IV-4 27 strain, including 7.4 
fold increase in BPK1, a bradyzoite pseudokinase (8, 42), and a nearly 10 fold increase in the 
bradyzoite specific surface antigen SRS9 (38-40).  These data are the first report of the mis-
expression of bradyzoite proteins in proliferating tachyzoites caused by the loss of a specific 
transcription factors.  The genes altered in the AP2IV-4 knockout strains are listed in Tables 3.1 
and 3.2. 
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AP2IV-4 inhibits expression of cyst wall and bradyzoite surface antigen mRNAs 
through direct promoter interaction.  Previous studies of ApiAP2 factors in Apicomplexa 
indicate these proteins bind DNA in a sequence specific manner (11, 12, 14-16, 18, 22, 23).  To 
assess DNA binding affinity for AP2IV-4, a GST-AP2IV-4 fusion protein (AP2 domain only) was 
expressed, purified and hybridized to a DNA microchip (protein binding microarray, (44)).  The 
resulting 8-nucleotide “consensus” sequence motif contains a monocystronic repeat of C/G (5’-
ACCCCCCT-3’/3’-TGGGGGGA-5’; enrichment score> 0.45; Fig. 3.5A).  Electrophoretic mobility 
shift assays (EMSA) using DNA probes containing C repeats were used to validate the 
specificity of GST-AP2IV-4 binding (Fig. 3.5B) (23, 34).  GST-AP2IV-4 bound DNA probes that 
contained greater than 35% C content, including those that contain the entire PBM sequence of 
C-repeats (Fig. 3.5B, lane 2).  GST-APIV-4 DNA interaction was successfully competed using 
300x unlabeled competitor DNA (Fig. 3.5B, lane 3) with DNA probes that contained at least 35% 
C nucleotides, whereas a DNA probe with less than 20% C content did not compete for GST-
AP2IV-4 protein interaction (Fig. 3.5B, lane 4).  Previous studies of ApiAP2s in Apicomplexa 
have used PBM motifs to verify enrichment at the promoters of regulatory targets (23) or 
genome wide bioinformatics searches to identify possible regulatory targets in the absence of 
gene deletion studies (11, 12, 44).  To determine if the AP2IV-4 DNA binding motif could be 
used to verify or expand upon the set of target genes identified in microarray analysis, we pulled 
the -2kb sequences upstream (5’UTR, start from ATG) from each mRNA that was greater than 
5-fold up or down regulated in the AP2IV-4 knockout strains (13 gene promoters, including 
AP2IV-4).  Unfortunately, basic bioinformatics determination of the enrichment of nucleotide C, 
including the full or partial occurrence of the 6bp C-rich PBM motif (Fig. 3.5A) was rarely present 
in any promoter.  This indicated the specificity of binding for AP2IV-4 is likely more complex 
than the enrichment of the C nucleotide in any short stretch of DNA, and may require the 
complete AP2IV-4 protein not present in the GST fusion protein.  
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In order to determine if AP2IV-4 directly represses known elements of the bradyzoite 
surface and tissue cyst components, we introduced the promoter region of 5 genes SAG4.2 (-
1521bp from ATG), BPK1 (-1572bp), SRS9 (-1550bp), MCP4 (-1511bp), and C3H ZnF (-
1543bp), TGGT1_226310, Table 3.2, highlighted gray) upstream of the firefly luciferase coding 
sequence.  This approach was successfully used to map developmental stage specific cis-
regulatory elements in Toxoplasma by transient dual luciferase assay (23, 34).  Each promoter 
luciferase construct was co-transfected with alpha-tubulin renilla luciferase control plasmid 
(20ug luc/10ug ren) into parental and Δap2IV-4 27 strains, grown for 30h at standard in vitro 
conditions and harvested for luciferase assay (34).  Of the 5 promoters tested, SAG4.2 (2.4 fold, 
red bar) and MCP4 (2.5 fold, blue bar) showed the greatest fold-increase in luciferase 
expression when comparing the Δap2IV-4 27 to the parent strain, providing evidence these 
promoters could be direct targets of the AP2IV-4 repressive mechanism (Fig. 3.5B).  While 
BPK1 (1.2 fold, orange bar), SRS9 (1.7 fold, green bar) and the C3HZnF (0.9 fold, purple bar) 
showed little change in luciferase expression (Fig. 3.5A), they follow the trend predicted 
identified in the Δap2IV-4 analysis.  Previous studies using transient luciferase assays indicate a 
reduction in luciferase activity when compared to the activity produced from a transgenic copy of 
the same promoter::luciferase expression cassette, indicating chromosomal integration may be 
critical to decipher the extent of AP2IV-4 binding to these promoters ((34) and Chapter 2).  
 
Discussion: 
In this study we describe the role of AP2IV-4, a member of the ApiAP2 DNA binding 
protein family in Toxoplasma.  Similar to other ApiAP2s, AP2IV-4 localizes exclusively to the 
nucleus of tachyzoite during S-phase through cytokinesis of the parasite cell cycle.  AP2IV-4 is 
not expressed in other stages of Toxoplasma development including the bradyzoite.  Genetic 
deletion of the AP2IV-4 locus in the type 1 genetic background (RH) in replicating tachyzoites 
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results in the mis-expression of mRNAs encoding tissue cyst wall and bradyzoite surface 
antigens.  We verified these observations using transient promoter luciferase assays and 
validated the mis-expression of bradyzoite specific proteins in the tachyzoite.  We verified that 
DNA binding domain of AP2IV-4 is capable of binding DNA with sequence specificity 
characterized by cytosine bias.  It is likely that these results are a first approximation, and it will 
require analysis of the intact protein in parasites to fully understand binding specificity in 
parasite chromosomes.   
AP2IV-4 is the first tachyzoite-specific protein identified that regulates the formation of 
tissue cysts and is the second Toxoplasma ApiAP2 repressor we have observed controlling 
bradyzoite development (AP2IX-9, Chapter 2) (23).  The discovery of AP2IV-4 highlights the 
concept that specific life cycle decisions begin upstream in the developmental pathway and 
provides insight into the mechanisms that link the tachyzoite cell cycle to bradyzoite 
development.  Together, AP2IV-4 and AP2IX-9 comprise two independent levels of 
transcriptional regulation preventing bradyzoite development in Toxoplasma and support the 
hypothesis that the tachyzoite is an intermediate growth stage that functions to expand parasite 
biomass and through dissemination the tachyzoite finds suitable host cell environments for 
which to develop end-stage bradyzoites (6, 23). In addition, the overlap of gene regulatory 
targets between AP2IV-4 and AP2IX-9 (Table 3.3) indicate there is some redundancy governing 
the induction of the bradyzoite developmental pathway and at least two levels of transcriptional 
repression preventing commitment to the bradyzoite end-stage (23) 
Our greatest clues to unfolding parasite development in Toxoplasma revolves around 
the central role asexual stage replication plays in the transition to growth-arrested end-stages 
(3-5).  DNA replication in the tachyzoite is required for bradyzoite development (3) and the 
tachyzoite is “poised” to enter the bradyzoite developmental pathway during each round of 
replication (34).  The sub-transcriptome of the tachyzoite S and mitotic phases is enriched in 
basal bradyzoite transcripts (34), which is a cell cycle timing that corresponds with peak AP2IV-
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4 expression.  This places AP2IV-4 perfectly within the tachyzoite cell cycle to regulate these 
critical developmental processes.  Repressing tissue cyst wall formation in the tachyzoite could 
provide the parasite with flexibility to maintain a replicative stage or quickly interpret 
“development” signals in the animal resulting in induction of bradyzoite differentiation when the 
parasite encounters the immune system and/or a tissue that favors tissue cyst longevity.  
Understanding how host signals are translated to turn off repressor mechanisms like AP2IV-4 
could help explain the remarkable tissue tropism observed in Toxoplasma infections. 
 
Materials and Methods: 
All transgenic strains and oligonucleotides used in this study are found in Tables 3.5 and 3.6.  
Detailed cell culture methods can be found in Chapter 2.  
Epitope fusion at the genomic locus.  Toxoplasma AP2IV-4 (TGGT1_318470) was 
tagged at the genomic locus with a triple copy of HA in RHΔku80 by homologous recombination 
using the pLIC-3xHA/DHFR plasmid (24) and transgenic clones isolated by limiting dilution.   
Immunofluorescence assays (IFA). Parasites were grown in HFF cells and prepared 
for immunofluorescence as described in Chapter 2.  Primary antibodies were used at the 
following concentrations: HA (Roche, rat mAb 3F10, 1:500); ISP1 (mouse pAb, 1:2000, Dr. 
Peter Bradley, UCLA); IMC1 (mouse mAb, 1:1000, Dr. Gary Ward, University of Vermont);  
biotin-labeled Dolichos biflorus agglutinin (DBA) (Vector labs, CA,1:3000); BPK1 and MCP4 
(mouse pAbs, 1:1000, Dr. John Boothroyd, Stanford University,); CST1 (mouse pAb, Salmon E, 
1:2000, Dr. Louis Weiss, Albert Einstein College of Medicine); SRS9 (rabbit pAb, 1:1000, Dr. 
Laura Knoll, University of Wisconsin).  Secondary antibodies by Alexa or streptavidin 
conjugated secondary antibodies were used at a 1:1000 dilution.  All images were collected with 
a Zeiss Axiovert microscope equipped with 100x objective. 
Western analysis.  Protein from 25x10^6 parasites were isolated, purified and whole 
parasite lysates collected as previously described (45) and subjected to electrophoresis on a 
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SDS-PAGE gel.  After transfer to nitrocellulose, the blots were probed with the following primary 
antibodies: HA (Roche, rat mAb 3F10, 1:500); CST1 (mouse pAb, Salmon E, 1:2000, Dr. Louis 
Weiss, Albert Einstein College of Medicine); the loading control TgNF3 (mouse pAb, 1:1000, Dr. 
Stan Tomavo, Pasteur Institute, Lille).  Detection of the proteins was completed using HRP 
conjugated antibodies (Jackson ImmunoResearch) followed by chemiluminescence reaction for 
visualization.    
Construction of the AP2IV-4 knockout constructs and strains.  3-fragment Gateway 
(Invitrogen).  Both the 5’ and 3’ UTR of the AP2IV-4 locus were PCR amplified from type I 
genomic DNA and used to create Gateway entry clones.  The 5’ UTR was cloned into the 
pDONRP4-P1r plasmid and the 3’UTR was cloned into the pDONRB2r-B3 plasmid by the BP 
recombination reaction.  After isolation of the entry clones, pDONRP4-P1R AP2IV-4 and 
pDONRP2r-P3-AP2IV-4 were combined in a LR recombination reaction with p221-HXGPRT to 
create the pDEST-AP2IV-4-HX knockout plasmid.  The final plasmid was introduced into the 
RHΔku80Δhx strain and transgenic parasites were selected using mycophenolic acid followed 
by clonal isolation by limiting dilution. loxP/CRE model: To create knockout of AP2IV-4, we used 
the RHΔku80 (24) strain that contains an inducible copy of CRE recombinase (diCRE)(32).  
First, TGGT1_318480, the gene immediately upstream of AP2IV-4 (head-to-tail configuration, 
See Fig. 3.3A), was tagged at the endogenous locus with a triple copy of the MYC epitope using 
a pLIC-3xMYC plasmid containing a loxP recognition site downstream of the HXGPRT 
selectable marker. Using the TGGT1_318480MYC (clone IB9) transgenic parasite, AP2IV-4 was 
tagged at the genomic locus using a 3xHA epitope with the pLIC-3xHA plasmid that contains a 
loxP site downstream of the DHFR selectable marker.  The resulting dual tagged (HA and MYC) 
transgenic (clone ID6) contains a “floxed” AP2IV-4 locus that can be excised by the inclusion of 
rapamycin (Millipore) in the culture medium.  To initiate CRE mediated excision of AP2IV-4HA, 
dual-tagged parasites were seeded at a 5:1 MOI in HFF cell lines, allowed to invade for 2hrs, 
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washed 3x with Hanks balanced salt solution (Corning) to remove all free floating parasites 
followed by 6h treatment with 50nM rapamycin.  After 6h, the parasites were isolated by needle 
passage and immediately cloned into 96 well plates by limiting dilution.   
RNA microarray analysis of AP2IV-4. Independent, biological replicates of RNA were 
isolated from 4 transgenic strains: Dual-tagged ID6, Δap2IV-4 27 and 30, and complemented 
(PSBM794)).  All quality control, hybridization steps and analysis using GeneSpring GX 
software (Agilent) are detailed in Chapter 2.  
Protein expression and DNA binding. Primers for cloning AP2IV-4 (AP2 domain only, 
amino acids 782-854) into pGEX4T3 for GST-AP2IV-4 production are found in Table 3.6.  
Protein binding microarray was completed on GST-AP2IV-4 as described in (11).  EMSA was 
completed as detailed in Chapter 2.  50ng of GST-AP2IV-4 protein was used in each reaction 
and sequences used for DNA probes can be found in Table 3.6. 
Dual luciferase assays.  Promoters for the following Toxoplasma genes were cloned by 
recombination (Invitrogen) into the pDEST-FLYLUC destination plasmid (34): SAG4.2 (-1521bp 
from ATG, TGGT1_280580), BPK1 (-1572bp, TGGT1_253330), SRS9 (-1550bp, 
TGGT1_320190), MCP4 (-1511bp, TGGT1_ 208730), and C3H ZnF (-1543bp, 
TGGT1_226310).  For the luciferase assay, 20ug of the promoter luciferase plasmid and 10ug 
of the alpha-tubulin renilla control plasmid were transfected into the dual-tagged parent strain or 
Δap2IV-4 27 (10^7 parasites/transfection; duplicate T25cm2).  Following 30h of growth, cultures 
were harvested for luciferase assay as previously described (34) and luciferase activity 
measured by the SpectraMax L (Molecular Devices).  
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Table 3.1: AP2IV-4 microarray data, FC>2.0, p<0.05. 
 
 
 
  
ToxoDB ID AP2IV-4 ID6 ave Δap2IV-4 27_ave Fold Change Up/Down
Δap2IV-4 27+ 
PSBM794 ave Description
TGME49_312320 106.6936985 2100.7939 19.7 up 161.486415 hypothetical protein
TGME49_261650 30.1045235 517.43505 17.2 up 48.216259 hypothetical protein
TGME49_207150 19.8299505 320.784485 16.2 up 36.601534 SRS49C (= SAG2D)
TGME49_207150 23.562158 373.90912 15.9 up 44.208669 SRS49C (= SAG2D)
TGME49_280580 59.611608 709.69407 11.9 up 116.291225 p18 surface antigen, SAG4 homolog
TGME49_301890 33.3452155 394.20108 11.8 up 153.39126 hypothetical protein
TGME49_053330 42.441423 455.802385 10.7 up 29.3462115 Bradyzoite psuedo-kinase (BPK1)
TGME49_320190 23.904911 183.617225 7.7 up 56.4885815 SRS16B (= SRS9)
TGME49_207130 49.047085 372.92303 7.6 up 54.04766 SRS49A (= SAG2Y)
TGME49_208730 88.755825 588.825685 6.6 up 97.556767 MCP4
TGME49_208740 654.500215 2872.40755 4.4 up 721.6958 microneme protein
TGME49_237170 64.062255 242.21042 3.8 up 73.417115 hypothetical protein
TGME49_273110 49.755682 163.00463 3.3 up 44.9005925 SRS30D
TGME49_215500 35.0186465 108.135635 3.1 up 30.3057525 TPR repeat containing protein
TGME49_250930 58.4050965 160.509565 2.7 up 130.12878 hypothetical protein
TGME49_235700 121.1170875 316.90724 2.6 up 281.10773 sedoheptulose-1,7 bisphosphatse
TGME49_250940 185.219655 453.487735 2.4 up 484.16975 hypothetical protein
TGME49_301210 98.675355 235.96863 2.4 up 91.77867 NAD(P) transhydrogenase 
TGME49_236010 446.692125 1066.0151 2.4 up 477.74938 prenylcysteine oxidase
TGME49_234440 203.68708 444.340655 2.2 up 172.26145 aminotransferase
TGME49_246070 40.580965 86.9793 2.1 up 41.3406685 SRS56A
TGME49_213072 156.343195 325.425615 2.1 up 141.60062 Sec1 domain containing family
TGME49_289600 1485.39215 705.55977 -2.1 down 1545.81355 HSP29
TGME49_232280 394.39877 178.77099 -2.2 down 400.62007 hypothetical protein
TGME49_306270 1059.3713 428.609695 -2.2 down 1203.83055 hypothetical protein
TGME49_200230 734.495785 335.469275 -2.2 down 788.28997 MIC17C
TGME49_289100 111.9262025 51.959771 -2.2 down 91.812313 hypothetical protein
TGME49_232410 3042.1741 1129.15805 -2.7 down 3392.98055 PDI family protein
TGME49_229930 1041.23265 373.767835 -2.8 down 1046.5455 p25-alpha domain-containing protein
TGME49_292110 82.5362 29.9735335 -2.8 down 96.84328 formate/nitrite transporter
TGME49_221630 123.8561 40.670391 -3.0 down 101.701485 hypothetical protein
TGME49_276930 465.69774 129.377525 -3.6 down 502.22539 hypothetical protein
TGME49_225790 346.03264 76.8506675 -4.5 down 316.146425 PDI family protein
TGME49_226310 195.83093 12.4797665 -15.7 down 67.813985 zinc finger (CCCH type)
TGME49_318470 191.551395 6.397996 -29.9 down 36.09117 AP2IV-4
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Table 3.2: AP2IV-4 microarray data, FC>5.0, p<0.05. 
 
 
 
  
ToxoDB ID AP2IV-4 ID6 ave Δap2IV-4 27_ave Fold Change Up/Down
Δap2IV-4 27+ 
PSBM794 ave Description
TGME49_312320 106.69 2100.79 19.7 up 161.49 hypothetical protein
TGME49_261650 30.10 517.44 17.2 up 48.22 hypothetical protein
TGME49_207150 19.83 320.78 16.2 up 36.60 SRS49C (= SAG2D)
TGME49_207150 23.56 373.91 15.9 up 44.21 SRS49C (= SAG2D)
TGME49_216140 20.88 323.67 15.5 up 58.51 ankyrin repeat-containing protein
TGME49_280580 59.61 709.69 11.9 up 116.29 p18 surface antigen, SAG4 homolog
TGME49_301890 33.35 394.20 11.8 up 153.39 hypothetical protein 
TGME49_253330 42.44 455.80 10.7 up 29.35 Bradyzoite psuedo-kinase (BPK1)
TGME49_320190 23.90 183.62 7.7 up 56.49 SRS16B (= SRS9)
TGME49_207130 49.05 372.92 7.6 up 54.05 SRS49A (= SAG2Y)
TGME49_208730 88.76 588.83 6.6 up 97.56 MCP4
TGME49_226310 195.83 12.48 -15.7 down 67.81 zinc finger (CCCH type)\
TGME49_318470 191.55 6.40 -29.9 down 36.09 AP2IV-4
promoter'luciferase'constructs'(Fig.'3.6)
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Table 3.3: AP2IV-4 and AP2IX-9 exhibit redundancy in gene regulatory targets 
 
 
 
  
Genbank Description
TGME49_059020 BAG1
TGME49_009760 hypothetical protein
TGME49_016140 ankyrin repeat-containing protein
TGME49_091040 LDH2
TGME49_068860 ENO1
TGME49_093790 hypothetical protein
TGME49_002020 DnaK-TPR
TGME49_007150  SAG2D (=SRS49C)
TGME49_090970 serine palmitoyltransferase
TGME49_032400 PAN domain-containing protein Total
TGME49_007210 hypothetical protein AP2IX+9-overlap,-FC>2-(Table-1) 2
TGME49_061650 hypothetical protein
TGME49_080570 bradyzoite surface antigen AP2IX+9-overlap,-FC>5-(Table-2) 8
TGME49_068210 AGC kinase
TGME49_007140 SAG2X (SRS49B) Total-repressed-by-IX+9-and-IV+4 10
TGME49_052640 TgPMA1
TGME49_007130 SAG2Y (= SRS49A)
TGME49_112320 hypothetical protein
TGME49_018910 hypothetical protein
TGME49_055210 peroxisomal-type ATPase, putative
TGME49_068220 hypothetical protein
TGME49_119340 kelch motif domain-containing protein
TGME49_080580 SAG4.2 (=p18)
TGME49_053330 BPK1
TGME49_091910 hypothetical protein
TGME49_090000 hypothetical protein
TGME49_040930 molybdenum cofactor biosynthesis protein c
TGME49_067670 hypothetical protein
TGME49_025290 B-NTPase
TGME49_008730 MCP4
TGME49_003290 hypothetical protein
TGME49_106450 short chain dehydrogenase family protein
TGME49_008740 microneme protein, putative
TGME49_089920 hypothetical protein
TGME49_009980 Rhoptry kinase family protein ROP42 (incomplete catalytic triad)
**35 genes downregulated by AP2IX-9 (Radke et al, 2013) 
10-genes-are-regulatory-targets-of-AP2IV+4-and-AP2IX+9
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Table 3.4: AP2IV-4 and AP2IX-9 repress genes activated by AP2XI-4. 
 
 
  
Genebank Description (activated by AP2XI-4)
TGME49_091040 Lactate dehydrogenase (LDH2) 
TGME49_068860 Enolase 1
TGME49_002020 Hypothetical (DnaK-TPR) 
TGME49_080570 SAG4, bradyzoite surface antigen Total
TGME49_007210  Hypothetical Repressed,by,AP2IX49 8
TGME49_016140 Ankyrin repeat-containing domain protein 
TGME49_078080 Hypothetical Repressed,by,AP2IV44 4
TGME49_021550 CMGC kinase, MAPK family, MEK kinase-related
TGME49_007150  SAG49C (= SAG2D) Repressed,by,AP2IX49,and,AP2IV44 4
TGME49_007130  SAG49A (= SAG2Y)
TGME49_059020 BAG1 Total,repressed,by,IV44,or,IX49 16
TGME49_120190 SRS16B (= SRS9) 
TGME49_040470 Hypothetical
TGME49_024170 SRS domain-containing protein 
TGME49_025290 Nucleoside-triphosphatase (B-NTPase)
TGME49_080580 P18 surface antigen
TGME49_061650 Hypothetical 
TGME49_009760 Hypothetical 
TGME49_111370 Methylmalonate-semialdehyde dehydrogenase, putative
TGME49_052640 Plasma-membrane proton-ATPase
TGME49_053330 Rhoptry kinase family protein, truncated
TGME49_053340 Hypothetical 
16/22,regulatory,targets,of,AP2IV44,and,AP2IX49,
overlap,with,the,activator,AP2XI44
**22,bradyzoite,specific,genes,activated,by,AP2XI44,(Walker,et,al,,2012)
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Table 3.5: Transgenic strains for AP2IV-4 study 
 
 
 
  
Name in this study experimental use Parent strain Transgene/selectable marker Drug Selection Clone #
AP2IV-4HA endogenous expression of AP2IV-4 RHΔhxgprt, Δku80 endogenous promoter::AP2IV-4(3xHA)/DHFR-TS pyrimethamine C9
TGGT1_318480MYC endogenous expression of 318480 RHΔhxgprt, Δku80 diCRE endogenous promoter::318480(3xMYC)/HXGPRT/loxP pyrimethamine IB9
AP2IV-4HA dual endogenous expression of AP2VI-1 RHΔhxgprt, Δku80 diCRE endogenous promoter::318480(3xMYC)/HXGPRT/loxP 
endogenous promoter::AP2VI-1(3xHA)/DHFR/loxP pyrimethamine/HXGPRT
ID6
Δap2IV-4 knockout of AP2IV-4 RHΔhxgprt, Δku80 diCRE endogenous promoter::318480(3xMYC)/DHFR-TS/loxP HXGPRT 27, 30
Transgenic strains produced for this study
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Table 3.6: Oligonucleotides for study of AP2IV-4. 
 
 
 
  
Oligonucleotide function Gene/locus Orientation Oligonucleotides (5'->3')
Tagging of endogenous gene loci with 
3xhemagglutinin (HA) or 3x MYC epitope tags
LIC 5' primer for AP2IV-4 AP2IV-4 Forward TACTTCCAATCCAATTTAATGCGACTCTCTCTGCCATTGGCCCG
LIC 3' primr for AP2IV-4 AP2IV-4 Reverse TCCTCCACTTCCAATTTTAGCGGCGAGCATGATGGTCTGCTTGACGTC
LIC AP2IV-4 5' primer to check for recombination AP2IV-4 Forward CAGGAGCTGTGTGAGCACGAGC
LIC-HA 3' primer to check for 3' recombination N/A Reverse CGCATATCGGGCACATCATAGGGAT
LIC 5' primer for TGGT1_318480 TGGT1_318480 Forward TACTTCCAATCCAATTTAATGCTGGTCCCGAGAAGAACCATGAG
LIC 3' primr for TGGT1_318480 TGGT1_318480 Reverse TCCTCCACTTCCAATTTTAGCTACAGGTGCGTCCTGTAAGGAACTGCT
LIC TGGT1_318480 5' primer to check for recombination TGGT1_318480 Forward GGAACGTGAGGCCGATGATGG
LIC-MYC 3' primer to check for 3' recombination N/A Reverse CTGTGTGAAATGCCACATGAAGAGTC
Overespression construct
AP2IV-4 CDS-MFEI AP2IV-4 Forward ATACAATTGGCCGCACCCGCACCGAGCGCG
AP2IV-4 CDS-ECORV AP2IV-4 Reverse
TATGATACTTCAGGCGAGCATGATGGTCTGCTTGACGTCGCCAGAAGGAGAGAGAAAAGACG
CAATGTCTCCTGTCTCGCCTCCTTCCGTCCCCTCTGTCGG
AP2IV-4 3 fragment knockout constructs
attB4 AP2IV-4 5' UTR AP2IV-4 Forward GGGGACAACTTTGTATAGAAAAGTTGAAGACGGTGACGGTGGTACGGTTG
attB1r AP2IV-4 5' UTR AP2IV-4 Reverse GGGGACTGCTTTTTTGTACAAACTTGCCCTGTGGAAGCCACTGCCTTG
attB2r AP2IV-4 3' UTR AP2IV-4 Forward GGGGACAGCTTTCTTGTACAAAGTGGAACGCAAGGCTGCCATGGAAGCG
attB3 AP2IV-4 3' UTR AP2IV-4 Reverse GGGGACAACTTTGTATAATAAAGTTGCCGACACTGAGGTGTGTGCGCG
AP2IV-4 3 Frag KO verify 5' UTR AP2IV-4 Forward GAGCCTGCCGTCGGACACTGG
AP2IV-4 3 Frag KO verify 3' UTR AP2IV-4 Reverse CTTCGCGTTCACCGAGGCGCC
Recombinant protein construct
pGEX4T3 AP2IV-4 recombinant protein-PBM Forward TATGGATCCGTACCCTTGAGAGCAGACGTGAC
pGEX4T3 AP2IV-4 recombinant protein-PBM Reverse ATAGCGGCCGCGTGCGAGAGGCACAGTTTGCCCTGA
Semi quantitive RT-PCR 
RT-PCR AP2IV-4 +5952 (from start) Forward GTCGCGTGATCCGCGATCAGG
RT-PCR AP2IV-4 @ stop codon Reverse GGCGAGCATGATGGTCTGCTTGACG
RT-PCR GAPDH Forward GTCAATCATTCTGTCAATTCGA
RT-PCR GAPDH Reverse ACACCATGTAGTCCAGGGACATG
DNA probes for EMSA
EMSA PBM motif validation Forward TTTGTAATATACGCTCCACCGCGTGCACCCCCCTCGACATGCCCCCGTATTGCTGATCG
EMSA PBM motif validation Reverse CGATCAGCAATACGGGGGCATGTCGAGGGGGGTGCACGCGGTGGAGCGTATATTACAAA
EMSA PBM scrambled cold Forward TACCCTGCCTCTTGTAGTAGTAACGTAAAAGAGGTAACGTGGTCAAATGCGATCAGAGAT
EMSA PBM scrambled cold Reverse ATCTCTGATCGCATTTGACCACGTTACCTCTTTTACGTTACTACTACAAGAGGCAGGGTA
Promoter luciferase constructs
AttB1 -1521 SAG4.2 SAG4.2 promoter Forward GGGG ACA AGT TTG TAC AAA AAA GCA GGC TTC CGGAGCTGAAAGGCGTGGAAC
AttB2 -1521 SAG4.2 SAG4.2 promoter Reverse GGGG AC CAC TTT GTA CAA GAA AGC TGG GTC TGC CAT TTTGCACACCGCGCG
AttB1 -1572 BPK1 BPK1 promoter Forward GGGG ACA AGT TTG TAC AAA AAA GCA GGC TTC GTGGGCAGACTGAGGGTCCTG
AttB2 -1572 BPK1 BPK1 promoter Reverse GGGG AC CAC TTT GTA CAA GAA AGC TGG GTC TGC CAT TGCCTCTTTCCGTGTTTG
AttB1 -1550 SRS9 SRS9 promoter Forward GGGG ACA AGT TTG TAC AAA AAA GCA GGC TTC CGAAGGGCCAGGTCAGCTTCC 
AttB2 -1550 SRS9 SRS9 promoter Reverse GGGG AC CAC TTT GTA CAA GAA AGC TGG GTC TTC CAT TGTGTCGACCCGTGT
AttB1 -1511 MCP4 MCP4 promoter Forward GGGG ACA AGT TTG TAC AAA AAA GCA GGC TTC CACGGGTTTGCGACGACACGT
AttB2 -1511 MCP4 MCP4 promoter Reverse GGGG AC CAC TTT GTA CAA GAA AGC TGG GTC CAC CAT CGTGGTACAAGTTCAGCACTC
AttB1 -1543 TGGT1_226310 (C3H ZnF) C3H Znf promoter Forward GGGG ACA AGT TTG TAC AAA AAA GCA GGC TTC CCAGCCGCCGAGGTGAGTTGG
AttB2 TGGT1_226310 (C3H ZnF) C3H Znf promoter Reverse GGGG AC CAC TTT GTA CAA GAA AGC TGG GTC CGG CAT CGTGAAATTCAACACTTGCAG
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Figure 3.1: AP2IV-4 is a dynamically regulated during the tachyzoite cell cycle. 
(A) Shown are 12 Toxoplasma ApiAP2s that are cell cycle regulated during the during the 
tachyzoite developmental stage.  One of the most dynamic (~10 fold change peak to trough 
mRNA), AP2IV-4 (red line) mRNA peaks during late S-phase to early mitosis and is dynamically 
down-regulated by the start of G1.  (B) AP2IV-4 was C-terminally tagged with 3xHA at the 
endogenous locus in RHΔku80.  AP2IV-4HA parasites were grown in HFF monolayers and co-
stained with α-HA (green for AP2IV-4HA expression) and α-IMC1 (black and white panel, cell 
cycle legend).  AP2IV-4HA is exclusively localized to the nucleus and the mRNA pattern is 
predictive of the protein expression pattern, corresponding to a S-phase through cytokinetic cell 
cycle timing.  (C) A schematic representation of the single exon, single AP2 domain containing 
AP2IV-4.  The predicted size of AP2IV-4 is ~250kDa (www.ToxoDB.org) which was fused 3xHA 
(~3.5kDa) and the size was confirmed (~254kDa) by western blot using α-HA antibodies.    
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Figure 3.2:  Pinpointing the cell cycle timing of AP2IV-4HA using the co-markers ISP1 and 
IMC1.  
(A) AP2IV-4HA parasites were grown in HFF monolayers and co-stained with α-ISPI (green, 
apical cap) and DAPI (blue, nucleic acid) to determine the exact timing of AP2IV-4HA (red) 
during the tachyzoite cell cycle.  Stabilization (a) of AP2IV-4HA began prior to daughter ISP1 
formation and before the nucleus flattens in late S-phase.  Maximum protein (b, c) accumulation 
is marked by the appearance and elongation of daughter apical structures and U-shaped 
nuclear morphology.  As the daughter apical cap (ISP1) matures and nuclear division is 
completed, AP2IV-4HA dissipated near the end of cytokinesis (d).  When all mother apical cap 
has been resolved and nuclear division completed (G1 phase), AP2IV-4HA is not detectable.  (B) 
Co-staining with α-IMC1 (green, internal daughters) shows late S-phase stabilization of AP2IV-
4HA, just prior to visualization of internal daughter IMC1.  Peak expression of AP2IV-4HA occured 
as the daughter inner membrane drives nuclear division (b, c).  Nearly complete daughter buds 
signify the degradation of AP2IV-4HA (d) and upon full resolution of the mother parasite AP2IV-
4HA is extinguished (e).    
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Figure 3.3:  Deletion of the AP2IV-4 locus results in a slow growth phenotype. 
(A) Schematic representation of AP2IV-4 knockout strategy.  First, the upstream loxP site was 
introduced by C-terminally tagging TGGT1_318480 at the endogenous locus with 3xmyc 
repeats using a vector containing a loxP recognition site and the HXPRT selectable marker.  
Next, AP2IV-4 was tagged at the endogenous locus with 3xHA, inserting the downstream loxP 
site using DHFR selection, completing the “floxing” of the AP2IV-4 locus.  Stabilization of CRE 
recombinase (50nM rapamycin, 6h) (32) results in the CRE mediated excision of the AP2IV-4 
locus.  (B) Semi-quantitative RT-PCR was completed on parent strain ID6 (P), Δap2IV-4 27 
(Δ27), Δap2IV-4 30 (Δ30) and their individual complemented populations.  AP2IV-4 specific 
primers were anchored one codon upstream of the stop codon extending 1367bp into the 
coding sequence and verified the lack of AP2IV-4 mRNA in knockout strains (Δ lanes).  GAPDH 
primers were designed around a 432bp intron, allowing detection of both mRNA (202bp, loading 
control) and contaminating genomic DNA (634bp, not detectable) within each sample.  (C) 
Parent (ID6 clone), Δap2IV-4 27 and Δap2IV-4 30 parasite strains were inoculated into T25cm2 
flasks (500 parasites/T25cm2 in triplicate) containing HFF cells and grown 7 days prior to 
assessing plaque number.  Early passage plague assays (<10 passages) exhibit a ~18 fold 
difference between parent and Δap2IV-4 (Parent=428 plaques; Δ27=31.3; Δ30=15.6, 3 replicate 
ave.) transgenics parasites.  Late passage (passages >20) is representative of two weeks 
continuous passage of the same culture and Δap2IV-4 parasite plaque numbers (Δ27=166.7; 
Δ30=204, 3 replicate ave.) are only two fold less than the dual tagged parent strain (340, 3 
replicate ave.).   
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Figure 3.4:  Tissue cyst wall and bradyzoite surface markers accumulate in the tachyzoite 
in parasites lacking AP2IV-4. 
(A) Δap2IV-4 27 strain parasites were grown in HFF cells for 24h at standard tachyzoite culture 
conditions (pH 7.0) and co-stained with IMC1 (green, tachyzoite marker) and a native antibody 
to CST1, a marker for tissue cyst wall.  The percentage of the population expressing CST1 in 
the parent (11.8%, white bars, dual tagged, ID6), Δap2IV-4 27 (35.7%, black bars) and 
complemented population (12.9%, gray bars) was quantified by random vacuole count.  
Increased stabilization of CST1 was detected by Western blot (α-CST1) in both Δap2IV-4 
transgenics as compared to the parent strain.  Images are representative of CST1 positive 
vacuoles.  TgNF3 (43kDa), a nucleolar protein, was used a loading control (46).  (B) 
Quantification of expression of cyst wall markers BPK1, MCP4, DBA and SRS9 was completed 
by random vacuole count for parent (white bars), Δap2IV-4 27 (back bars) and complemented 
strains (grey bars).  For each cyst wall protein, positive vacuoles occupy a greater percentage of 
the population (BPK1 (22.5%), MCP4 (32.0%), DBA (21.9%), and SRS9 (27.4%)) in the Δap2IV-
4 27 strain (black bars) when compared to the parent (white bars).  Complementation restores 
the natural expression pattern of each bradyzoite protein to parental levels (gray bars). All 
images are representative of positive expression of the bradyzoite protein indicated in a type 1 
tachyzoite at pH 7.0.  
 90 
 
 
Figure 3.5:  AP2IV-4 binds DNA in a sequence specific manner. 
(A) Protein binding microarray was completed using GST-AP2IV-4 and the representative 
sequence logo indicates position weight matrices compiled for each base.  The consensus 
sequence is a 6bp monocystronic repeat of nucleotide C.  (B) An electrophoretic mobility shift 
assay was completed on 300ng of GST-AP2IV-4 using 20fmol of a 59bp biotinylated DNA probe 
containing >35% C nucleotides, including a 6bp repeat of C.  A slowly migrating complex was 
identified (lane 2, top arrow) that was specifically competed by non-biotinylated probe 
(CCCCCC) (lane 3) but not by a scrambled probe containing less than 20% C bases (lane 4).  
See Table 3.6 for DNA sequences. 
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Figure 3.6:  AP2IV-4 represses cyst wall and bradyzoite surface antigens through direct 
promoter interaction.   
Promoters from SAG4.2 (2.4 fold, red bar), BPK1 (1.2 fold, orange bar), SRS9 (1.7 fold, green 
bar), MCP4 (2.5 fold, blue bar), and TGGT1_226310 (0.9 fold, purple bars) were fused to firefly 
luciferase and co-transfected in to parent and Δap2IV-4 27 strains with alpha-tubulin renilla 
luciferase for normalization (33).  After transfection, parasites were inoculated into T25cm2 
flasks and grown for 30h (pH 7.0, 37C) prior to harvest.  Fold change luciferase between parent 
and AP2IV-4 knockout strains was calculated by dividing the luciferase counts of each promoter 
by the average renilla luciferase from all promoters.   
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CHAPTER FOUR: 
An ApiAP2 factor with unusual chromosome binding activity is required for bradyzoite 
development in Toxoplasma gondii 
 
Introduction: 
In nature, Toxoplasma exhibits a heteroxenous life cycle that includes a sexual stage 
exclusive to the feline definitive host and the intermediate, asexual stage capable of infecting 
most warm-blooded animals, including humans.  The intermediate life cycle involves at least 
three independent developmental stages.  The end-stage sporozoite and bradyzoite initiate 
infections from environmental contact with oocysts or food contaminated with tissue cysts, 
respectively.  Each of these end-stages develop into the asexual replicating tachyzoite stage, 
which is the cause of acute disease in people and animals (1, 2).  The ability of the tachyzoite to 
recycle back into the dormant bradyzoite tissue cyst is the cause of life-long infections in the 
intermediate host (3).  This is a unique developmental adaptation of Toxoplasma and a few 
other coccidian parasites, as development is not reversible in most of the coccidian family 
members studied including the large number of Eimeria spp. that cause livestock disease.  
Complex changes in gene expression accompany each step in the Toxoplasma developmental 
pathway (4-6), however, the molecular switch mechanisms controlling development of the 
clinically important tachyzoite to bradyzoite step has yet to be characterized.   
The recent discovery of a major lineage of proteins in Apicomplexa (ApiAP2 factors) that 
are weakly similar to the APETALA 2 (AP2) group of transcription factors found in plants may 
provide evidence for the regulation of gene-specific transcriptional mechanisms in these 
parasites (7).  Mechanistic studies of ApiAP2s in P. berghei and Toxoplasma reveal critical roles 
for stage specific regulation of developmental gene expression, both as transcriptional 
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activators (8-10) and repressors (11).  Combined, these studies identify the first gene specific 
transcriptional regulators in Apicomplexa parasites.  A novel, non-transcriptional role was 
identified for PFSIP2 in the heterochromatic binding of sub-telomeric regions of P. falciparum 
chromosomes during the intraerythrocytic cycle of development (12), indicating apicomplexans 
have evolved new mechanisms for these DNA binding proteins not observed in the distant AP2 
factors of plants.     
So far, ApiAP2 studies have focused on AP2s whose expression is limited to a single 
developmental stage.  Here we describe AP2VI-1, which is one of the most dynamically 
regulated ApiAP2 mRNAs in Toxoplasma with peak expression during S-phase of tachyzoite 
cell cycle.  AP2VI-1 is also expressed throughout the bradyzoite stage of development, 
including end-stage tissue cysts in the murine brain.  AP2VI-1 is non-essential in type I, 
laboratory adapted strains, however, genetic deletion was unsuccessful in developmentally 
competent strains of Toxoplasma, indicating the role for AP2VI-1 likely involves a mechanism 
required for bradyzoite development.  
 
Results: 
Toxoplasma AP2VI-1 is a dual ApiAP2 domain factor.  The Toxoplasma genome 
encodes 68 AP2 DNA binding domain-containing proteins with from 1-8 ApiAP2 binding 
domains (4, 13).  AP2VI-1 is an example of an ApiAP2 factor with a tandem ApiAP2 domain.  
While both AP2 domains contained within AP2VI-1 are canonical, the secondary structure of the 
domains are not identical.  Domain 1 contains 3 full beta-sheets and the single alpha helix 
characteristic of the AP2 family, whereas domain 2 has 3 truncated beta-pleated sheets and a 
full helix.  Initial computer predictions of the AP2VI-1 gene presented a single exon gene 
encoding one of the smaller ApiAP2 factors with a mass of ~32 kDa (286 amino acids, 
www.ToxoDB.org).  To verify the predicted size of this factor we epitope tagged the protein 
using a C-terminal fusion gene knock-in strategy (14) (see also Material and Methods).  The 
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resulting Western blot indicated the AP2VI-1HA fusion protein is ~80kDa, not the predicted 
~32kDa factor demonstrating that the translational start is considerably upstream of the 
computer annotation (an in-frame ATG encodes a 579 amino acid protein) (Fig. 4.1B).  Also, 
histone acetylation patterns identify the position of the AP2VI-1 promoter and newer RNA 
sequencing confirms the larger protein we observed in our biochemical analysis.  Finally, we 
confirmed that AP2VI-1 is encoded by a longer mRNA (1737bp) by RT-PCR.     
AP2VI-1 expression studies.  AP2VI-1 is one of 24 ApiAP2 genes that are transcribed 
once per cycle with peak mRNA levels distributed throughout the division cycle (4).  AP2VI-1 
mRNA is one of the most abundant and dynamically regulated of all the Toxoplasma ApiAP2s 
with peak expression during S phase of the eight-hour tachyzoite cell cycle (Fig. 4.1A, green).  
In order to confirm the dynamic change of AP2VI-1 in parasite division, we engineered a 
parasite expressing AP2VI-1YFP at the endogenous locus and the secondary marker IMC1TFP for 
live visualization of parasite division and cell cycle progression.  As with previously tagged 
AP2s, AP2VI-1YFP localized exclusively to the nucleus and the mRNA expression pattern was 
predictive of protein expression.  Live imaging of tachyzoites that express AP2VI-1YFP confirmed 
the periodic nature of expression and the S-phase mRNA timing of this factor.  Still-frame 
images were taken across an 8-hour time course (10min/image) and we were able to capture 
AP2VI-1YFP expression in 4 separate vacuoles (#1-4) that nicely demonstrated  tight intra-
vacuole synchrony in an otherwise asynchronous population (Fig. 4.1C).  In this series, AP2VI-
1YFP was first detected in the vacuole with 16 parasites (#1, Fig. 4.1C), followed by the vacuole 
of 4 (#2, Fig. 4.1C), then the vacuoles with 2 parasites (Fig. 4.1C, vacuoles #3 and #4).  
Duration of AP2VI-1YFP expression was ~90 minutes, which is measured by following expression 
from the 140 to 210 minute images for the vacuole of 4 parasites (#2, Fig. 4.1C).  Daughter 
formation follows within 30 minutes the disappearance of AP2VI-1YFP (see insert image of the 
300 minute still-frame) that is consistent with the S-phase assignment of this AP2 factor.  The 
inset image shows the formation of daughter buds was coincident with the disappearance of 
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AP2VI-1YFP expression.  A separate time-lapse of a single parasite vacuole quantified AP2VI-
1YFP expression during one complete tachyzoite division cycle (Fig. 4.1D).  The estimated length 
of AP2VI-1YFP expression during the tachyzoite cell cycle is ~90 minutes, with a peak-to-peak 
expression time that matches the ~8h peak-to-peak of the encoded mRNA and cell cycle 
pattern of expression (Fig. 4.1D).   
 Live imaging (Fig. 4.1) of endogenous AP2IVI-1YFP fusion protein indicated a tightly 
regulated, S-phase exclusive expression pattern of which ~20% of parasites in an 
asynchronous population were positive for this factor.  To further pinpoint the cell cycle timing of 
AP2VI-1HA, a series of co-markers were utilized to define the timing of initiation and degradation 
of AP2VI-1HA within a single division cycle.  To date, there are well-defined markers for the 
centrocone (membrane occupation and recognition nexus protein 1, MORN1 (15, 16) and the 
apical cap (IMC sub-compartment protein 1, ISP1, (17) whose morphological changes from the 
G1/S-phase boundary through mitosis of tachyzoite cell cycle will be used to define the 
expression timing of AP2VI-1HA.  Previous data indicate AP2VI-1HA is expressed during S-phase 
but is absent once internal daughter structures are initiated (Fig. 4.1C, inset).  We first co-
stained AP2VI-1HA parasites with MORN1 (α-MORN1, a gift from Ke Hu, Indiana University), a 
marker that is duplicated at START and initially localizes to the daughter centrocone and is the 
earliest marker for the basal complex in Toxoplasma (15, 16). As shown in Fig. 4.2Aa, AP2VI-
1HA is absent from S-phase parasites that lack MORN1 ring structures.  AP2VI-1HA is first 
detected in parasites with fully formed MORN1 rings (Fig. 4.2Ab) and maximum expression of 
AP2VI-1HA is coincident with the separation of the daughter centrocones (Fig. 4.2Ac), a timing 
that suggests the parasites have committed to nuclear division.  Decreased AP2VI-1HA 
expression was seen as MORN1 rings flattened (Fig. 4.2Ad) and is no longer detected as 
MORN1 migrated down the internal daughters of the dividing parasite (Fig. 4.2Ae).  Next, the 
timing of AP2VI-1HA expression was determined by co-localization with the apical cap protein 
ISP1 ((17) 7e8, a gift from Dr. Peter Bradley, UCLA) and was consistent with the MORN1 
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marker.  Initiation of AP2VI-1HA expression is detected when only the mother apical cap is 
visible (Fig. 4.2Bb) and maximum expression of AP2VI-1HA corresponded with the appearance 
of small ring structures underneath the mother apical cone that define the newly formed 
daughter apical scaffold (Fig. 4.2Bc).  AP2VI-1HA expression is rapidly degraded just prior to the 
completion of the mature daughter apical cap (Fig. 4.2Bd and e)(17) and the onset of nuclear 
division is visualized only after AP2VI-1HA is undetectable in all parasites (Fig. 4.2Ae and Fig. 
4.2Be, DAPI, blue).  Together, the measurements of AP2VI-1 expression timing indicate a factor 
that spans the transition between S-phase and mitosis as indicated by the duplication and 
separation of the daughter centrocones and appearance of the daughter apical cones.   
AP2VI-1 defines a specific subpopulation in differentiating parasites.  Recent 
transcriptome analysis of Toxoplasma development both in vitro and in vivo (5) indicates AP2VI-
1 is expressed across the clinically important tachyzoite and bradyzoite developmental stages of 
the intermediate host life cycle.  The best evidence for ApiAP2 functions in the Apicomplexa has 
come from studies of parasite development (i.e. in P. berghei (9, 10) and Toxoplasma (8, 11)).  
To further our understanding of the role of AP2VI-1 in Toxoplasma development, we 
endogenously tagged the AP2VI-1 locus using 3xHA in the developmentally competent 
PruΔku80Δhx (type II genetic background) strain (18).  Similar to the RHΔku80 (14),  
PruΔku80Δhx parasites preferentially undergo homologous recombination, which allows for 
introduction of an epitope tag at the endogenous locus in a developmentally competent strain 
(18).  In the tachyzoite, PruAP2VI-1HA maintained its dynamic cell cycle regulation (Fig. 4.1A for 
RH mRNA) and is expressed in ~25% of an asynchronous population (Fig. 4.3A, green bar), 
which is a similar level to AP2VI-1HA (~20%, data not shown) in type I-RH transgenic parasites 
(Figs. 4.1 and 4.2).  Several options are available for induction of bradyzoite differentiation in the 
Toxoplasma in vitro model (19-22), however the most common method is treatment with 
alkaline pH (pH 8.2) media.  PruAP2VI-1HA expression was evaluated at time points 24h, 48h 
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and 72h post bradyzoite induction to quantify expression during bradyzoite development.  At 
24h, PruAP2VI-1HA is expressed in 22% of vacuoles (Fig. 4.3A, light blue bar) with little increase 
(26%) seen at the 48h time point (Fig. 4.3A, blue bar).  Roughly 34% of vacuoles were positive 
for PruAP2VI-1HA expression at the 72h time point (Fig. 4.3A, red bar), indicating there is little 
change in the expression of PruAP2VI-1HA during bradyzoite development in vitro.   
It is known that bradyzoite development disrupts the intra-vacuolar cell cycle synchrony 
within an individual vacuole (23) and, as illustrated in Fig. 4.3B, AP2VI-1 (α-AP2VI-1, green) is 
not expressed in every single nucleus (blue nuclei, DAPI) within a bradyzoite tissue cyst 
(Dolichos, red).  Whether the heterogeneity of PruAP2VI-1HA expression indicates a 
subpopulation of parasites at a different phase of the tachyzoite cell cycle (active replication) or 
that have fully developed into a G0/G1 end-stage bradyzoite, has not yet been determined.  
From the previous study of the inducible transcriptional repressor AP2IX-9 (11), we also 
confirmed PruAP2VI-1HA expression in tissue cysts contained within the brains of mice 21 days 
post infection (Fig. 4.3C) (11). 
Establishing AP2VI-1 conditional expression models.  Conditional regulation of gene 
expression is a powerful tool to study the function of proteins in Apicomplexa parasites.  In 
Toxoplasma, the most common approach for conditional expression is to swap the gene specific 
promoter with a tetracycline inducible promoter that provides control of gene expression at the 
transcriptional level (24-29).  Recently, the fusion of proteins with the ddFKBP protein allows for 
stabilization or rapid degradation of the fusion protein based on the presence or absence of a 
small molecule ligand, Shield-1 (30-32).  We first modified the ddFKBP conditional expression 
approach by constructing an ectopic expression vector that contained a N-terminal ddFKBP 
protein fused in frame to 3xHA repeats for protein visualization.  The constitutively expressed 
alpha-tubulin promoter drives the transcription of the ddFKBP fusion cassette and the plasmid 
contains a chloramphenicol selectable marker for stabile integration (see Fig. 4.4A for 
schematic).  We successfully isolated a transgenic clone in RHΔhx parasites with a Shield-1 
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dependent copy of AP2VI-1 (DDAP2VI-1, see Materials and Methods) that preserved both the 
cell cycle timing of expression and the nuclear localization (Fig. 4.4A, 100nM Shield-1 panel).  
This indicates the dynamic regulation of AP2VI-1 in the tachyzoite may be attributed to post-
transcriptional mechanisms, not just transcriptional input.  In the absence of Shield-1, 
expression of DDAP2VI-1 was still detected (Fig. 4.4A, no Shield-1 panel) by IFA and verified by 
Western blot with a native antibody raised against AP2VI-1 (Fig. 4.4A, No Shield, 100nM Shield-
1 and 500nM Shield-1).  There is no detectable difference in stabilization or accumulation of 
DDAP2VI-1 using 100nM or 500nM (Fig. 4.4A, Western).  These data indicate the constitutive 
expression of DDAP2VI-1 from the alpha-tubulin promoter overcame both Shield-1 and natural 
proteolytic pathways active in the parasite and does not allow full ablation of DDAP2VI-1 
expression.  Thus, the background expression of DDAP2VI-1 would not allow for the creation of a 
null transgenic parasite for AP2VI-1 (Fig. 4.4A, No Shield-1, Western blot).   
To overcome the stabilization of the Shield-1 dependent copy of AP2VI-1 in the absence 
of Shield-1, we replaced the alpha-tubulin promoter with the endogenous promoter from AP2VI-
1 (see Fig. 4.4B for schematic and Materials and Methods), which provides the native 
transcriptional context for the ectopic copy (EnDDAP2VI-1).  We isolated transgenic clones of 
EnDDAP2VI-1 in RHΔhx and detect no expression of the EnDDAP2VI-1 transgene in the absence of 
Shield-1 (Fig. 4.4B, no Shield-1 panel) while stabilization with 100nM Shield-1 resulted in both 
the correct nuclear localization and cell cycle timing of expression (Fig. 4.4B, 100nM Shield-1 
panel).  Induction of EnDDAP2VI-1 with Shield-1 was confirmed by Western blot and complete 
ablation of the EnDDAP2VI-1 signal is achieved in the absence of Shield-1 (Fig. 4.4B).  The 
concentration of Shield-1 had no effect on fusion protein stabilization (Fig. 4.4B, Western).  The 
Shield-1 dependent regulation of AP2VI-1 illustrates an effective approach for regulating 
expression of this factor in Toxoplasma and highlights the importance of using authentic 
transcriptional elements in generating these types of models. 
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Genetic knockout studies indicate AP2VI-1 is essential for bradyzoite 
development.  To interrogate the potential role for AP2VI-1 in the tachyzoite cell cycle we 
attempted genetic knockout using several different approaches. First, we attempted to replace 
the AP2VI-1 locus with a modified cosmid (PSBLE44) that allowed us to replace the AP2VI-1 
locus with the phleomycin marker (33, 34).  The recombineered cosmid was introduced into 
RHΔhx (type I) parasites and after two rounds of phleomycin drug treatment isolated clones 
were screened by PCR to verify replacement of the AP2VI-1 locus with the drug selectable 
marker.  Cosmid based deletion of AP2VI-1 was successful in ~20% of isolates screened (for a 
summary of all knockout attempts, see Table 4.1), however, due to the mis-prediction of the 
original gene locus (Fig. 4.1B), only the 3’ half of AP2VI-1 locus was excised.  While the 3’ half 
included both AP2 DNA binding domains, we wanted to verify the N-terminal half was not 
sufficient for AP2VI-1 function.  To address this issue, we used the 3-fragment Gateway 
(Invitrogen) recombinational cloning method that allows gene-flanking regions to be cloned 
around a selectable marker (35) (Fig. 4.5A).  The 5’ and 3’ flanking regions of the complete 
AP2VI-1 gene locus were cloned by recombination around the HXGPRT selectable marker and 
introduced into RHΔku80 strain tachyzoites (14).  Deletion of the AP2VI-1 locus was verified for 
two (Δap2VI-1 clones 8 and 33; of 11, Fig. 4.5B) clonal isolates by standard PCR with primers 
that flank the gene locus (Fig. 4.5A for primer location), at the mRNA level by RT-PCR (Fig. 
4.5C) and finally Western blot analysis with an antibody to the native protein (Fig. 4.5D).  As 
indicated in Fig. 4.4B, standard PCR led to the mischaracterization of a single clonal isolate 
(Δap2VI-1 clone 42), that was correctly identified by RT-PCR (Fig. 4.5C) and Western blot (Fig. 
4.5D), that contained a functional copy of AP2VI-1.  No detectable differences in growth or 
protein expression pattern as assessed by IFA with known cell cycle markers for the 
centrosome (hCentrin2) and the centrocone (MORN1) or defined changes in nuclear 
morphology during the tachyzoite cell cycle were attributed Δap2VI-1 transgenic isolates (data 
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not shown).  Furthermore, microarray analysis of Δap2VI-1 transgenic parasites revealed no 
significant changes in gene expression associated with the loss of AP2VI-1 mRNA expression 
(data not shown), which indicated AP2VI-1 is non-essential to the laboratory-adapted type 1 
strain parasites.  Unfortunately, the RH strain is defective in bradyzoite development, thus, this 
knock out strain could not be used to assess the role of AP2VI-1 in tachyzoite to bradyzoite 
development.   
The completion of the bradyzoite transcriptome indicates AP2VI-1 is abundantly 
expressed in the bradyzoite stage, which we confirmed at the protein level in animals ((5, 11) 
and Fig 4.3C).  Given that AP2VI-1 is non-essential to the tachyzoite stage, we hypothesized 
the main role AP2VI-1 may not be to regulate cell cycle progression in the tachyzoite, but 
instead, to control some aspect of bradyzoite development or bradyzoite survival.  To test 
whether AP2VI-1 has a role in the bradyzoite, we attempted gene knockouts in the 
developmentally competent PruΔku80Δhx strain (18) using the 3-fragment AP2VI-1 knockout 
construct successfully used to delete AP2VI-1 in RH strains (Fig. 4.5A).  After drug selection 
and clonal isolation, a viable Δap2VI-1 transgenic parasite in the type II genetic background was 
never recovered (0 of 109 clones, Table 4.1) indicating that AP2VI-1 likely has an important role 
in developmentally competent strains.   
Its possible genetic deletion of AP2VI-1 in the PruΔku80Δhx strain results in a slow 
growing parasite that would be outgrown in a culture containing parasites with a wild-type copy 
of AP2VI-1.  To explore this hypothesis, we adopted a plasmid based loxP/CRE system 
successfully implemented in the deletion of MORN1, a Toxoplasma gene originally classified as 
essential (15, 16).  Briefly, the PTKO_II plasmid (a gift from Dr. Ke Hu, Indiana University) 
contains three cloning sites; a 5’ site for cloning for the 5’UTR of the target gene, a middle 
cloning site, flanked by two loxP sites, allows the cloning of the gene coding sequence, and the 
3’site for cloning the 3’UTR of the target gene (15).  We successfully cloned all three fragments 
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(5’UTR, coding sequence, 3’UTR, see Materials and Methods) of the AP2VI-1 locus creating an 
AP2VI-1 gene replacement cassette in which the coding sequence was “floxed” with loxP 
recognition sites (Fig. 4.5E, schematic).  We introduced the AP2VI-1 gene replacement cassette 
into PruΔku80Δhx and successfully isolated a transgenic strain (PruQ-AP2VI-1HA-PTKOII) 
containing a “floxed” AP2VI-1 locus (Fig. 4.5E, schematic,).  In this system, CRE mediated 
removal of the AP2VI-1 locus is achieved by co-transfection with a plasmid carrying an active 
copy of CRE recombinase (pminCRE-GFP) (15).  Initial attempts to delete the AP2VI-1 locus in 
this transgenic were unsuccessful (two experiments, Table 4.1).  The failure to recover viable 
Δap2VI-1 transgenic parasites in developmentally competent (type II, PruΔku80Δhx) parasite 
strains illustrates that AP2VI-1 has an important role in the bradyzoite developmental pathway.  
The ease in epitope tagging the AP2VI-1 locus in type 1 and II strains and our ability to readily 
disrupt this locus in the type I RHΔku80 strain parasites indicates that our failure to delete this 
factor from a developmentally competent strain is not due to a refractory chromosome locus. 
AP2VI-1 binds DNA with distinct sequence requirements.  DNA binding is a hallmark 
of AP2 domain containing proteins (7, 36, 37).  In order to determine the preferred DNA binding 
sequence for AP2VI-1 protein-binding microarrays (PBMs) were completed (36, 38).  For 
AP2VI-1, we constructed three different GST-AP2 fusion proteins, one for each individual AP2 
domain and a third containing both AP2 domains including the interceding linker sequence (Fig. 
4.1B).  Expressed and purified GST-AP2 fusion proteins were subjected to a DNA microchip 
containing every possible 10mer DNA sequence and GST-AP2VI-1 interaction with DNA 
resulted in a fluorescent signal that corresponded to a specific DNA sequence.  These 
sequences were aligned and scored resulting in a position weight matrix representative of the 
DNA binding affinity for each GST-AP2 fusion protein (38).  For the dual domain GST-AP2VI-1, 
the primary PBM motif (5’-CCTCATGAG-3’/3’-GGAGTACTC-5’, enrichment score=0.495) 
contained a core TCATGA palindrome (Fig. 4.6A) while the secondary motif consists of a pure 
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purine track (5’-AAAAGAGG-3’/3’-GGAGAAAA-5’, enrichment score=0.491).  These data 
indicate some flexibility in the recognition sequence required for AP2VI-1 binding (39) To 
determine if each PBM motif correlated to an individual AP2 domain, we hybridized the motifs 
separately to determine the DNA specificity of each domain.  Interestingly, the only GST-AP2VI-
1 protein to bind DNA with sequence specificity contained both AP2 domains and the linker 
sequence.  GST-AP2VI-1 fusions proteins with the individual AP2 domains from AP2VI-1 did not 
bind DNA, indicating both AP2 domains and possibly the linker sequence are required for DNA 
binding.  Genome wide bioinformatics assessment of putative AP2VI-1 gene regulatory targets 
with the PBM motifs indicated showed no significant enrichment of the predicted sequences in 
the regulatory regions of co-expressed mRNAs, as had been suggested in other Apicomplexa 
(38).  
 To determine the DNA binding specificity of AP2VI-1 we conducted electromobility shift 
assays (EMSA) using the GST-AP2VI-1 fusion protein containing both DNA binding domains 
and DNA probes containing one or both core PBM motifs (Fig. 4.6A) (11, 40).  We verified GST-
AP2VI-1 formed a single protein-DNA complex (Fig. 4.6B, lane 2) with a probe that contained 
only the secondary PBM motif (5’-AAAAGAGG-3’/3’-GGAGAAAA-5’), but not the primary motif 
(5’-CCTCATGAG-3’/3’-GGAGTACTC-5’).  Competition with 300x unlabeled wild-type DNA 
probe (Fig. 4.6B, lane 3) prevented protein-DNA interaction whereas DNA probes containing 
mutations within the AP2VI-1 DNA binding motif did not compete for GST-AP2VI-1 DNA 
interaction (300x, Fig. 4.6B, lane 4).  The dual nature of DNA binding for AP2VI-1 may be 
reflected in the distinct sequences identified in the PBM motifs, however, we were unable to 
confirm DNA binding of each individual domain by gel shift assay.  These data validated that 
AP2VI-1 binds DNA in a sequence specific manner that was predicted by the PBM motifs and 
likely requires both AP2 domains, a phenomenon described previously in an AP2 involved in 
chromosome end biology in P. falciparum (12).   
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Genome wide binding of AP2VI-1 indicate strong binding to the peri-centromeric 
regions on each chromosome.  The nuclear localization (Fig. 4.1C) and DNA binding (Fig. 
4.6B) of AP2VI-1 predicts interaction with parasite chromatin.  Determining, at the full genome 
level, the localization of AP2VI-1HA could provide clues to its function during development.  To 
map the genome wide occupation of AP2VI-1, we performed chromatin immunoprecipitation-
DNA microchip (ChIP-chip) analysis using the AP2VI-1HA tagged strain, an approach 
successfully employed to map acetylation patterns of active promoters in Toxoplasma (41).  
Briefly, AP2VI-1HA strain tachyzoites were subjected to formaldehyde treatment to crosslink 
protein to the chromatin.  Following isolation and shearing (.2kb-1kb fragments) of nuclear 
material, specific AP2VI-1HA protein-DNA interactions were isolated by incubation with an 
antibody to HA (Roche).  AP2VI-1HA bound DNA was purified and subjected to genome wide 
amplification and the resulting DNA was hybridized to a 650kb tiling array (41).  The most 
significant DNA occupation of AP2VI-1HA localized to the peri-centromeric regions on 12 of 14 
chromosomes, a pattern nearly identical to the recently described centromere histone H3 
variant CenH3 (Fig. 4.7A) (42). In addition to the peri-centromeric localization, AP2VI-1HA 
occupied to its own locus and was enriched across the promoter and coding sequence, which 
indicated AP2VI-1HA may regulate its own transcription through a negative-feedback loop (Fig. 
4.7B).  It is important to note that localization to the peri-centromere is unique to AP2VI-1 as 
other AP2s have different binding patterns (Kim, Sullivan and White, unpublished).  
To verify AP2VI-1HA localization and quantify the enrichment at the peri-centromeric 
regions, we used chromatin immunoprecipitation followed by quantitative PCR (ChIP-qPCR) 
(11, 41).  Tiled amplicons (75-150bp) that spanned the peri-centromeric region of Chr.Ia were 
designed to match the loci occupied by AP2VI-1HA in ChIP-chip data sets (Fig. 4.7A).  A non-
target region on Chr.Ia was selected as a chromosome specific control for enrichment.  AP2VI-
1HA specific and control (rabbit IgG) ChIP DNA were isolated and amplified as in ChIP-chip 
experiments, however instead of hybridization to a DNA array, the resulting DNA was used as 
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the template for qPCR.  Quantification of enrichment of AP2VI-1HA bound DNA at six loci tiled 
across the Chr.Ia peri-centromeric region (1-6, Fig. 4.7C, see Materials and Methods for 
chromosome coordinates for each probe) was completed.  Relative enrichment is consistent 
across all six probes (average of 4.2 fold) and ranged from 2-fold (Fig. 4.7C, black bar) to nearly 
7-fold (Fig. 4.7C, red bar) enrichment of AP2VI-1HA (Fig. 4.7C). These data are independent 
verification of the novel, peri-centromeric DNA binding pattern of AP2VI-1HA that strongly 
correlate with the centromere defining histone variant CenH3 (Fig. 4.7A, blue track) (42) 
observed in ChIP-chip experiments.  Similar to the sub-telomeric localization of PfSIP2 AP2 
(12), it is likely AP2VI-1 is not a transcriptional regulator, instead has adopted a role in 
chromatin biology at the centromere during asexual development.   
 
Discussion: 
In this study we have characterized the expression of AP2VI-1 in Toxoplasma.  AP2VI-1 
is expressed across the intermediate life cycle, exhibiting dynamic cell cycle regulation during 
the tachyzoite stage and high levels of expression in tissue cysts produced in vitro and in tissue 
cysts obtained from infections of mouse brain.  The tight protein expression of AP2VI-1 in the 
tachyzoite cell cycle is also seen in ectopic constructs employing tubulin promoters suggesting 
there is a strong post-transcriptional mechanism also operating to achieve cell cycle timing in 
this developmental stage.  We successfully employed the ddFKBP/Shield-1 conditional 
expression model with two separate promoters, providing evidence that nuclear AP2 factors are 
amenable to conditional expression using this model.  AP2VI-1 binds DNA with sequence 
specificity, though preferred sequence motifs were not predictive of gene regulatory targets.  
Surprisingly, genome wide binding of AP2VI-1 localized the protein to the peri-centromeric 
regions on all Toxoplasma chromosomes, revealing a novel binding pattern that could implicate 
AP2VI-1 in the structure of the centromere or heterochromatin maintenance.  AP2VI-1 also 
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localizes to the promoter, gene body, and 3’UTR of its own locus, suggesting AP2VI-1 may 
regulate its own expression through a negative feed back loop.   
Genetic deletion of AP2VI-1 in type I strain parasites revealed no changes in gene 
expression associated with the loss of AP2VI-1 or any observable growth defects.  However, 
multiple attempts to recover viable Δap2VI-1 transgenic parasites in developmentally competent 
strains were unsuccessful, indicating AP2VI-1 is essential for successful completion of 
bradyzoite development.  The essential nature of AP2VI-1 in native strains of Toxoplasma 
indicates a role in regulating development of the bradyzoite tissue cyst.  The S-phase timing of 
peak expression corresponds with the time in the tachyzoite cell cycle when the decision to 
continue replicating as a tachyzoite or “switch” to the end-stage bradyzoite is thought to be 
made (23, 43).  The success or failure of a viable genetic knockout of AP2VI-1 is based on the 
developmental competence of the parasite strain.  This dichotomy provides insight into 
Toxoplasma development.  First, the commitment to bradyzoite development requires a slowing 
of the tachyzoite replication cycle and laboratory adapted strains, especially RH strains, are 
locked into a fast replicating state (19, 23, 44).  Second, in genetic strains capable of the 
complete life cycle, the promoters of bradyzoite specific transcripts, like BAG1 and LDH2, are 
hyper-acetylated during the tachyzoite division cycle (40), indicating they are primed for active 
gene expression, likely waiting for the proper signals to execute the bradyzoite “switch”.  The 
hyper-acetylation of bradyzoite promoters is not observed in laboratory-adapted strains, 
consistent with their inability to complete development (40).  Therefore, the observation AP2VI-1 
is only essential for developmentally competent strains support the hypothesis its function is 
intimately tied to chromatin mechanisms active only during bradyzoite development.   
The localization of AP2VI-1 to the peri-centromeric regions of all identified Toxoplasma 
chromosomes suggests it may also have a role in chromosome maintenance and/or replication.  
Previous studies of PFSIP2 (12), a dual AP2 domain protein in P. falciparum, suggest 
Apicomplexa species have adapted DNA binding proteins not only to regulate developmental 
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gene expression, but in the structure of heterochromatin and integrity of sub-telomeric regions 
of chromosomes.  In addition, overexpression of PfSIP2 had no effect on gene expression, 
similar to our findings in the overexpression of DDAP2VI-1 in RH strains.  Toxoplasma ApiAP2s 
are known to interact with the chromatin remodelers histone deacetylase 3 (HDAC3) and 
histone acetylase GCN5B, which is consistent with a role in epigenetic mechanisms (45, 46).  
Combined with the localization of AP2VI-1 to peri-centromeric regions and the lack of 
transcriptional changes associated with Δap2VI-1 transgenic parasites, our data appear to point 
towards a chromosome function for AP2VI-1 that is required for parasite development.   
 
Materials and Methods: 
 
All transgenic strains developed and the sequence designs of the oligonucleotides can be found 
in Tables 4.2 and 4.3.  All cell culture methods can be found in Chapter 2 of the dissertation. 
Gene fusion with epitope tags.  AP2VI-1 (TGGT1_240460) was tagged at the 
endogenous locus in both RHΔhxΔku80 (type I) and PruΔku80Δhx (type II) strains that 
preferentially undergo homologous recombination using the pLIC-3xHA/DHFR or pLIC-
YFP/DHFR plasmid (14, 18). Transgenic parasites were selected using 1uM pyrimethamine and 
clones isolated by limiting dilution.   
Immunofluorescence assays (IFA). Parasites cultures were cultured in HFF cells and 
slides prepared as described in Chapter 2.  Primary antibodies were used at the following 
concentrations: HA (Roche, rat mAb 3F10, 1:500); ISP1 (mouse pAb, 1:2000, Dr. Peter Bradley, 
UCLA); MORN1 (rat pAb, 1:200, Dr. Ke Hu, Indiana University); AP2VI-1 (rabbit, pAb, 1:500); 
biotin-labeled Dolichos biflorus agglutinin (DBA) (Vector labs, CA,1:3000).  Alexa and 
streptavidin conjugated secondary antibodies were all used at 1:1000 dilution.  All images were 
collected using a 100x Nikon objective on a Zeiss Axiovert microscope.  Live fluorescence.  
Images were collected using a Delta Vision microscope equipped with a 100x objective and a 
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temperature chamber to maintain 37C and proper CO2 levels over the 8h time course.  
Vacuoles were imaged every 10 minutes for both YFP (544nm) and TFP (581nm) filters and 
composite images compiled.  All live imaging was collected by Dr. Boris Striepen and Dr. Carly 
Jordan at the University of Georgia.  
Conditional expression model for AP2VI-1. For conditional expression of AP2VI-1, the 
full length coding sequence of the single exon gene was PCR amplified from genomic DNA and 
incorporated in-frame XmaI/SbfI sites to clone into the pCTNDDHA3 plasmid (Dr. Boris 
Striepen, University of Georgia).  This resulted in a fusion protein that contains the ddFKPB 
(11.2kDa) and 3xHa (4.4kDa) N-terminally fused to the AP2VI-1 protein (62.7kDa) for a final 
mass of ~78.3kDa.  To introduce the endogenous AP2VI-1 promoter into pCTNDDHA3-AP2VI-
1, we PCR amplified 1600 nucleotides upstream of the start codon from genomic DNA using 
primers that incorporated SpeI/BglII restriction sites for cloning.  We digested both the 
pCTNDDHA3-AP2VI-1 plasmid and the AP2VI-1 promoter PCR product with SpeI/BglII, and 
following purification of each component, subjected the DNA fragments to ligation, creating the 
pAP2VI-1-NDDHa3-AP2VI-1 plasmid.  Both pCTNDDHA3-AP2VI-1 (DDAP2VI-1) and pAP2VI-1-
NDDHa3-AP2VI-1 (EnDDAP2VI-1) were transfected into RHΔhx.  Transgenic parasites were 
selected using chloramphenicol (34ug/mL) and cloned by limiting dilution.   
Gene knockout models for AP2VI-1.  Cosmid recombineering:  The AP2VI-1 locus is 
overlapped by the cosmid PSBLE44 (www.ToxoDB.org).  PSBLE44-AP2VI-1 KO cosmid was 
created by cosmid recombineering as previously described (33, 34) using the phleomycin 
selectable marker to replace the C-terminal half of AP2VI-1, including both AP2 DNA binding 
domains.  The PSBLE44-AP2VI-1 KO cosmid was introduced into RHΔhx strain parasites with 
transgenic parasites selected with phleomycin (50ug/uL) and cloned by limiting dilution.  3-
fragment Gateway (Invitrogen).  Both the 5’ and 3’ UTR of the AP2VI-1 locus were PCR 
amplified from type I genomic DNA and used to create Gateway entry clones.  The 1757bp 5’ 
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UTR was cloned into the pDONRP4-P1r plasmid and the 1953bp 3’UTR was cloned into the 
pDONRB2r-B3 plasmid by the BP recombination reaction.  After isolation of the entry clones, 
pDONRP4-P1R AP2VI-1 and pDONRP2r-P3-AP2VI-1 were combined in a LR recombination 
reaction with p221-HXGPRT to create the pDEST-AP2VI-1-HX knockout plasmid.  The final 
plasmid was introduced into RHΔku80Δhx (type I) and PruΔku80Δhx (type II) strains and 
transgenic parasites were selected using mycophenolic acid followed by clonal isolation by 
limiting dilution.  PTKO_II model:  The PTKO_II and pminCRE-GFP plasmids were kindly 
provided by Dr. Ke Hu, Indiana University and can be found in (15).  To create the PTKO_II-
AP2VI-1 HX knockout plasmid, we first replaced the original multiple cloning site II (MCSII, (15)) 
with the following linker for restriction mediated cloning: BglII-AscI-FseI-SbfI-StuI.  There are 3 
multiple cloning sites (MCS) for restriction enzyme mediated cloning in the PTKO_II plasmid 
and the plasmid is constructed with the following elements: MCSI (5’ flank)-loxP site-MCSII 
(gene coding sequence)-HXGPRT-loxP-MCSIII (3’ flank).  PCR of the 5’UTR (NotI/EcoRV for 
cloning), AP2V-1 coding sequence (BglII/SbfI) and 3’UTR (HindIII/ApaI) of AP2VI-1 was 
amplified from Prugniaud (type II) genomic DNA for the gene flanking regions and from 
PruAP2VI-1HA (clone 1) to provide visualization of protein expression.  AP2VI-1 sequences were 
ligated into the PTKO_II in the following order: 1) 3’UTR 2) gene coding sequence and 3) 
5’UTR.  PTKO_II-AP2VI-1 HX was transfected into PruΔku80Δhx.  Transgenic parasites were 
selected using mycophenolic acid and isolated by limiting dilution.  The “floxed” AP2VI-1 
transgenic was transfected with pminCRE-GFP CRE to induce expression of CRE and the 
AP2VI-1 locus.  After overnight recovery, the population was needle passed and cloned by 
limiting dilution.  All primers can be for the knockout models are located in Table 4.3.  
Protein-DNA binding. Protein binding microarrays and electromobility shift assays 
(EMSA) were conducted as described in Chapter 2.  EMSA reactions with GST-AP2VI-1 dual 
domain protein contained 1 ug of protein per reaction.   
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ChiP-qPCR probe designs.  ChIP-chip and ChIP-qPCR were conducted on the 
transgenic strain AP2VI-1HA (clone A2).  For experimental details on ChIP-chip, please see (41) 
and for detailed methods for ChIP-qPCR please refer to Chapter 2.  Six tiled probes across the 
peri-centromere of chromosome Ia and a control probe can be found with the following genome 
coordinates (www.ToxoDB.org, GT1 genome): Probe 1: 485454 to 485666; Probe 2: 486672 to 
486900; Probe 3: 488124 to 488325; Probe 4: 487989 to 488275; Probe 5: 490451 to 490734; 
Probe 6: 492133 to 492421; Control region ChrIa: 658332 to 658582.  All probes were designed 
using Primer3 software (47) and amplified 75-150 bp regions.  Relative enrichment values were 
determined using the equation 2^-(ΔCt target-ΔCt non-target) where the change in Ct value of specific 
versus nonspecific chromatin at target and non-target loci was calculated. 
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Table 4.1: AP2VI-1 knockout frequencies: 
 
 
  
Strain designation Clonal lineage Knockouts/Total screened Knockout construct
RHΔhxgprt Type I strain 11 of 50 3"fragment"(Fig."4.5A)
RHΔhxgprtΔku80 Type I strain 7 of 50 3"fragment"(Fig."4.5A)
0 of 109 3"fragment"(Fig4."5A)
0"of"42 PTKO_II"(Fig."4.5E)
0"of"119 PTKO_II"(Fig."4.5E)
PruΔhxgprt, Δku80 (Prugniaud) Type II strain
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Table 4.2: Transgenic strains created for AP2VI-1 study 
 
 
  
Name in this study experimental use Parent strain Transgene/selectable marker Drug Selection Clone #
RH-AP2VI-1HA endogenous expression of AP2VI-1 RHΔhxgprt, Δku80 endogenous promoter::AP2VI-1(3xHA)/DHFR-TS pyrimethamine A2
AP2VI-1YFP
endogenous expression of AP2VI-1 
endogenous expressionf of IMC1 
RHΔhxgprt, Δku80 endogenous promoter::AP2VI-1(YFP)/DHFR-TS 
tub::(IMC1-2xTFP)/sagCAT
pyrimethamine 
chloramphenicol IB9
DDAP2VI-1 conditional expression of AP2VI-1 RHΔhxgprt tub::(DD-3xHA)-AP2VI-1/sagCAT chloramphenicol B6, B10
EnDDAP2IV-4 conditional expression of AP2IX-9 RHΔhxgprt endogenous promoter::(DD-3xHA)-AP2VI-1/sagCAT pyrimethamine IB9, 2C2
RHQ-Δap2VI-1 knockout of AP2VI-1 RHΔhxgprt, Δku80 HXGPRT, 3 fragment Gateway phleomycin 8, 33
PruQ-AP2VI-1HA endogenous expression of AP2VI-1 Pru Δhxgprt, Δku80 endogenous promoter::AP2VI-1(3xHA)/DHFR-TS pyrimethamine 1, 2
PruQ-AP2VI-1HA_PTKOII knockout of AP2VI-1 Pru Δhxgprt, Δku80 loxP/endogenous promoter::AP2VI-1(3xHA)/HXGPRT/loxP mycophenolic acid 13, 14
Transgenic strains produced for this study
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Table 4.3: Oligonucleotides for AP2VI-1 study 
 
 
  
Oligonucleotide function Gene/locus Orientation Oligonucleotides (5'->3')
Tagging of endogenous gene loci with 
3xhemagglutinin (HA)  and YFP epitope tags
LIC 5' primer for AP2VI-1  AP2VI-1 Forward TACTTCCAATCCAATTTAATGCGAACAGACATTCACATCGGACTTATCTCCAAC
LIC 3' primr for  AP2VI-1  AP2VI-1 Reverse TCCTCCACTTCCAATTTTAGCCGCGTGGGCCGCTGATACTTCAGC
LIC  AP2VI-1 5' primer to check for recombination  AP2VI-1 Forward GAG AAG CAA GAG GCC ACA GAG GCC
LIC-HA 3' primer to check for 3' recombination N/A Reverse CGCATATCGGGCACATCATAGGGAT
Overespression construct
AP2I-1 CDS cloning into pCTDDHA3 AP2VI-1 CDS Forward AGTCCCCGGGGCGTCACAACTCTGTGCCGGC
AP2I-1 CDS cloning into pCTDDHA3 AP2VI-1 CDS Reverse AGTCCCTGCAGGTCACGCGTGGGCCGCTGATAC
AP2VI-1 promoter replacement in pCTDDHA3 5'UTR AP2VI-1 Forward GTAACTAGTCCTGACACGTCCCAACTAGAG
AP2VI-1 promoter replacement in pCTDDHA3 5'UTR AP2VI-1 Reverse TACAGATCTGGTTGAAGAATCTGAAGCCTAGAC
AP2VI-1 knockout constructs
Cosmid recombineering (PSBLE44) cosmid PSBLE44 Forward
CTGGATATTTGCTGGGGCGCTACCGCCAATGTGTCTGGATGGCCAGCTGCCCTC
GACTACGGCTTCCATTGGCAAC
Cosmid recombineering (PSBLE44) cosmid PSBLE44 Reverse
CACGCGTGGGCCGCTGATACTTCAGCAACCGCCGCTGTCTTGGTGGAACCATA
CGACTCACTATAGGGCGAATTGG
attB4 AP2VI-1 5'UTR AP2VI-1 Forward GGGGACAACTTTGTATAGAAAAGTTGAACCGACGCTGCTAGCAGGACAC
attB1r AP2VI-1 5'UTR AP2VI-1 Reverse GGGGACTGCTTTTTTGTACAAACTTGCGGCAATGTATCCACGCGAGTCTC
attB2r AP2VI-1 3'UTR AP2VI-1 Forward GGGGACAGCTTTCTTGTACAAAGTGGAAGGCATGCGAGAATTCTGCCATCC
attB3 AP2VI-1 3'UTR AP2VI-1 Reverse GGGGACAACTTTGTATAATAAAGTTGCCGAATGAACAGGCTGGCGTTTCCGG
AP2VI-1 3 fragment KO verify 5'UTR AP2VI-1 Forward GGAAGCTGCCGCTAGAGTAACGATGG
AP2VI-1 3 fragment KO verify 3'UTR AP2VI-1 Reverse GAACCAGGTATCTCCTGGGAGCG
AP2VI-1_5’UTR_NotI_cre 5'UTR AP2VI-1 Forward ATA GCGGCCGC CCGCAAGGGCAGCCTTGACCTTCG
AP2VI-1_5’UTR_EcoRV_cre 5'UTR AP2VI-1 Reverse ATA GATATC TGAAGAATCTGAAGCCTAGACAAGGC
AP2VI-1_CDS_BglII_cre AP2VI-1 CDS Forward ATA AGATCT ACCATGGCGTCACAACTCTGTGCC
AP2VI-1_CDS_SbfI_cre AP2VI-1 CDS Reverse ATA CCTGCAGG GAGCACGCGCAGTAAAGAATTTAATCGG
AP2VI-1_3’UTR_HindIII_cre 3'UTR AP2VI-1 Forward ATA AAGCTT CTTGGATCTTGGTCGAGGGCG
AP2VI-1_3’UTR_ApaI_cre 3'UTR AP2VI-1 Reverse ATA GGGCCC ATGCTGCACAGGCGCCGCGGAA
AP2VI-1 CRE verify N/A Forward GATGCTCAAGGCATGCATCCGCC
AP2VI-1 CRE verify N/A Reverse GCAGTACTGGACAAGAAGGATCTC
AP2VI-1 CRE activity N/A Forward CCGCGGCTTCATGAGTTGCAG
AP2VI-1 CRE activity N/A Reverse CCAAAGAACGCCGCCCTCGAC
Recombinant protein construct
pGEX4T3 Domain 1 GST protein Forward ATACCATGGATCCGCAAAGAAGCTTCCCAAGCTAGCAGGT
pGEX4T3 Domain 1 GST protein Reverse ATGGTATGCGGCCGCATCATTCTCACTATGTTTGGACAT
pGEX4T3 Domain 2 GST protein Forward ATACCATGGATCCAACAAAAACGTATGCTACGAGACTCTA
pGEX4T3 Domain 2 GST protein Reverse ATGGTATGCGGCCGCCGAATTCCCCTGGCGACAAGACACTG
DNA probes for EMSA
EMSA PBM Validation Forward
TACCCTGCCTCTTGCTCATGAGCAAATTACGCGATCAAAAGAGGTAGTAG
GGTAGAGAT
EMSA PBM Validation Reverse
ATCTCTACCCTACTACCTCTTTTGATCGCGTAATTTGCTCATGAGCAAGAG
GCAGGGTA
EMSA PBM Validation Scram. Forward
GACTTGCTTGGTGAATGCCGTGCAGTGTATGTACAGTGTGTGTTGTTAAC
GTTTCCCTA
EMSA PMB Validation Scram. Reverse
TAGGGAAACGTTAACAACACACACTGTACATACACTGCACGGCATTCACCA
AGCAAGTC
Semi quantitive RT-PCR 
RT-PCR AP2VI-1 CDS Forward CCGTCTAGCCACTCTGAGACTCGC
RT-PCR AP2VI-1 @ stop Reverse GTATCAGCGGCCCACGCGTGA
RT-PCR GAPDH Forward GTCAATCATTCTGTCAATTCGA
RT-PCR GAPDH Reverse ACACCATGTAGTCCAGGGACATG
Target regions for ChIP-qPCR
ChIP-qPCR Chr.IA centromere set 1 Forward GAAGACAGCTGCATGCGTAA
ChIP-qPCR Chr.IA centromere set 1 Reverse ATCCTGCACTGAGTGACGTG
ChIP-qPCR Chr.IA centromere set 2 Forward CCGTCGACTAGAAGCCACTT
ChIP-qPCR Chr.IA centromere set 2 Reverse TAGCATGACGCAATTTCCAG
ChIP-qPCR Chr.IA centromere set 3 Forward CGAGGTAGTATTCGGGAACG
ChIP-qPCR Chr.IA centromere set 3 Reverse TTCGCTGTATCTGCCCTTTT
ChIP-qPCR Chr.IA centromere set 4 Forward CGGAAATGACCAACAACACA
ChIP-qPCR Chr.IA centromere set 4 Reverse TCTTCCCATGTTTTCGTTCC
ChIP-qPCR Chr.IA centromere set 5 Forward GCTCCGAATCGGTTAGAATG
ChIP-qPCR Chr.IA centromere set 5 Reverse AACTCGGCCTTTGTGTATGG
ChIP-qPCR Chr.IA centromere set 6 Forward CTGTAGCTGGAGGCGAAATC
ChIP-qPCR Chr.IA centromere set 6 Reverse CCAGACCTCGAAGGAAAACA
ChIP-qPCR Chr.IA control locus 1 Forward AGGCGACAAGAGGAAAGACA 
ChIP-qPCR Chr.IA control locus 1 Reverse AGTAACGGCGAGAGGAAACA
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Figure 4.1:  AP2VI-1 is dynamically regulated during S-phase of the tachyzoite cell cycle.  
(A) The mRNA curves for AP2VI-1 (green), AP2IX-4 (blue) and AP2IV-4 (red) show highly 
cyclical expression patterns.  AP2IX-4 (1.42h) and AP2VI-1 (1.7h) peak during S-phase with 
AP2IV-4 (2.66h) peak timing in late S-phase to early mitosis. (B) Schematic representation of 
the dual AP2 domain containing AP2VI-1.  Western blot analysis of endogenously tagged 
AP2VI-1HA parasites revealed a ~80kDa fusion protein, nearly double the predicted length 
(www.ToxoDB.org).  (C) The still-frame images were taken from an 8 h time lapse (10 
min/image) of AP2VI-1YFP (green) parasites that expressed the secondary marker, IMC1TFP (red) 
to visualize parasite division.  Nuclear AP2VI-1YFP expression in four vacuoles nicely 
demonstrates the tight synchrony inside the tachyzoite vacuole.  AP2VI-1YFP expression unfolds 
first in the vacuole of 16 (#1), followed by the vacuole of 4 (#2), and then vacuoles containing 2 
parasites (#3; #4).  Inset image (300 min) shows the formation of daughter buds immediately 
following the disappearance of AP2VI-1 in vacuole #4 confirming the late S phase to early 
mitosis timing of peak expression for this factor.  (D) A second time-lapse series of a single 
parasite indicates the duration of AP2VI-1YFP expression was ~90 min, with 8 h peak-to-peak 
expression, which matches the profile of the encoded mRNA.   
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Figure 4.2:  Defining the cell cycle timing of AP2VI-1HA using co-markers MORN1 and 
ISP1. 
(A) AP2VI-1HA parasites were cultured in HFF monolayers and co-localized with α-MORN1 
(green, apical cap) and DAPI (nucleic acid, blue).  Initial appearance of AP2VI-1HA (red) is 
coincident with the appearance MORN1 rings (b), prior to the separation of the centrosome.  
Maximum stability of AP2VI-1HA occurs with mature MORN ring structures (c) and detection 
wanes as the MORN1 rings flatten (d).  AP2VI-1HA is not visible in any parasites with immature 
MORN rings (a) or in parasites where MORN1 has switched to the basal complex of the internal 
daughters (e). (B) Co-staining of AP2VI-1HA (red) parasites with α-ISP1 (green) and DAPI 
(nucleic acid, blue) indicate initiation of AP2VI-1HA occurs prior to daughter apical cap formation 
(b) and achieves peak stabilization as daughter apical cap is formed (c).  Apical cap rings signify 
the degradation of AP2VI-1HA expression (d) and AP2VI-1HA is no longer detectable when the 
apical cap of the internal daughters is mature (e).  Nuclear morphology restricts AP2VI-1HA to S-
phase of the cell cycle, prior to the flattened or U-shaped nucleus of mitosis.  Scale bar=5 µm 
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Figure 4.3:  AP2VI-1 is expressed during bradyzoite development.   
(A) The quantification of PruAP2VI-1HA positive parasites across development was determined 
by immunofluorescence.  PruAP2VI-1HA parasites were grown in HFF monolayers and % HA 
positive vacuoles determined by random vacuole count.  In tachyzoite culture conditions, 
PruAP2VI-1HA is expressed in 25.8% of an asynchronous population (Tz, green bar).  Induction 
of bradyzoite development using alkaline pH (8.2) indicates PruAP2VI-1HA is expressed in 
22.1% (24h Bz, light blue), 26.8% (48h Bz, blue) and 34.4% of vacuoles at 72h (red) post 
bradyzoite induction. (B) Alkaline treatment of type III CTG parasites for 48h indicates a 
heterogenic nuclear expression of AP2VI-1 (green, α-AP2VI-1) within the developing tissue cyst 
(Dolichos, red).  Parasites negative for AP2VI-1 are indicated by DAPI staining (blue). (C) 
PruAP2VI-1HA was used to infect mice and 4 weeks post inoculation brain cysts were purified 
and subjected to immunofluorescence. Nearly every tissue cyst stained was positive for 
PruAP2VI-1HA (green).    
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Figure 4.4: Conditional expression of AP2VI-1 using ddFKBP and Shield-1 
(A) Conditional expression of DDAP2VI-1 (see schematic) is achieved by stabilizing the 
transgene using 100nM or 500nM Shield-1 ligand.  DDAP2VI-1 (green, α-HA) localizes to the 
nucleus and maintains S-phase cell cycle expression (100nM Shield-1 panel).  In the absence 
of Shield-1, background expression of the transgene from the constitutive alpha-tubulin 
promoter is detectable by IFA (no Shield-1 panel).  Western blot using α-AP2VI-1 antibodies 
detects both wild type AP2VI-1 and Shield-1 dependent DDAP2VI-1, note the expression of 
DDAP2VI-1 in the absence of Shield-1. α-PCNA1 was used as a loading control. (B) In the 
absence of Shield-1 EnDDAP2VI-1 is not detectable (no Shield-1 panel).  Conditional expression 
of EnDDAP2VI-1 (green, α-HA) (see schematic) is achieved by addition of 100nM or 500nM 
Shield-1 to culture medium (100nM Shield-1 panel).  Western blot analysis (α-AP2VI-1) 
indicates null expression of EnDDAP2VI-1 in the absence of Shield-1 and no difference in 
accumulation by increased Shield-1 concentration (100nM or 500nM).  α-PCNA1 was used as a 
loading control (48).  Cell cycle key as determined by IMC1 co-staining (G1=G1 phase; 
S=S=phase; M=mitosis). 
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Figure 4.5:  AP2VI-1 is non-essential to laboratory strains, but essential to native strains 
of Toxoplasma.   
(A) Schematic representation of the deletion construct for the AP2VI-1 locus.  The 5’ and 3’ 
UTR of AP2VI-1 were cloned around the HXGPRT selectable marker using the 3-fragment 
system (Invtrogen, (36)). (B) The primary screen for Δap2VI-1 was standard PCR using nested 
primers within the HXGPRT marker and either upstream (5’) or downstream (3’) locus specific 
primers (primer location in A, PCR screen). Three possible Δap2VI-1 transgenics were identified 
(8, 33 and 42) (C) RT-PCR using the full-length AP2VI-1 mRNA (Par, 1801bp cDNA) verify 
clones 8 and 33 as Δap2VI-1 transgenics, but not clone 42.  GAPDH mRNA was used as a 
loading control (202bp) and is designed around an intron to detect genomic DNA contamination 
(634bp, not detectable).  (D) Cytoplasmic and nuclear extracts from Δap2VI-1 transgenics were 
collected and subjected to Western blot analysis with antibodies to AP2VI-1 (α-AP2VI-1).  
AP2VI-1 in not expressed in any protein fraction for Δap2VI-1 8 or 33, but detected in 42 as well 
as in the transgenic AP2VI-1HA.  (E) A schematic representation of the loxP/CRE design for 
AP2VI-1 in PruΔku80Δhx.  Note the AP2VI-1 HA coding sequence and HXGPRT selectable 
marker are flanked by loxP recognition sites, indicating both are removed during CRE mediated 
excision.   
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Figure 4.6: AP2VI-1 binds DNA with sequence specificity.  
(A) Logo representation of the preferred DNA binding sequence for GST-AP2VI-1 generated 
from probing an Agilent DNA microarray with purified GST-protein.  Two core motifs were found 
for AP2VI-1, the first containing a palindromic sequence centered around a core CATG and the 
second consisting an unusual purine rich sequence (A/G only).  (B) An electrophoretic motility 
shift was conducted with the dual domain GST-AP2VI-1 protein (1ug) and a 59bp-biotynilated 
DNA probe containing both the 5’-CCTCATGAG-3’ and 5’-AAAAGAGG-3’ (20fmol) PBM motifs.  
The arrow denotes a specific protein-DNA complex (lane 2) that is only competed with 300x 
non-biotinylated probe (lane 3), but not a scrambled probe (lane 4).  
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Figure 4.7:  Genome wide occupation of AP2VI-1HA binding in vivo reveals AP2VI-1 tightly 
binds peri-centromere regions on all chromosomes.  
A.  AP2VI-1HA is localizes to the peri-centromere on all Toxoplasma chromosomes.  AP2VI-1HA 
was subjected to chromatin immunoprecipitation and recovered genomic fragments used to 
probe a genome-wide chip array (ChIP-chip).  The highest scoring binding regions on all 
chromosomes correlate precisely to the binding sites of CenH3, the histone H3 variant 
distinguishing centromeric DNA and (B) across the AP2VI-1 locus.  (C) Chromatin 
immunoprecipitation was completed on AP2VI-1HA parasites with both α-HA (specific chromatin) 
and α-IgG (non-specific chromatin) antibodies.  Equal amounts of specific and non-specific 
chromatin were subjected to quantitative PCR at 6 loci across the peri-centromeric region on 
chromosome Ia (Chr.Ia) and compared to a single non-target locus within Chr.Ia.  Specific 
enrichment of AP2VI-1HA is seen across the locus (2-7 fold) the peri-centromeric locus.  
Relative enrichment was calculated using the equation 2^-(ΔCt target-ΔCt non-target) where the change 
in Ct value of specific versus nonspecific chromatin at target and non-target loci. 
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CHAPTER FIVE: 
Summary and future directions 
 
Note to readers: 
Portions of this chapter have been previously published in: Toxoplasma development--
turn the switch on or off? Cell Microbiol. 2014 Apr;16(4):466-72. doi: 10.1111/cmi.12267. Epub 
2014 Feb 16 and are used with permission from John Wiley and Sons.  
 
Summary: 
This dissertation highlights the role of the newly discovered transcription factors of the 
ApiAP2 family in regulating the transcriptional events required for successful bradyzoite 
development in Toxoplasma.  For human disease the key developmental switch is that from the 
tachyzoite to the mature bradyzoite, which is not well understood at the molecular level.  Our 
initial hypothesis, based solely on developmental gene expression gene expression patterns, 
was that ApiAP2s were going to regulate genes that exhibited similar timing of expression.  In 
other words, ApiAP2s cyclically expressed during the tachyzoite cell cycle were responsible for 
driving cell cycle progression and ApiAP2s expressed in the bradyzoite were going to drive 
bradyzoite development.  Included in this simple hypothesis, was the assumption that ApiAP2 
factors were going to be transcriptional activators responsible for driving developmental gene 
expression.  Fortunately, in this case, our original hypothesis was wrong and this dissertation 
begins to lay the foundation for a new paradigm in Toxoplasma development.  As opposed to 
the historical view of bradyzoite development being controlled only by transcriptional activators, 
these data suggest tissue cyst formation is guided by a delicate interplay between 
transcriptional activation promoting bradyzoite formation and at least two levels of transcriptional 
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repressors acting to prevent this commitment step (Fig. 5.1).  AP2IX-9 (Chapter 2) is induced in 
response to parasite stress, however, is absent from both the replicating tachyzoite and the 
end-stage, bradyzoite containing tissue cyst.  AP2IX-9 also promotes tachyzoite growth in 
alkaline conditions, thus, AP2IX-9 may help balance the need for parasite expansion with 
efficient production of the transmissible tissue cyst.  Preliminary data based on the expression 
of AP2IX-9 in skeletal muscle cells suggests the natural equivalent of alkaline stress may be the 
host cell environment, and that, in vitro, alkaline treatment results in changes in the host-
parasite signaling which leads to bradyzoite development (Radke, Luder and White, 
unpublished).   
A second repressor, AP2IV-4 (Chapter 3), is the first tachyzoite exclusive ApiAP2 to be 
directly tied to bradyzoite development in Toxoplasma.  It is well understood that cycle 
progression and bradyzoite development are tightly coupled with the expression of basal 
bradyzoite transcripts occurring late in the tachyzoite cell cycle.  AP2IV-4, expressed from 
mitosis through cytokinesis in the dividing tachyzoite, represses key components of the 
bradyzoite tissue cyst wall structure as well as bradyzoite-specific surface proteins.  The role of 
the tachyzoite cell cycle in controlling the initiation of bradyzoite development is consistent with 
the known requirement for replication before differentiation.  Apicomplexa life cycles involve a 
series of entries or exits from the parasite division cycle reflecting a requirement for 
chromosome replication to achieve the chromatin remodeling that drives gene expression 
reprograming.  How the centromeric factor AP2VI-1 (Chapter 4) operates within these 
chromosome mechanisms is not understood, however, our inability to disrupt this factor in type 
II strains suggests this factor is required for developmental competency. 
The complexity of repressor mechanisms preventing bradyzoite gene expression in the 
tachyzoite indicates that of the competing tasks of increasing parasite numbers or producing the 
correct end-stage form for transmission, the amplification of parasite mass drives this pathway.  
Why use a series of repressors to govern this process?  The data suggests the default pathway 
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in asexual development is the formation of the bradyzoite containing tissue cyst.  Therefore, 
Toxoplasma has evolved a series “road blocks” preventing premature development of the 
transmissible end-stage providing a mechanism to ensure proper expansion of the replicative 
stage within the host.  Control of ApiAP2 repressors may also explain the host tissue tropisms 
long understood associated with tissue cyst formation.  Not every animal tissue is suitable for 
bradyzoite development, but how these host environments signal developmental choices in the 
parasite is a mystery (Fig. 5.2).  New evidence suggests a parasite casein kinase II and host 
anti-growth factor CDA1 can influence specific pathways that are responsible for sensing the 
host cell environment and informing the parasites decision to continue replication or to develop 
into bradyzoites (1).  Furthermore, recent studies indicated the growth status of the host cell 
plays a major role in determining the cell type where bradyzoite development unfolds (2-4).  
Host-parasite interactions in parasite development is one of the frontiers of Apicomplexa 
research and the identification of the transcriptional sensors in Toxoplasma offer new tools to 
dissect these critical signal transduction pathways.  
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Figure 5.1: Bradyzoite development is the default pathway in the asexual life cycle of 
Toxoplasma.  
There are at least two steps involved in the commitment to bradyzoite development.  Step 1 
involves the slowing of tachyzoite replication (pre-bradyzoite) associated with onset of 
bradyzoite specific gene expression and Step 2 is the commitment of the pre-bradyzoite to form 
the latent, mature bradyzoite.  At least two levels of repressors govern this process.  AP2IV-4, 
active only during the tachyzoite cell cycle, acts to repress bradyzoite surface antigens and 
tissue cyst wall components during the replicative cycle.  Second, AP2IX-9, is a transient 
repressor that acts to prevent premature commitment to the mature cyst.  Together, these 
ApiAP2s provide the parasite the flexibility to adapt to different host tissues and to modulate to 
host immune responses to successfully achieve the transmissible, end stage bradyzoite tissue 
cyst, ensuring life long infection within the host.    
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Figure 5.2: The new model of Toxoplasma asexual development.  The lifecycle of 
Toxoplasma gondii in the intermediate host is associated with major developmental transitions: 
sporozoite (G0/G1) differentiation to the replicating tachyzoite and the interconversion of the 
tachyzoite and the mature bradyzoite (also G0/G1).  In natural infections, tachyzoite expansion 
is limited by two major forces: 1) the competition between bradyzoite repressors acting late in 
every cell cycle (S/M/C phase) and activators governing development of mature bradyzoites and 
2) the interaction with host cell signals that influence the tachyzoite to continue growing or exit 
from the cell cycle to develop the latent, mature bradyzoite. 
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Future directions from these studies:  
Further studies of AP2IX-9.  The AP2IX-9 factor provides a new model from which to 
understand the mechanisms responsible for the bradyzoite development and provides insight 
into how the developmental switch is employed. However, this is a single factor in a complex 
mechanism and further work is necessary to understand the biology of developmental gene 
expression. For AP2IX-9, several lines of experiments need to be explored.  First, we need to 
determine if host cell type (neurons or muscle cells) influence the expression pattern of AP2IX-
9, thereby providing a mechanism in which AP2IX-9 (or other AP2s like it) have a role in 
determining the ideal host cell in which to terminally differentiate (2-4).  Second, we hypothesize 
ApiAP2 proteins are unstable in the absence of DNA binding and one mechanism we suggest is 
that AP2IX-9 is readily degraded in the tachyzoite because it requires a change in chromatin 
state in order to bind its target DNA sequences and is supported by the presence of the AP2IX-
9 mRNA in the tachyzoite (Fig. 2.6A).  To test this hypothesis, we need to swap the DNA 
binding domain of AP2IX-9 with that of a DNA binding domain of a constitutive or non-essential 
ApiAP2 that is expressed during the tachyzoite cell cycle.  If successful, this would provide a 
mechanism to stabilize AP2IX-9 expression during the tachyzoite cell cycle and monitor 
associated gene expression changes in both the tachyzoite and bradyzoite stages of 
development. 
A better understanding of both the DNA sequences and protein residues required for 
AP2IX-9 interaction with chromosomes and other proteins would be valuable in understanding 
the mechanism of AP2IX-9 function.  Reagents for promoter specific EMSA (BAG1, B-NTPase) 
with Toxoplasma nuclear extracts allow for determination of the minimal DNA bases required for 
AP2IX-9 protein binding.  Protein binding microarray on GST-IX-9 fusion proteins containing 
mutations in the DNA binding domain would provide a platform to express and determine which 
residues affect AP2IX-9 DNA binding specificity when compared to wild type (Fig. 2.3A).  DNA 
binding can be assessed using EMSAs (Fig. 2.3B and Fig. 2.4) and promising mutations 
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introduced into the ddFKBP/Shield-1 model to test for function or the creation of a dominant 
negative phenotype. 
We have identified two other ApiAP2 factors, AP2Ib-1 and AP2IV-3 (Fig. 2.2B) that have 
a similar mRNA expression pattern across development (5, 6).  AP2Ib-1 does not appear 
amenable for epitope tagging at the C-terminus, however, other approaches such as N-terminal 
fusion with the conditional expression ddFKBP/Shield-1 model may allow for characterization of 
AP2Ib-1 expression during tachyzoite to bradyzoite development.  We have successfully 
epitope tagged AP2IV-3 in the chromosome locus.  Preliminary data for PruQ-AP2IV-3HA 
indicates a very similar expression pattern to PruQ-AP2IX-9HA. Therefore, conditional 
expression AP2IV-3 would provide may provide valuable insight into independent or functional 
redundancy in the roles AP2IX-9 and AP2IV-3.  Directed knockouts of AP2Ib-1 and AP2IV-3 
should also be performed to determine if they are essential to developmentally competent 
strains of Toxoplasma. 
Further studies of AP2IV-4.  The study of AP2IV-4 and its role regulating development 
in Toxoplasma is ongoing.  Several lines of experimentation are needed to complete a 
manuscript on these factor are outlined below and will further define the AP2IV-4 mechanism. 
Due to the fast culture adaptation of Δap2IV-4 strain parasites, the reduced growth 
phenotype is incomplete (Fig. 3.3C, early vs. late passage).  We next need to determine if the 
reduced plaque number in the AP2IV-4 knockout parasites was due to diminished ability to 
invade and replicate or, on the other hand, if a slower replication rate resulted in less visible 
plaques at 7 days post infection.  These experiments are critical to determining the role of 
AP2IV-4 in regulating cell cycle progression (Table 3.1).  These experiments will require the re-
isolation of an AP2IV-4 knockout strain that is straightforward (10/51 isolates were knockouts in 
the original screen). 
Because the AP2IV-4 knockout strain was generated in a type 1 (RH strain, 
background), a genetic linage resistant to bradyzoite development both in vitro and in vivo, 
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reviewers of this manuscript may request a repeat of the knockout phenotype in 
developmentally competent strains (type II or III).  We are in the process of re-creating a dual 
tagged (TGME49_318480) transgenic parasite with AP2IV-4 “floxed” in the type II PruΔku80.  
There currently is no type II or III diCRE strains (7) for rapamycin induced CRE expression, 
however, a plasmid that encodes the CRE recombinase has successfully been implemented in 
Toxoplasma (8) and is available for our use.  This is a primary focus going forward. 
We showed 1-3.5 fold up-regulation of luciferase expression from bradyzoite promoters 
in Δap2IV-4 parasites using transient transfection (Fig. 3.6).  However, previous studies (9) 
indicate promoter::luciferase expression is not as robust do outside of their native chromatin 
context or need to be integrated within the chromatin in order to function to drive luciferase 
expression (Radke and White, unpublished).  To test this hypothesis, we are constructing 
transgenic strains expressing SAG4.2 (-1521)::flyluc and MCP4 (-1511)::flyluc in both parent 
(ID6) and Δap2IV-4 27 strains.  For example, the transgenic BAG1::flyluc (PruIC2, (33)) 
expresses luciferase 10 to 15 fold better than transient transfected BAG1::flyluc and other 
promoters (LDH2 and B-NTPase) follow a similar pattern of luciferase induction (Radke and 
White, unpublished). 
To determine if the interaction with AP2IV-4 and its gene targets is specific, we will also 
conduct chromatin immunoprecipitation followed by quantitative PCR (ChIP-qPCR).  Through 
chemical cross-link of AP2IV-4 protein to its regulatory DNA sequences and their subsequent 
isolation, we can quantify the enrichment, if any, of AP2IV-4 at the promoters of genes targets 
SAG4.2, BPK1, SRS9, MCP4 and the C3H ZnF.  This method was successfully implemented 
for AP2IX-9 by tiling qPCR probes across target promoters (10). 
While the most straightforward explanation is that AP2IV-4 directly regulates target 
mRNAs SAG4.2, BPK1, SRS9, CST1 and MCP4 (11-16) among others through direct promoter 
interaction (Fig. 3.5 and 3.6), it also shows the 15.7-fold down-regulation of a mRNA encoding a 
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C3H ZnF (TGGT1_226310, Table 3.2, green highlight).  Zinc finger proteins are a diverse family 
of proteins and have been implicated in many cellular processes in eukaryotic cells including 
DNA or RNA binding and RNA processing and stability ((17), reviewed in (18)).  In various 
species of plants, C3H type zinc fingers are involved in flowering, daylight dependent 
embryogenesis (19-23) as well as growth and stress responses (24, 25).  In addition, a recent 
study indicates C3H zinc fingers in regulation of plant hormones abscisic and jasmonic acid 
(26).  The observation that C3H zinc fingers regulate developmental processes in plants 
suggests we cannot rule out that the primary regulatory target of AP2IV-4 is C3H Znf.  The 
subsequent up-regulation of bradyzoite specific transcripts in the Δap2IV-4 transgenic could 
plausibly be attributed to the down-regulation of C3H Znf.  In other words, the C3H Znf directly 
represses specific tissue cyst wall and bradyzoite surface antigens and removal of its 
transcriptional activator (AP2IV-4) within the tachyzoite results in their up-regulation.  To test 
this hypothesis, we will complement the Δap2IV-4 phenotype by overexpression (constitutive 
and conditional) of the C3H ZnF gene and determine if the expression phenotype is rescued by 
microarray and IFA using the native antibodies (Fig. 3.4A,B).  If the C3H ZnF rescues the 
Δap2IV-4 we have the first insight into a novel, likely post-transcriptional regulation of gene 
expression by an RNA binding protein Apicomplexa.  In the event the C3H ZnF does not 
complement the Δap2IV-4 phenotype, we will proceed in verifying the direct interaction of 
AP2IV-4 with its regulatory targets. 
Further studies of AP2VI-1.  The difficulty in disrupting the AP2VI-1 locus in 
developmentally competent strains has been a challenge to pining down the function of this 
factor.  Further attempts to knockout AP2VI-1 using the PruΔku80Δhx AP2VI-1 “floxed” 
transgenic strain (Fig. 4.5E) need to be completed in a modified way.  The activation CRE 
recombinase in this strain results in the removal of the AP2VI-1 locus and the HXGPRT 
selectable marker used for stabile integration.  Parasites within the population that maintain a 
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functional copy of HXGPRT can be eliminated by treatment with 6-thioxanthine, the counter 
selection for HXGPRT.  This negative counter selection will help remove wild-type AP2VI-1 
parasites and enrich the culture for AP2VI-1 knockout parasites. 
Second, as illustrated in Fig. 4.1A, the AP2VI-1 mRNA shares a nearly identical cell 
cycle expression pattern to AP2IX-4 that is also maintained during the bradyzoite developmental 
stages, suggesting they could have redundant function.  Like AP2VI-1, AP2IX-4 is non-essential 
to laboratory-adapted strains (Sullivan and White, unpublished) and therefore reciprocal 
knockouts of the other ApiAP2 (knockout of AP2IX-4 in the Δap2VI-1 transgenic, and knockout 
of AP2VI-1 in the Δap2IX-4 transgenic) will reveal any redundant function for this ApiAP2 pair.  
Furthermore, successful Δap2IX-4 transgenics have been recovered in native strains of 
Toxoplasma and exhibit a diminished ability of bradyzoites to persist in vitro (Sullivan and White, 
unpublished).  In the event a viable Δap2VI-1 transgenic is never recovered, redundant function 
with AP2IX-4, a nearly identically expressed ApiAP2, may provide a mechanism to predict the 
function of AP2VI-1. 
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